A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole) Plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women With Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer With No Prior Systemic Therapy in This Disease Setting
Phase: PHASE3
Conditions: Breast Cancer
Sponsor: Eli Lilly and Company

Protocol I3Y-MC-JPBM(a) 
 
A Randomized, Double-Blind, Placebo-Controlled, Phase 
3 Study of Nonsteroidal Aromatase Inhibitors 
(Anastrozole or Letrozole) plus LY2835219, a CDK4/6 
Inhibitor, or Placebo in Postmenopausal Women with 
Hormone Receptor-Positive, HER2-Negative 
Locoregionally Recurrent or Metastatic Breast Cancer 
with No Prior Systemic Therapy in this Disease Setting 
 
NCT02246621 
 
Approval Date: 13-Nov-2015 

13Y-MC-JPBM(a) Clinical Protocol 
Page 1 
LY2835219 
 
 
 
1. Protocol  13Y-MC-JPBM(a) 
A Randomized, Double-Blind, Placebo-Controlled, Phase 
3 Study of Nonsteroidal Aromatase 1nhibitors 
(Anastrozole or Letrozole) plus LY2835219, a CDK4/6 
1nhibitor, or Placebo in Postmenopausal Women with 
Hormone Receptor-Positive, HER2-Negative 
Locoregionally Recurrent or Metastatic Breast Cancer 
with No Prior Systemic Therapy in this Disease Setting 
 
 
 
 
 
LY2835219 
 
 
Eli Lilly and Company 
Indianapolis, Indiana USA 46285 
 
Protocol Approved by Lilly:  03 September 2014 
Amend ent (a) Electronically Signed and Approved by Lilly 
on date provided below. 
 
 
 
 
 
 
 
 
Approval Date: 13-Nov-2015 GMT 
Confidential 1nformation 
The information contained in this protocol is confidential and is intended for the use of 
clinical investigators.  It is the property of Eli Lilly and Company or its subsidiaries and 
should not be copied by or distributed to persons not involved in the clinical investigation of 
LY2835219, unless such persons are bound by a confidentiality agreement with Eli Lilly 
and Company or its subsidiaries.  This document and its associated attachments are 
subject to United States Freedom of Information Act Exemption 4. 
This study is a global, multicenter, double-blind, placebo-controlled, Phase 3 trial for 
postmenopausal women with hormone receptor-positive, HER2-negative locoregionally 
recurrent or metastatic breast cancer randomized to receive nonsteroidal aromatase 
inhibitors (anastrozole or letrozole) with or without LY2835219. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 2 
LY2835219 
 
 
 
2. Synopsis 
Study Rationale 
LY2835219 is an oral, selective, and potent small molecule cyclin-dependent kinase (CDK) 4 
and 6 (CDK4 and CDK6) dual inhibitor with antitumor activity within multiple preclinical 
pharmacology models and an acceptable toxicity profile in nonclinical species.  LY2835219 
mesylate has been shown to significantly inhibit tumor growth in multiple murine xenograft 
models for human cancer. Studies with LY2835219 across breast cancer cell lines indicate 
differential sensitivity to CDK4 and CDK6 inhibition based on histological and genetic 
characteristics.  Growth inhibition in vitro across a diverse panel of 46 breast cancer cell lines, 
representing the known molecular subgroups of breast cancer, indicates that sensitivity to CDK4 
and CDK6 inhibition is greater in estrogen receptor-positive (ER+) breast cancers with luminal 
histology. 
LY2835219 has demonstrated evidence of single-agent clinical activity in a tumor-specific 
cohort of women with metastatic breast cancer (mBC).  In Study I3Y-MC-JPBA (JPBA), 
47 patients with a median of 7 prior systemic regimens received therapy with LY2835219. 
Among the 36 patients with hormone receptor-positive (HR+) mBC, there were 9 patients with 
confirmed partial responses (PR) for an objective response rate (ORR) of 25%.  Further, of these 
36 patients with HR+ mBC, the clinical beneffiitt rate (CBR:  PR + stable disease [SD] 2'24 weeks) 
was 61%, and the disease control rate (DCR:  PR + SD) was 80.6%.  A total of 14 patients were 
continuing treatment at the time of analysis (Patnaik et al. 2014).  In the same study, LY2835219 
demonstrated an acceptable safety profile for women with HR+ mBC.  The most common 
treatment-emergent adverse events (TEAEs) were diarrhea, nausea, fatigue, neutropenia, and 
vomiting.  There were no treatment discontinuations attributable to an AE.  The clinical activity 
and safety profile support further evaluation of LY2835219 in mBC. 
Non-steroidal aromatase inhibitors (NSAI, letrozole and anastrazole) are approved and 
commonly used endocrine therapy in the first-line setting for postmenopausal women with HR+ 
mBC.  The evaluation of LY2835219 in combination with an NSAI is of interest since both 
classes of drugs have acceptable and distinct safety profiles.  The current study will assess if 
additional clinical benefit may be achieved in this disease setting with this drug combination. 
Study I3Y-MC-JPBM (JPBM) is a randomized, double-blind, placebo-controlled, Phase 3 study 
evaluating treatment of LY2835219 with NSAI or placebo with NSAI in postmenopausal women 
with HR+, human epidermal growth factor receptor 2-negative (HER2-) locoregionally recurrent 
or metastatic breast cancer who have not received prior systemic therapy in this disease setting. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 3 
LY2835219 
 
 
 
Clinical Protocol Synopsis: Study 13Y-MC-JPBM 
 
Name of Investigational Product: LY2835219 
Title of Study: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal Aromatase 
Inhibitors (Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women 
with Hormone Receptor-Positive, HER2-Negative Locoregionally Recurrent or Metastatic Breast Cancer with No 
Prior Systemic Therapy in this Disease Setting 
Number of Planned Patients: 450 
Entered:  500 
Enrolled/Randomized: 450 
Completed:  450 
Phase of Development: 3 
Length of Study: approximately 91 months 
Planned first patient visit:  Oct 2014  
Planned last patient visit:  May 2022 
Planned interim analyses:  189 (approximately 70% of the planned) progression-free survival (PFS) events and 
230 (approximately 85% of the planned) PFS events 
Objectives:  The primary objective of Study I3Y-MC-JPBM is to compare treatment with LY2835219 plus NSAI 
therapy versus placebo plus NSAI therapy with respect to PFS in postmenopausal women with HR+, HER2- 
locoregionally recurrent or metastatic breast cancer who have not received prior systemic therapy in this disease 
setting. 
The secondary objectives of the study are to compare the combination treatment of LY2835219 and NSAI therapy 
versus placebo plus NSAI therapy with respect to the following: 
 
overall survival [OS]; 
 
OS rate at 1, 2, and 3 years; 
 
ORR (complete response [CR] + PR); 
 
duration of response [DoR] (CR + PR); 
 
DCR (CR + PR + SD); 
 
CBR (CR + PR + SD 2' 6 months); 
 
safety and tolerability 
 
change in symptom burden using the European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), EORTC QLQ-BR23 (breast) questionnaire, and 
health status scores from the EuroQol 5-Dimension 5 Level (EQ-5D 5L). 
 
pharmacokinetics (PK) of LY2835219, its metabolites, and NSAI therapy 
The exploratory objectives are: 
• 
To explore potential biomarkers related to the mechanism of action of LY2835219, the cell cycle, and/or 
the pathogenesis of breast cancer. 
• 
To explore change in tumor size. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 4 
LY2835219 
 
 
 
 
Study Design: Study JPBM is a multicenter, randomized, double-blind, placebo-controlled Phase 3 study 
evaluating treatment of LY2835219 with NSAI or placebo with NSAI in postmenopausal women with HR+, 
HER2- locoregionally recurrent (not amenable to curative therapy) or metastatic breast cancer who have not 
received prior systemic therapy in this disease setting. Approximately 450 patients will be randomized 2:1 
between the 2 arms. Patients will be randomized using the following stratification factors: nature of disease 
(visceral metastases versus bone-only metastases versus other) and prior (neo)adjuvant endocrine therapy 
(aromatase inhibitor therapy versus other versus no prior endocrine therapy). 
Diagnosis and Main Criteria for Inclusion and Exclusions:  Patients are eligible to be included in the study if 
they meet following criteria:  1) have a diagnosis of HR+, HER2- breast cancer; 2) have locoregionally recurrent 
disease not amenable to resection or radiation therapy with curative intent or metastatic disease; 3) have 
postmenopausal status due to either surgical/natural menopause or amenorrheic (non-treatment-induced) for at 
least 12 months; 4) have either measurable disease or nonmeasurable bone-only disease; 5) have a performance 
status :S1 on the Eastern Cooperative Oncology Group (ECOG) scale; 6) have adequate organ function; 7) have 
discontinued previous localized radiotherapy for palliative purposes or for lytic lesions at risk of fracture prior to 
randomization and recovered from the acute effects of therapy; 8) are female and 2'18 years of age; 9) are able to 
swallow capsules; 10) have given written informed consent prior to any study-specific procedures; 11) are reliable, 
willing to be available for the duration of the study, and are willing to follow study procedures. 
Patients will be excluded from the study if they meet any of the following criteria:  12) have visceral crisis, 
lymphangitic spread, or leptomeningeal carcinomatosis; 13) have inflammatory breast cancer; 14)  have clinical 
evidence or a history of central nervous system (CNS) metastasis; 15) are currently receiving or have previously 
received endocrine therapy for locoregionally recurrent or metastatic breast cancer; 16) have received prior 
(neo)adjuvant endocrine therapy with a disease-free interval :S12 months from completion of treatment; 17) are 
currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast 
cancer; 18) have received prior treatment with everolimus; 19) have received prior treatment with any CDK4 and 
CDK6 inhibitor (or participated in any CDK4 and CDK6 inhibitor clinical trial for which treatment assignment is 
still blinded); 20) have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents <7 days 
prior to randomization; 21) are currently receiving an investigational drug in a clinical trial or participating in any 
other type of medical research judged not to be scientifically or medically compatible with this study; 22) have 
received treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of 
randomization for a nonmyelosuppressive or myelosuppressive agent, respectively; 23) have had major surgery 
within 14 days prior to randomization; 24) have received recent (within 28 days prior to randomization) yellow 
fever vaccination; 25) have serious preexisting medical conditions that, in the judgment of the investigator, would 
preclude participation in this study; 26) have a personal history of any of the following conditions:  syncope of 
cardiovascular etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest; 27) have a history 
of any other cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete 
remission with no therapy for a minimum of 3 years; 28) have received an autologous or allogeneic stem-cell 
transplant; 29) 
have active bacterial or fungal infection or detectable viral infection. 
Test Product, Dosage, and Mode of Administration: LY2835219 will be supplied as capsules administered 
orally, 150 mg every 12 hours on Days 1 to 28 of a 28-day cycle. 
Planned Duration of Treatment: 
Treatment period:  until disease progression or other discontinuation criteria are fulfilled. 
Short-term follow-up (postdiscontinuation):  30 days 
Long-term follow-up (postdiscontinuation):  until death 
Reference Therapy, Dose, and Mode of Administration: Placebo will be supplied as capsules administered 
orally every 12 hours on Days 1 to 28 of a 28-day cycle. In both arms, either letrozole or anastrazole will be 
administered orally.  Where required, anastrazole 1-mg or letrozole 2.5-mg tablets will be supplied. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 5 
LY2835219 
 
 
 
 
 
Criteria for Evaluation: 
Efficacy: 
• 
• 
• 
• 
• 
•     
Safety: 
• 
PFS (Response Evaluation Criteria in Solid Tumors [RECIST] v1.1) 
OS 
OS at 1, 2, and 3 years 
ORR (RECIST v1.1) 
DoR (RECIST v1.1) 
DCR (RECIST v1.1) 
AEs using MedDRA 
Health Outcomes: 
 
EORTC QLQ-C30 and EORTC QLQ-BR23:  Describe target tumor symptom changes 
 
EQ-5D 5L: Describe health status changes 
Pharmacokinetics: 
 
Population PK parameters for LY2835219 and possibly LY2835219 metabolites and letrozole or 
anastraszole 
Exploratory: 
 
Potential biomarkers related to the mechanism of action of LY2835219, the cell cycle, and/or the 
pathogenesis of breast cancer 
 
Time course of change in tumor size 

13Y-MC-JPBM(a) Clinical Protocol 
Page 6 
LY2835219 
 
 
 
 
Statistical Methods: 
Statistical: 
The primary objective of this study is to compare treatment with LY2835219 plus NSAI therapy versus placebo 
plus NSAI therapy with respect to progression-free survival (PFS) in postmenopausal women with HR+, HER2- 
locoregionally recurrent or metastatic breast cancer.  An important secondary objective of this study is to compare 
the 2 arms with respect to OS. 
A 3-look group sequential design on the primary endpoint of PFS will be utilized, with 2 interim analyses and 
1 final PFS analysis occurring at approximately 189, 230, and 270 investigator-assessed PFS events,, respectively. 
A fixed alpha-spending method will be used to maintain the cumulative 1-sided type I error rate of .025. Assuming 
a hazard ratio of 0.67, this design yields more than 80% statistical power to detect superiority of the LY2835219 
plus NSAI arm over placebo plus NSAI arm with the use of a 1-sided log-rank test and a cumulative type I error 
rate of 0.025. 
OS is an important secondary endpoint for this study. OS will be tested only if the test of PFS is significant. 
final OS analysis will occur after approximately 315 OS events have been observed. 
Efficacy: 
The 
The PFS and OS analyses to test the superiority of LY2835219 to placebo in improving PFS and OS will use the 
log-rank test stratified by the stratification variables.  Additional analyses will be performed using the 
Kaplan-Meier method to estimate the PFS and OS curves and rates, and the Cox proportional hazard model will be 
used to estimate the PFS and OS hazard ratios and corresponding 95% confidence interval. 
 
Safety: 
All safety summaries and analyses will be based on the Safety Population, defined as all enrolled patients receiving at 
least 1 dose of study treatment.  Patients will be grouped according to treatment received in Cycle 1. 
 
Health Outcomes: 
Change in pain and symptom burden wiillll be analyzed descriptively and treatment arms will be compared using a 
repeated measures model, where appropriate. 
 
Pharmacokinetics: 
PK parameters for LY2835219 in plasma (clearanc  , exposure, volume of distribution, and half-lives) and 
inter-individual PK variability will be computed using nonlinear mixed effect modeling implemented in 
NONMEM.  If warranted by the data, PK parameters for LY2835219 metabolites and anastrozole or letrozole in 
plasma and inter-individual variability estimates will also be computed using nonlinear mixed-effect modeling 
implemented in NONMEM. 
 
Pharmacodynamics: 
Pharmacodynamic data (such as neutrophil, lymphocytes, or platelets counts in blood) may be analyzed by means 
of NONMEM and connected to the population PK model for LY2835219 and/or anastrozole or letrozole in a 
PK/pharmacodynamic model. 
 
Biomarkers: 
Summary statistics will include means, medians, corresponding standard errors, quartiles, and ranges. Biomarkers 
with discrete measures, such as genotype locus, will be summarized in frequency tables. Correlative analyses may 
be performed to investigate associations between biomarkers and clinical endpoints. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 7 
LY2835219 
 
 
 
3. Table of Contents 
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 
Study of Nonsteroidal Aromatase 1nhibitors (Anastrozole or 
Letrozole) plus LY2835219, a CDK4/6 1nhibitor, or Placebo in 
Postmenopausal Women with Hormone Receptor-Positive, 
HER2-Negative Locoregionally Recurrent or Metastatic 
Breast Cancer with No Prior Systemic Therapy in this 
Disease Setting 
Section 
Page 
1. 
Protocol I3Y-MC-JPBM(a) A Randomized, Double-Blind, Placebo- 
Controlled, Phase 3 Study of Nonsteroidal Aromatase Inhibitors 
(Anastrozole or Letrozole) plus LY2835219, a CDK4/6 Inhibitor, or 
Placebo in Postmenopausal Women with Hormone Receptor- 
Positive, HER2-Negative Locoregionally Recurrent or Metastatic 
Breast Cancer with No Prior Systemic Therapy in this Disease 
Setting ......................................................................................................................................1 
2. 
Synopsis ...................................................................................................................................2 
3. 
Table of Contents ....................................................................................................................7 
4. 
Abbreviations and Definitions ...............................................................................................14 
5. 
Introduction ...........................................................................................................................20 
5.1. 
Rationale for Amendment (a)  .......................................................................................... 22 
6. 
Objectives ..............................................................................................................................23 
6.1. 
Primary Objective  ............................................................................................................ 23 
6.2. 
Secondary Objectives  ...................................................................................................... 23 
6.3. 
Exploratory Objectives ..................................................................................................... 23 
7. 
Study Population ....................................................................................................................24 
7.1. 
7.2. 
Inclusion Criteria ..............................................................................................................24 
Exclusion Critteria ................................................................................................................................. 25 
7.2.1. 
Rescreening  .............................................................................................................27 
7.3. 
Discontinuations  ..............................................................................................................27 
7.3.1. 
Discontinuation of Patients  .....................................................................................27 
7.3.2. 
Discontinuation of Study Sites  ................................................................................28 
7.3.3. 
Discontinuation of the Study  ...................................................................................28 
8. 
Investigational Plan ...............................................................................................................29 
88.1. Summary of Study Design ................................................................................................29 
88.1.1. 
Study Completion and End of Trial .........................................................................30 

13Y-MC-JPBM(a) Clinical Protocol 
Page 8 
LY2835219 
 
 
 
88.1.2. 
Continued Access Period ........................................................................................ 31 
88.2. Discussion of Design and Control ................................................................................... 32 
9. Treatment .............................................................................................................................. 33 
9.1. 
Treatments Administered ................................................................................................ 33 
9.2. 
Materials and Supplies .................................................................................................... 34 
9.3. 
Method of Assignment to Treatment ............................................................................... 35 
9.4. 
Selection and Timing of Doses ........................................................................................ 35 
9.4.1. 
Special Treatment Considerations .......................................................................... 37 
9.4.1.1. 
Dose Adjustments and Delays  .............................................................................. 37 
9.4.1.1.1. 
Dose Adjustments........................................................................................ 38 
9.4.1.1.1.1. 
Blinded Study Drug ............................................................................... 38 
9.4.1.1.1.2. 
Anastrozole or Letrozole ....................................................................... 38 
9.4.1.1.2. 
Dose Suspension (within a Cycle) and Cycle Delay  .................................. 38 
9.4.1.1.3. 
Hematologic Toxicity .................................................................................. 39 
9.4.1.1.4. 
Nonhematological Toxicity ......................................................................... 39 
9.4.1.1.4.1. 
Diarrhea ................................................................................................. 40 
9.5. 
Blinding ........................................................................................................................... 40 
9.5.1. 
Unblinding at Interim Analyses  ............................................................................. 40 
9.5.2. 
Emergency Unblinding ........................................................................................... 40 
9.5.3. 
Inadvertent Unblinding ........................................................................................... 41 
9.6. 
Concomitant Therapy ...................................................................................................... 41 
9.6.1. 
Surgery and/or Radiotherapy for Locoregionally Recurrent 
Breast Cancer .......................................................................................................... 42 
9.6.2. 
Radiotherapy  .......................................................................................................... 42 
9.6.3. 
Supportive Care  ...................................................................................................... 42 
9.6.4. 
Growth Factors ........................................................................................................ 42 
9.6.5. 
Supportive Management for Diarrhea ..................................................................... 43 
9.6.6. 
Bisphosphonates and RANK-L Targeted Agents ................................................... 43 
9.7. 
Treatment Compliance  .................................................................................................... 43 
9.7.1. 
Patient Diaries  ............................................................................................................. 44 
10. 
Efficacy, Health Outcome/Quality-of-Life Measures, Safety 
Evaluations, Sample Collection and Testing, and Appropriateness of 
Measurements  ...................................................................................................................... 45 
10.1. 
Efficacy Measures  .......................................................................................................... 45 
10.1.1. 
Efficacy Assessments at Baseline and during Study                                     Treatment 
 ................................................................................................................................  45 
10.1.2. 
Efficacy Assessments during Postdiscontinuation Follow-Up ............................... 46 
10.1.3. 
Primary Efficacy Measure....................................................................................... 46 
10.1.4. 
Secondary Efficacy Measures ................................................................................. 47 

13Y-MC-JPBM(a) Clinical Protocol 
Page 9 
LY2835219 
 
 
 
10.1.5. 
Exploratory Measures ............................................................................................. 48 
10.2. 
Health Outcome/Quality-of-Life Measures ..................................................................... 49 
100.2.1. 
Patient-Reported Outcomes .................................................................................... 49 
100.2.1.1. 
Health-Related Quality of Life ................................................................ 49 
100.2.1.2. 
Health Status ........................................................................................ 50 
100.2.2. 
Resource Utilization ................................................................................................ 50 
10.3. 
Safety Evaluations ........................................................................................................... 50 
100.3.1. 
Adverse Events  ....................................................................................................... 51 
100.3.1.1. 
Serious Adverse Events  .......................................................................... 52 
100.3.1.2. 
Suspected Unexpected Serious Adverse Reactions ........................................... 53 
100.3.2. 
Other Safety Measures ............................................................................................ 54 
100.3.2.1. 
Electrocardiograms .................................................................................. 54 
100.3.3. 
Safety Monitoring ................................................................................................... 54 
100.3.4. 
Complaint Handling ................................................................................................ 55 
10.4. 
Sample Collection and Testing ........................................................................................ 55 
100.4.1. 
Samples for Study Qualification and Health Monitoring ........................................ 55 
100.4.2. 
Samples for Biomarkers .......................................................................................... 56 
100.4.2.1. 
Archived Tumor Tissue ........................................................................... 56 
100.4.2.2. 
Blood Samples for Pharmacogenetic Evaluations  ............................................ 57 
100.4.2.3. 
Plasma Samples for Exploratory Biomarker Evaluations  ................................. 57 
100.4.3. 
Samples for Drug Concentration Measurements 
Pharmacokinetics .................................................................................................... 57 
10.5. 
Appropriateness of Measurements .................................................................................. 58 
1. 
Data Quality Assurance  ........................................................................................................ 59 
1.1. 
Data Capture System  ...................................................................................................... 59 
12. 
Sample Size and Statistical Methods .................................................................................... 60 
12.1. 
Determination of Sample Size  ........................................................................................ 60 
12.2. 
Statistical and Analytical Plans  ...................................................................................... 60 
12.2.1. 
12.2.2. 
12.2.3. 
General Considerations  ...........................................................................................60 
Patient Disposition  ..................................................................................................61 
Patient Characteristics  .............................................................................................61 
12.2.4. 
Concomitant Therapy  ............................................................................................. 61 
12.2.4.1. 
Postdiscontinuation Therapy  .............................................................................61 
12.2.5. 
Treatment Compliance  ........................................................................................... 62 
12.2.6. 
Primary Outcome and Methodology ....................................................................... 62 
12.2.7. 
Secondary Outcomes and Methodology ................................................................. 64 
12.2.7.1. 
Overall Survival ...................................................................................... 64 

13Y-MC-JPBM(a) Clinical Protocol 
Page 10 
LY2835219 
 
 
 
12.2.7.2. 
Objective Response Rate, Disease Control Rate, and 
Clinical Benefit Rate ..........................................................................................64 
12.2.8. 
Sensitivity Analysis ..........................................................................................65 
12.2.9. 
Pharmacokinetic and Pharmacodynamic Analyses ..........................................66 
12.2.10. Biomarker Analyses .........................................................................................66 
12.2.11. Health Outcome/Quality-of-Life Analyses ......................................................66 
12.2.11.1. Health-Related Quality of Life ................................................................ 66 
12.2.11.2. Resource Utilization ................................................................................ 67 
12.2.11.3. Health State Utility .................................................................................. 67 
12.2.12. Safety Analyses ................................................................................................67 
12.2.13. Subgroup Analyses ..........................................................................................68 
12.2.14. Interim Analyses ..............................................................................................69 
12.2.14.1. Safety Interim Analyses .......................................................................... 69 
12.2.14.2. Efficacy Interim Analyses ....................................................................... 69 
12.2.14.3. Pharmacokinetic/Pharmacodynamic Interim Analyses  .....................................70 
13. 
Informed Consent, Ethical Review, and Regulatory Considerations  ....................................71 
13.1. 
Informed Consent .............................................................................................................71 
13.2. 
Ethical Review ..................................................................................................................71 
13.3. 
Regulatory Considerations ...............................................................................................71 
13.3.1. 
Investigator Information...................................................................................72 
13.3.2. 
Protocol Signatures ..........................................................................................72 
13.3.3. 
Final Report Signature  ....................................................................................72 
14. 
References .............................................................................................................................73 

13Y-MC-JPBM(a) Clinical Protocol 
Page 11 
LY2835219 
 
 
 
List of Tables 
Table 
Page 
Table JPBM.9.1. 
Treatment Regimens/Dosing Schedule ..................................................... 34 
Table JPBM.9.2. 
Toxicity Dose Adjustments and Delays of Blinded Study Drug for 
Study JPBM .............................................................................................. 37 
Table JPBM.9.3. 
Dose Adjustments for Blinded Study Drug .............................................. 38 
Table JPBM.10.1. 
Secondary Efficacy Endpoints .................................................................. 48 
Table JPBM.10.2. 
Exploratory Measures ............................................................................... 48 
Table JPBM.10.3. 
Adverse Event and Serious Adverse Event Reporting Guidelines  .......... 51 
Table JPBM.12.1. 
Rules for Determining Date of Progression or Censor for 
Progression-Free Survival ......................................................................... 63 

13Y-MC-JPBM(a) Clinical Protocol 
Page 12 
LY2835219 
 
 
 
List of Figures 
Figure 
Page 
Figure JPBM.8.1. 
Illustration of study design. ....................................................................... 29 
Figure JPBM.8.2. 
Study period and continued access period diagram  .................................. 31 

13Y-MC-JPBM(a) Clinical Protocol 
Page 13 
LY2835219 
 
 
 
List of Attachments 
Attachment 
Page 
Attachment 1. 
Protocol JPBM Study Schedule .................................................................76 
Attachment 2. 
Protocol JPBM Clinical Laboratory Tests .................................................85 
Attachment 3. 
Protocol JPBM Hepatic Monitoring Tests for Treatment-Emergent 
Abnormality ...............................................................................................86 
Attachment 4. 
Protocol JPBM ECOG Performance Status ...............................................87 
Attachment 5. 
Protocol JPBM RECIST Criteria 1.1 .........................................................88 
Attachment 6. 
Protocol JPBM Sampling Summary ..........................................................95 
Attachment 7. 
Protocol JPBM Electrocardiogram and Pharmacokinetic Sampling 
Schedule .....................................................................................................96 
Attachment 8. 
Protocol JPBM Inducers, Strong Inhibitors of CYP3A, or 
Substrates of CYPs with Narrow Therapeutic Range  ...............................97 
Attachment 9. 
Protocol JPBM CTCAE 4.03 Diarrhea Definition  ....................................98 
Attachment 10. 
Protocol JPBM Amendment (a) Summary   A Randomized, 
Double-Blind, Placebo-Controlled, Phase 3 Study of Nonsteroidal 
Aromatase Inhibitors (Anastrozole or Letrozole) plus LY2835219, 
a CDK4/6 Inhibitor, or Placebo in Postmenopausal Women with 
Hormone Receptor-Positive, HER2-Negative Locoregionally 
Recurrent or Metastatic Breast Cancer with No Prior Systemic 
Therapy in this Disease Setting  .................................................................99 

13Y-MC-JPBM(a) Clinical Protocol 
Page 14 
LY2835219 
 
 
 
4. Abbreviations and Definitions 
 
Term 
Definition 
 
 
AE 
Any untoward medical occurrence in a patient or clinical investigation subject 
administered a pharmaceutical product and that does not necessarily have a causal 
relationship with this treatment.  An adverse event can therefore be any unfavorable and 
unintended sign (including an abnormal laboratory finding), symptom, or disease 
temporally associated with the use of a medicinal (investigational) product, whether or 
not related to the medicinal (investigational) product. 
 
ALT 
alanine aminotransferase 
 
ANC 
absolute neutrophil count 
 
ASCO 
American Society of Clinical Oncology 
 
AST 
aspartate aminotransferase 
 
audit 
A systematic and independent examination of the trial-related activities and documents 
to determine whether the evaluated trial-related activities were conducted, and the data 
were recorded, analyzed, and accurately reported according to the protocol, applicable 
standard operating procedures (SOPs), good clinical practice (GCP), and the applicable 
regulatory requirement(s). 
A procedure in which one or more parties to the trial are kept unaware of the treatment 
blinding/masking 
 
 
 
 
 
 
 
 
 
 
 
CAP 
CBR 
CDK 
C1 
assignment(s).  Unless otherwise specified, blinding will remain in effect until final 
database lock. 
A single-blind study is one in which the investigator and/or his staff are aware of the 
treatment but the patient is not, or vice versa, or when the sponsor is aware of the 
treatment but the investigator and/his staff and the patient are not. 
A double-blind study is one in which neither the patient nor any of the investigator or 
sponsor staff who are involved in the treatment or clinical evaluation of the patients are 
aware of the treatment received. 
 
College of American Pathologists 
clinical benefit rate 
cyclin-dependent kinase 
confidence interval 
CNS 
central nervous system 

13Y-MC-JPBM(a) Clinical Protocol 
Page 15 
LY2835219 
 
 
 
 
collection database 
A computer database where clinical trial data are entered and validated. 
 
complaint 
A complaint is any written, electronic, or oral communication that alleges deficiencies 
related to the identity, quality, purity, durability, reliability, safety or effectiveness, orr 
performance of a drug or drug delivery system. 
 
compliance 
Adherence to all the trial-related requirements, good clinical practice (GCP) 
requirements, and the applicable regulatory requirements. 
 
continued access 
period 
The period between study completion and end of trial during which patients on 
study therapy who continue to experience clinical benefit may continue to receive 
study therapy until one of the criteria for discontinuation is mett.. 
 
CR 
complete response 
 
CRF/eCRF 
case report form/electronic case report form 
Sometimes referred to as clinical report form:  A printed or electronic form for 
recording study participants' data during a clinical study, as required by the protocol. 
 
CRP 
clinical research physician 
Individual responsible for the medical conduct of the study.  Responsibilities of the 
CRP may be performed by a physician, clinical research scientist, global safety 
physician, or other medical officer. 
 
CSR 
clinical study report 
 
CT 
computed tomography 
 
CTCAE 
Common Terminology Criteria for Adverse Events 
 
CTS 
 
 
 
 
 
 
DCR 
DMC 
DoR 
change in tumor size 
A measure of tumor dynamics from which tumor response is derived.  Tumor size is the 
sum of tumor measurements across all target tumors at a given evaluation (RECIST 
criteria). 
 
disease control rate 
 
Data Monitoring Committee 
duration of response 
ECG 
electrocardiogram 
 
ECOG 
Eastern Cooperative Oncology Group 

13Y-MC-JPBM(a) Clinical Protocol 
Page 16 
LY2835219 
 
 
 
 
end of trial 
End of trial is the date of the last visit or last scheduled procedure for the last patient. 
 
enroll 
The act of assigning a patient to a treatment.  Patients who are enrolled in the trial are 
those who have been assigned to a treatment. 
 
enter 
Patients entered into a trial are those who sign the informed consent form. 
 
EORTC QLQ-BR23 
European Organization for Research and Treatment of Cancer Quality off Life 
Questionnaire-Breast Cancer 
 
EORTC QLQ-C30 
European Organization for Research and Treatment of Cancerr Quality of Life 
Questionnaire-Core 30 
 
EQ-5D 5L 
EuroQol 5-Dimension 5 Level 
 
ER+ 
estrogen receptor-positive 
 
ERB/1RB 
ethical review board/institutional review board 
A board or committee (institutional, regional, or national) composed of medical and 
nonmedical members whose responsibility is to verify that the safety, welfare, and 
human rights of the patients participating in a clinical trial are protected. 
 
GCP 
good clinical practice 
 
H0 
null hypothesis 
 
Ha 
alternative hypothesis 
 
HER2- 
human epidermal growth factor receptor 2-negative 
 
H1V 
human immunodeficiency virus 
 
HR+ 
hormone receptor-positive 
 
1B 
 
1CF 
 
1CH 
 
1HC 
Investigator's Brochure 
informed consent form 
International Conference on Harmonisation 
immunohistochemistry 

13Y-MC-JPBM(a) Clinical Protocol 
Page 17 
LY2835219 
 
 
 
 
1nformed consent 
A process by which a patient voluntarily confirms his or her willingness to participate  in 
a particular trial, after having been informed of all aspects of the trial that are relevant to 
the patient's decision to participate. Informed consent is documented by means of a 
written, signed, and dated informed consent form. 
 
interim analysis 
An interim analysis is an analysis of clinical trial data, separated into treatment groups, 
that is conducted before the final reporting database is created/locked. 
 
investigational 
product 
A pharmaceutical form of an active ingredient or placebo being tested or used as 
a reference in a clinical trial. 
 
investigator 
A person responsible for the conduct of the clinical trial at a trial site.  If a trial is 
conducted by a team of individuals at a trial site, the investigator is the responsible 
leader of the team and may be called the principall investigator. 
 
1RC 
Internal Review Committee 
 
1TT 
intention-to-treat 
The principle that asserts that the effect of a treatment policy can be best assessed by 
evaluating on the basis of th   intention to treat a patient (that is, the planned treatment 
regimen) rather than the actual treatment given.  It has the consequence that 
patients allocated to a treatment group should be followed up, assessed, and 
analyzed as members of that group irrespective of their compliance to the planned 
course of treatment. 
 
1WRS 
interactive web-response system 
 
legal representative 
An individual, judicial, or other body authorized under applicable law to consent on 
behalf of a prospective patient to the patient's participation in the clinical study. 
 
Lilly Safety System 
Global safety database that tracks and reports serious adverse and spontaneous events 
occurring while using a drug/drug delivery system. 
 
LLT 
 
mBC 
MedDRA 
L wer Level Term 
metastatic breast cancer 
Medical Dictionary for Regulatory Activities 
MR1 
magnetic resonance imaging 
 
N  1 
National Cancer Institute 
 
NSA1 
nonsteroidal aromatase inhibitor 

13Y-MC-JPBM(a) Clinical Protocol 
Page 18 
LY2835219 
 
 
 
 
ORR 
objective response rate 
 
OS 
overall survival 
 
patient 
A study participant who has the disease or condition for which the investigational 
product is targeted. 
 
PD 
progressive disease 
 
PET 
positron emission tomography 
 
PFS 
progression-free survival 
 
PgR 
progesterone receptor 
 
PK 
pharmacokinetic 
 
PR 
partial response 
 
PS 
performance status 
 
PT 
Preferred Term 
 
QTc 
corrected QT interval 
 
randomize 
the processs of assigning patients to an experimental group on a random basis 
 
RANK-L 
receptor activator of nuclear factor kappa-B ligand 
 
Rb 
REC1ST 
retinoblastoma 
 
Response Evaluation Criteria in Solid Tumors 
reporting database 
A point-in-time copy of the collection database.  The final reporting database is used to 
produce the analyses and output reports for interim or final analyses of data. 
 
re-screen 
to screen a patient who was previously declared a screen failure for the same study 
 
SAE 
SAP 
serious adverse event 
Statistical Analysis Plan 

13Y-MC-JPBM(a) Clinical Protocol 
Page 19 
LY2835219 
 
 
 
 
screen 
The act of determining if an individual meets minimum requirements to become part of 
a pool of potential candidates for participation in a clinical study. In this study, 
screening involves invasive or diagnostic procedures and/or tests (for example, 
diagnostic psychological tests, X-rays, blood draws). For this type of screening, 
informed consent for these screening procedures and/or tests shall be obtained; this 
consent may be separate from obtaining consent for the study. 
 
screen failure 
patient who does not meet one or more criteria required for participation in a trial 
 
SD 
stable disease 
 
SMD 
Senior Management Designee 
 
SOC 
System Organ Class 
 
study completion 
This study will be considered complete after the final analysis/evaluation of overall 
survival is performed. 
 
SUSARs 
suspected unexpected serious adverse reactions 
 
TEAE 
treatment-emergent adverse event 
Any untoward medical occurrence that either occurs or worsens at any time after 
treatment baseline and that does not necessarily have to have a causal relationship 
with this treatment. 
 
ULN 
upper limit of normal 
 
VAS 
visual analog scale 

13Y-MC-JPBM(a) Clinical Protocol 
Page 20 
LY2835219 
 
 
 
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 
Study of Nonsteroidal Aromatase 1nhibitors (Anastrozole or 
Letrozole) plus LY2835219, a CDK4/6 1nhibitor, or Placebo in 
Postmenopausal Women with Hormone Receptor-Positive, 
HER2-Negative Locoregionally Recurrent or Metastatic 
Breast Cancer with No Prior Systemic Therapy in this 
Disease Setting 
5. 1ntroduction 
Breast cancer is one of the most common cancers in women.  In 2012, there were approximately 
1.7 million new cases of breast cancer worldwide; since 2008, the worldwide incidence of breast 
cancer has increased by more than 20% and mortality has increased by 14% (Bray et al. 2013; 
Ferlay et al. 2013).  While early stage disease is treatable, patients with metastatic breast cancer 
(mBC) have a median overall survival (OS) of only 2 to 3 years (Cardoso et al. 2012). The 
treatment for women diagnosed with hormone receptor positive (HR+) mBC includes endocrine 
therapy.  In postmenopausal women, aromatase inhibitors (including anastrozole and letrozole) 
are recommended for the initial treatment of mBC, if not used in the adjuvant setting or if 
discontinued for at least 12 months (Cardoso et al. 2012).  However, de novo or acquired 
resistance to adjuvant endocrine therapy and metastatic breast cancer remains an important 
clinical challenge. 
Cyclin D1 interacts with cyclin-dependent kinases 4 and 6 (hereafter CDK4 and CDK6) in an 
active protein complex that promotes cell proliferation (Velasco-Velazquez et al. 2011).  Many 
HR+ breast cancers demonstrate an intact retinoblastoma tumor suppressive function, however, 
overexpression of cyclin D1 protein by oncogenic signaling occurs in approximately 30% to  
50% of cancers.  Cyclin D1 is regarded as the most frequently overexpressed gene in primary 
breast cancer, with amplification of the encoding gene, CCND1, occurring in approximately 15% 
of breast cancers (Casimiro et al. 2014).  Therefore, CDK4 and CDK6 represents a potential 
therapeutic target for HR+ breast cancer. Consequently, further evaluation of CDK4 and CDK6 
inhibitorss to improve clinical outcomes for women with HR+ breast cancer is warranted. 
During the cell cycle, the G1 restriction point controls entry into S phase and is essential for 
proper regulation of cell proliferation (Sherr 1996; Ortega et al. 2002). CDK4 and CDK6 
participates in a complex with the D-type cyclins to initiate progression through the 
G1 restriction point. The CDK4 and CDK6 - cyclin D1 complex regulates the G1 restriction 
point through phosphorylation and inactivation of the retinoblastoma (Rb) tumor suppressor 
protein, thereby promoting S phase entry.  Alterations in this pathway occur frequently in human 
cancers and involve: 1) loss of functional CDK inhibitors through deletion or epigenetic 
silencing; 2) activating mutations and/or overexpression of CDK4 and CDK6 or the D-type 
cyclins; and 3) loss of functional Rb through mutation or deletion. Except for tumors with 
functional loss of Rb, which functions downstream of the CDK4 and CDK6 - cyclin D1 
complex, most cancers are potentially sensitive to pharmacologic inhibition of CDK4 and 

13Y-MC-JPBM(a) Clinical Protocol 
Page 21 
LY2835219 
 
 
 
CDK6. From a therapeutic standpoint, the goal of inhibiting CDK4 and CDK6 with a small 
molecule is to prevent cell cycle progression through the G1 restriction point, thus arresting 
tumor growth. 
LY2835219 represents a selective and potent small molecule inhibitor of CDK4 and CDK6 wiith 
acceptable physical characteristics, pharmacokinetic (PK) properties, and safety profile in 
nonclinical species.  There may be important opportunities to tailor therapy with LY2835219 for 
patients with breast cancer.  Specifically, studies with LY2835219 indicate differential 
sensitivity to CDK4 and CDK6 inhibition based on histological and genetic 
characteristics. Growth inhibition in vitro across a diverse panel of 46 breast cancer cell lines, 
representing the known molecular subgroups of breast cancer, indicates that sensitivity to CDK4 
and CDK6 inhibition is greater in ER+ breast cancers with luminal histology.  In accordance 
with the known biology of CDK4 and CDK6, the results also indicate that many of these 
sensitive cell lines are also characterized as having amplification of CCND1, which is the gene 
that encodes cyclin D1.  These results are consistent with previous studies which demonstrate 
that effective induction of G1 cell cycle arrest by LY2835219 is dependent upon the presence of 
Rb. 
Findings from the Phase 1 Study JPBA indicate that the LY2835219 single-agent maximum 
tolerated dose of 200 mg administered orally every 12 hours demonstrates an acceptable safety 
profile.  LY2835219 has demonstrated evidence of clinical activity in women with mBC at doses 
of both 150 mg and 200 mg every 12 hours.  Additionally, preliminary analysis of PK data from 
Study JPBA for LY2835219 as a single agent at 150 mg and 200 mg every 12 hours indicates 
that the range of steady-state exposures is comparable for the 2 doses.  In Study JPBA, 47 
patients with a median of 7 priorr systemic regimens received therapy with LY2835219. In the 
mBC cohort, the most common treatment-emergent adverse events (TEAEs) possibly related to 
study drug included diarrhea, nausea, fatigue, neutropenia, and vomiting.  Among 36 patients 
with HR+ mBC receiving LY2835219, there were 9 patients with confirmed partial responses 
(PR) for an objective response rate of 25%.  Further, in these 36 patients, the clinical benefit rate 
(CBR; PR + stablle disease [SD] 2'24 weeks) was 61%, and the disease control rate (DCR; [PR + 
SD]) was 80.6%.  A total of 14 patients were continuing treatment at the time of analysis 
(Patnaik et al. 2014). 
Study JPBA findings support further investigation of LY2835219 in combination with standard 
endocrine therapy for women with HR+ locoregionally recurrent or metastatic breast cancer. 
Non-steroidal aromatase inhibitors (NSAI, anastrazole and letrozole) are approved and 
commonly used endocrine therapy in the first-line setting for postmenopausal women with HR+ 
mBC.  The evaluation of LY2835219 in combination with an NSAI is of interest since both 
classes of drugs have acceptable and distinct safety profiles. Safety and tolerability of 
LY2835219 in combination with endocrine therapies (including anastrozole and letrozole) are 
being further evaluated in patients with HR+, HER2- mBC, in an ongoing Phase 1b study, I3Y- 
MC-JPBH (JPBH).  As of 21 July 2014, 35 patients received at least one dose of combination 
therapy (20 with letrozole, 15 with anastrazole). Preliminary safety data from Study JPBH have 
shown a consistent adverse event profile for LY2835219 administered at 200 mg every 12 hours 

13Y-MC-JPBM(a) Clinical Protocol 
Page 22 
LY2835219 
 
 
 
in combination with NSAI as was observed in the Study JPBA mBC single-agent cohort. 
However, at the 200 mg dose, the incidence of treatment-emergent Grade 3 diarrhea was greater 
in combination with NSAI than when LY2835219 was administered alone (25.7% and 13.6%, 
respectively). Clinical and PK findings from the single-agent Phase 1 Study JPBA and 
preliminary safety data from the LY2835219/NSAI combination in Study JPBH support 150 mg 
every 12 hours as the recommended dose for LY2835219 in Study I3Y-MC-JPBM (JPBM). 
The current Phase 3 Study JPBM will evaluate the clinical safety and efficacy of NSAI plus 
LY2835219 or placebo in postmenopausal women with HR+, HER2- locoregionally recurrent 
(not amenable to curative therapy) or metastatic breast cancer who have not previously received 
systemic therapy in this disease setting. 
More information about the known and expected benefits and risks of LY2835219 may be found 
in the Investigator's Brochure (IB). Information on AEs expected to be related to the 
LY2835219 may be found in Section 7 (Development Core Safety Information) of the IB. 
Information on serious adverse events (SAEs) expected in the study population independent of 
drug exposure and that will be assessed by the sponsor in aggregate, periodically during the 
course of the study, may be found in Section 6 (Effectss in Humans) of the IB. 
More detailed information about the known and expected benefits and risks of anastrozole or 
letrozole may be found in the following:  Patient Information Leaflet, Package Insert, or 
Summary of Product Characteristics. 
5.1. Rationale for Amendment (a) 
Study JPBM protocol was amended to update the dosing guidance for cases of hematologic 
toxicity and diarrhea and guidance on the use of blood cell growth factors.  Lilly conducted a 
review across several clinical trials of abemaciclib in breast cancer and concluded that there were 
some inconsistencies.  This amendment will harmonize the dosing guidance and clarify that 
blood cell growth factors are only to be used in a manner consistent with American Society of 
Clinical Oncology (ASCO) guidelines. 
Further modifications were performed for clarity with supportive management for diarrhea and 
coadministration with substrate drugs of CYPs with narrow therapeutic margin. 
Furthermore, the statistical analysis plan (SAP) was updated.  The number of events required to 
perform the final PFS analysis was decreased from 312 events to 270 events based on the 
following rationale.  The results of PALOMA-1 (palbociclib + letrozole vs letrozole) and 
PALOMA-3 (palbociclib + fulvestrant vs fulvestrant) indicate the effect of CDK 4 and 6 
inhibitors in combination with endocrine therapy may have a larger effect than was originally 
assumed during the development of this protocol.  As a result, the assumed hazard ratio has been 
changed from 0.714 (corresponding to an increase in median PFS from 10 months to 14 months) 
to 0.67 (increase in median PFS from 10 months to 15 months). In addition, the interim analysis 
boundaries, timing of interim analyses, and OS analysis plan were modified. 
Minor typographical and formatting edits were made throughout the document for clarity and 
consistency. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 23 
LY2835219 
 
 
 
 
 
6.1. Primary Objective 
6. Objectives 
The primary objective of this study is to compare treatment with LY2835219 plus NSAI therapy 
versus placebo plus NSAI therapy with respect to PFS in postmenopausal women with HR+, 
HER2- locoregionally recurrent or metastatic breast cancer who have not received priorr systemic 
therapy in this disease setting. 
 
6.2. Secondary Objectives 
The secondary objectives of the study are to compare the combination treatment of LY2835219 
and NSAI therapy versus placebo plus NSAI therapy with respect to the following: 
 OS; 
 OS rate at 1, 2, and 3 years; 
 ORR (CR + PR); 
 duration of response (CR + PR); 
 DCR (CR + PR + SD); 
 CBR (CR + PR + SD 2'6 months); 
 the safety and tolerability; 
 change in symptom burden from baseline using the EORTC QLQ-C30, EORTC 
QLQ-BR23 (breast) questionnaire, and health status scores from the EQ-5D 5L; and 
 the PK of LY2835219, its metabolites, and NSAI therapy. 
 
6.3. Exploratory Objectives 
 To explore potential biomark rs related to the mechanism of action of LY2835219, 
the cell cycle, and/or the pathogenesis of breast cancer. 
 To explore change in tumor size. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 24 
LY2835219 
 
 
 
7. Study Population 
Individuals who do not initially meet the criteria for participation in this study (screen failure) 
may be re-screened (Section 7.2.1). 
Study participants should be instructed not to donate blood or blood products during the study or 
for 2 weeks following the last dose of study drug. 
Prospective approval of protocol deviations to recruitment and enrollment criteria (also known as 
protocol waivers or exemptions) is not permitted. 
 
7.1. 
1nclusion Criteria 
Patients are eligible to be included in the study only if they meet all off the following criteria: 
[1] 
have a diagnosis of HR+, HER2- breast cancer.  Although not required as a 
protocol procedure, metastatic disease should be considered for biopsy 
whenever possible to reassess HR and HER2 status if clinically indicated. 
• 
To fulfill the requirement for HR+ disease, a breast cancer must express, 
by immunohistochemistry (IHC), at least one of the hormone receptors 
(ER, progesterone receptor [PgR]) as defined in the relevant American 
Society of Clinical Oncology (ASCO)/College of American Pathologists 
(CAP) Guidelines (Hammond et al. 2010). 
• 
To fulfill the requirement of HER2- disease, a breast cancer must not 
demonstrate, at initial diagnosis or upon subsequent biopsy, 
overexpression of HER2 by either IHC or in-situ hybridization (ISH) as 
defined in the relevant ASCO/CAP guidelines (Wolff et al. 2013). 
[2] 
have locoregionally recurrent disease not amenable to resection or radiation 
therapy with curative intent or m  tastatic disease 
[3] 
have postmenopausal status, defined as meeting one of the following 
conditions: 
• 
Prior bilateral o phorectomy 
• 
Age 2'60 y ars 
• 
Age <60 years and amenorrheic (non-treatment-induced amenorrhea 
sec  ndary to tamoxifen, toremifene, ovarian suppression, or 
chemotherapy) for at least 12 months. Follicle-stimulating hormone 
(FSH) and estradiol must be in the postmenopausal range. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 25 
LY2835219 
 
 
 
[4] 
have one of the following as defined by the RECIST v1.1 (Eisenhauer et al. 
2009; refer to Attachment 5): 
• 
Measurable disease 
• 
Nonmeasurable bone-only disease. Nonmeasurable bone-only disease 
may include any of the following: blastic bone lesions, lytic bone 
lesions without a measurable soft tissue component, or mixed lytic- 
blastic bone lesions without a measurable soft tissue component. 
[5] 
have a PS of :S1 on the ECOG scale (see Attachment 4) 
[6] 
have adequate organ function, including: 
 hematologic:  absolute neutrophil count (ANC) 1.5 x 109/L, platelets 
100 x 109/L, and hemoglobin 8 g/dL.  Patients may receive erythrocyte 
transfusions to achieve this hemoglobin level at the discretion of the 
investigator; however, initial study drug treatment must not begin earlier 
than the day after the erythrocyte transfusion. 
 hepatic:  bilirubin 1.5 times the upper limit of normal (ULN) and alanine 
aminotransferase (ALT) and aspartate aminotransferase (AST) 3.0 times 
ULN (or ALT and AST :S5 times ULN if liver metastases are present). 
 renal:  serum creatinine 1.5 times ULN. 
[7] 
have discontinued previous localized radiotherapy for palliative purposes or 
for lytic lesions at risk of fracture at least 2 weeks prior to randomization and 
recovered from the acute effects of therapy (until the toxicity resolves to either 
baseline or at least Grade 1) except for rresidual alopecia or peripheral 
neuropathy. 
[8] 
are female and 2'18 years of age 
[9] 
are able to swallow capsules 
[10] 
have given written informed consent prior to any study-specific procedures 
[1] 
are reliable, willing to be available for the duration of the study, and are 
willing to follow study procedures. 
 
7.2. Exclusion Criteria 
Patients will be excluded from the study if they meet any of the following criteria: 
[12] have visceral crisis, lymphangitic spread, or leptomeningeal carcinomatosis. 
Visceral crisis is not the mere presence of visceral metastases but implies 
severe organ dysfunction as assessed by symptoms and signs, laboratory 
studies, and rapid progression of the disease. 
[13] have inflammatory breast cancer. 
[14] have clinical evidence or a history of CNS metastasis. Screening is not 
required for enrollment. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 26 
LY2835219 
 
 
 
[15] are currently receiving or have previously received endocrine therapy for 
locoregionally recurrent or metastatic breast cancer. [Note: A patient may be 
enrolled if she received prior (neo)adjuvant endocrine therapy (including , but 
not limited to anti-estrogens or aromatase inhibitors) for localized disease. In 
addition, a patient may be enrolled if she has received :S2 weeks of NSAI in 
this disease setting immediately preceding screening and agrees to discontinue 
NSAI until study treatment initiation.] 
[16] have received prior (neo)adjuvant endocrine therapy (e.g., anti-estrogens or 
aromatase inhibitors) with a disease-free interval :S12 months from completion 
of treatment. 
[17] are currently receiving or have previously received chemotherapy for 
locoregionally recurrent or metastatic breast cancer.  [Note:  Patients may be 
enrolled if they received prior (neo)adjuvant chemotherapy for localized 
disease.] 
[18] have received prior treatment with everolimus 
[19] have received prior treatment with any CDK4 and CDK6 inhibitor (or 
participated in any CDK4 and CDK6 inhibitor clinical trial for which 
treatment assignment is still blinded) 
[20] have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted 
agents (for example, denosumab) <7 days prior to randomization 
[21] are currently receiving an investigational drug in a clinical trial or 
participating in any other type of medical research judged not to be 
scientifically or medically compatible with this study.  If a patient is currently 
enrolled in a clinical trial involving non-approved use of a device, then 
agreement with the investigator and Lilly clinical research physician (CRP) is 
required to establish eligibility. 
[22] have received treatment with a drug that has not received regulatory approval 
for any indication within 14 or 21 days of randomization for a 
nonmyelosuppressive or myelosuppressive agent, respectively. 
[23] have had major surgery within 14 days prior to randomization to allow for 
post-operative healing of the surgical wound and site(s). 
[24] have received recent (within 28 days prior to randomization) yellow fever 
vaccination. 
[25] have serious preexisting medical conditions that, in the judgment of the 
investigator, would preclude participation in this study (for example, history 
of major surgical resection involving the stomach or small bowel, or 
preexisting Crohn's disease or ulcerative colitis). 
[26] have a personal history within the last 12 months of any of the following 
conditions: syncope of cardiovascular etiology, ventricular tachycardia, 
ventricular fibrillation, or sudden cardiac arrest. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 27 
LY2835219 
 
 
 
[27] have a history of any other cancer (except non-melanoma skin cancer or 
carcinoma in-situ of the cervix), unless in complete remission with no therapy 
for a minimum of 3 years. 
[28] have received an autologous or allogeneic stem-cell transplant. 
[29] have active bacterial or fungal infection or detectable viral infection (for 
example, human immunodeficiency virus [HIV] or viral hepatitis).  Screening 
is not required for enrollment. 
 
7.2.1. Rescreening 
A patient who fails screening is allowed to screen again after signing a new informed consent 
form (ICF) and will be assigned a new patient number under the conditions specified in this 
section. 
The following patients may be eligible for rescreening if any of the following circumstances: 
 Patients who have become eligible to enroll in the study as the result of a protocol 
amendment. 
 Patient status has changed such that the eligibility criterion that caused the patient 
to screen fail would no longer cause the patient to screen fail again. 
 Patients who complete screening and meet all inclusion and exclusion 
requirements but are unable to be enrolled due to extenuating circumstances (such 
as, severe weather, death in family, child illness). 
The investigator should contact the Lilly CRP prior to rescreening a patient. 
 
7.3. Discontinuations 
7.3.1. Discontinuation of Patients 
The criteria for enrollment must be followed explicitly.  If the investigator site identifies a patient 
who did not meett enrollment criteria and who was inadvertently enrolled, the sponsor must be 
notified.  If the sponsor identifies a patient who did not meet enrollment criteria and who was 
inadvertently enrolled, the investigator site will be notified.  A discussion must occur between  
the sponsor CRP and the investigator to determine whether the patient may continue in the study, 
with or without study drug.  Inadvertently enrolled patients may be maintained in the study and 
on study drug when the Lilly CRP agrees with the investigator that it is medically appropriate for 
that patient.  The patient may not continue in the study with or without study drug if the Lilly 
CRP does not agree with the investigator's determination it is medically appropriate for the 
patient to continue.  The investigator must obtain documented approval from the Lilly CRP to 
allow the inadvertently enrolled patient to continue in the study with or without study drug. 
In addition, patients will be discontinued from the study treatment (that is, blinded study drug 
and/or NSAI) and/or from the study in the following circumstances: 
 progressive disease (PD) as defined by RECIST v1.1 

13Y-MC-JPBM(a) Clinical Protocol 
Page 28 
LY2835219 
 
 
 
 enrollment in any other clinical trial involving an investigational drug or enrollment 
in any other type of medical research judged not to be scientifically or medically 
compatible with this study 
 investigator decision 
o the investigator decides that the patient should be discontinued from the study 
or study treatment 
o if the patient, for any reason, requires treatment with another therapeutic agent 
that has been demonstrated to be effective for treatment of the study 
indication, discontinuation from the study treatment occurs prior to 
introduction of the new agent 
 patient decision 
o the patient or the patient's designee (for example, legal guardian) reque ts to 
be withdrawn from the study or study treatment 
 sponsor decision 
o Lilly stops the study or stops the patient'ss participation in the study for 
medical, safety, regulatory, or other reasons consistent with applicable laws, 
regulations, and good clinical practice (GCP) 
The reason and date of discontinuation will be collected for all patien s. All randomized patients 
who discontinue regardless of whether or not they received study d ug, will have procedures 
performed as shown in the Study Schedule (Attachment 1). 
 
7.3.2. Discontinuation of Study Sites 
Study site participation may be discontinued if Lilly, t  e investigator, or the ethical review board 
(ERB) of the study site judges it necessary for medical, safety, regulatory, ethical, or other 
reasons consistent with applicable laws, regulations, and GCP. 
7.3.3. Discontinuation of the Study 
The study will be discontinued if Lilly judges it necessary for medical, safety, regulatory, ethical, 
or other reasons consistent with applicable laws, regulations, and GCP. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 29 
LY2835219 
 
 
 
8. 1nvestigational Plan 
8.1. Summary of Study Design 
Study JPBM is a multicenter, randomized, double-blind, placebo-controlled, Phase 3 study 
evaluating treatment of LY2835219 with NSAI or placebo with NSAI in postmenopausal women 
with HR+, HER2- locoregionally recurrent (not amenable to curative therapy) or  metastatic 
breast cancer who have not received prior systemic therapy in this disease setting . 
Figure JPBM.8.1 illustrates the study design. 
 
 
Abbreviations:  HER2- = human epidermal growth factor receptor 2-negative; HR+ = hormone receptor- 
positive; N = number; NSAI = nonsteroidal aromatase inhibitor; PD = progressive disease. 
 
Figure JPBM.8.1. 
1llustration of study design. 
Approximately 450 patients will be randomized 2:1 between the 2 arms: 
 Experimental Arm A: LY2835219 150 mg orally every 12 hours on Days 1 to 28 plus 
either anastrozole 1 mg or letrozole 2.5 mg once daily of a 28-day cycle 
 Control (Placebo) Arm B: Placebo orally every 12 hours on Days 1 to 28 plus either 
anastrozole 1 mg or letrozole 2.5 mg once daily of a 28-day cycle 
Patients will be randomized using the following stratification factors:  nature of disease (visceral 
metastases versus bone-only metastases versus other) and prior (neo)adjuvant endocrine therapy 
(aromatase inhibitor therapy versus other versus no prior endocrine therapy).  The presence of 
visceral metastases refers to lung, liver, pleural, peritoneal, or adrenal gland involvement at the 
time of randomization. Prior (neo)adjuvant endocrine therapy refers to aromatase inhibitor 
therapy (e.g., anastrozole, exemestane and letrozole) vs. other (e.g., tamoxifen and fulvestrant) 
vs. no prior endocrine therapy. 
Database lock for the interim analyses for efficacy will occur when approximately 189 and 
230 investigator-assessed PFS events have been observed. Database lock for the final analysis of 
the PFS endpoint will occur when approximately 270 investigator-assessed PFS events have 

13Y-MC-JPBM(a) Clinical Protocol 
Page 30 
LY2835219 
 
 
 
been observed. The final analysis of OS will occur when approximately 315 OS events have 
been observed. All patients will be followed for survival information until death or study 
completion, whichever comes first. 
Terms used to describe the periods during the study are defined below: 
 Baseline:  begins when the ICF is signed and ends at the first study treatment dose (or at 
discontinuation, if no treatment is given).  This may be up to 28 days prior to the first 
study treatment dose. 
 Study Period:  begins at the first study treatment dose and ends at study completion. 
The study period does not include the continued access period. 
o Study Treatment Period:  begins at the first study treatment dose and ends when 
the patient and the investigator agree that the patient will no longer continue study 
treatment.  This date is to be reported on the electronic case report form (eCRF) as 
the Date of Discontinuation from study treatmentt. 
 Postdiscontinuation Follow-Up:  begins the day after the patient and the investigator 
agree that the patient will no longer continue study treatment. 
o Short-term follow-up begins the day after the patient and the investigator agree 
that the patient will no longer continue study treatment and lasts approximately 
30 days. 
o Long-term follow-up begins the day after short-term follow-up is completed and 
continues until the patient's death or overall study completion. 
 Continued Access Period:  begins after study completion and ends at the end of trial. 
During the continued access period, patients on study treatment who continue to 
experience clinical benefit may continue to receive study treatment (except placebo) until 
one of the criteria for discontinuation is met. 
o The continued access period includes continued access period short-term follow- 
up. 
o Continued access short-term follow-up:  begins the day after the patient and the 
investigator agree that the patient will no longer continue treatment in the 
continued access period and lasts approximately 30 days. 
 
8.1.1. Study Completion and End of Trial 
This study will be considered complete (that is, the scientific evaluation will be complete [study 
completion]) following the evaluation of final OS data (refer to Figure JPBM.8.2) as determined 
by Lilly.  Investigators will continue to follow the study schedule for all patients until notified by 
Lilly that study completion has occurred. 
"End of ttrriial" refers to the date of the last visit or last scheduled procedure for the last patient. 
The end of trial occurs after study completion and after the last patient has discontinued study 
treatment and completed continued access period follow-up (Figure JPBM.8.2). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 31 
LY2835219 
 
 
 
 
 
Abbreviations:  OS = overall survival; PFS = progression-free survival. 
 
Figure JPBM.8.2. 
Study period and continued access period diagram. 
 
8.1.2. Continued Access Period 
After study completion, all patients who are on study treatment and who are eligible for the 
continued access period will be unblinded.  Patients receiving study treatment and experiencing 
ongoing clinical benefit may continue to receive study treatment in the continued access period 
until one of the criteria for discontinuation is met (Section 7.3.1).  During the continued access 
period, placebo will no longer be administered, and crossover will not be permitted.  Lilly will 
notify investigators when the continued access period begins. 
Patients who are in short-term follow-up when the continued access period begins will continue 
in short-term follow-up until the 30-day short-term follow-up visit is completed.  Long-term 
follow-up does not apply. 
Patients who are in long-term follow-up when the continued access period begins will be 
discontinued from long-term follow-up. 
During the continued access period, all AEs, SAEs, and study drug exposure will be reported on 
the CRF.  Serious adverse events will also be reported to Lilly Global Patient Safety (see Section 
10.3.1).  In the event that an SAE occurs, Lilly may request additional information (such as local 
laboratory results, concomitant medications, and hospitalizations) in order to evaluate the 
reported SAE. 
a 
Lilly will notify sites when this begins and ends. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 32 
LY2835219 
 
 
 
Investigators will perform any other standard procedures and tests needed to treat and evaluate 
patients; however, the choice and timing of the tests will be at the investigator's discretion. Lilly 
will not routinely collect the results of these assessments. 
8.2. Discussion of Design and Control 
A randomized, controlled design is being used in this study. Randomization minimizes 
systematic bias in the selection and assignment of patients to study therapy and provides 
justification for inferential statistical methods to be used on data from this study. Using an 
appropriate concurrent control arm enables direct statistical estimation of benefiittss and harms due 
to study therapy and minimizes bias in the assessment and interpretation of observed treatment 
effects.  Patients will be stratified for differences in factors thought to be associated with clinical 
outcomes to further reduce the potential for bias and improve the power of the analyses. 
Assessment of bias is further minimized by the use of a double blind and placebo control (see 
Section 9.3). 
Investigational treatment administration in this study is double-blind; that is, patients, 
investigational sites, and the sponsor study team do not have immediate access to investigational 
treatment assignments for any patients.  This design feature minimizes potential bias due to 
knowledge of patient's treatment during evaluation of study endpoints, at the patient level or 
aggregated across patients. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 33 
LY2835219 
 
 
 
9. Treatment 
9.1. Treatments Administered 
The following treatments will be administered in this study: 
 Experimental Arm A:  LY2835219 150 mg orally every 12 hours plus either anastrozole 
1 mg or letrozole 2.5 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle. 
 Control (Placebo) Arm B:  Placebo orally every 12 hours plus either anastrozole 1 mg or 
letrozole 2.5 mg orally every 24 hours on Days 1 to 28 of a 28-day cycle. 
Blinded study drug is defined as LY2835219 or placebo. Study treatment iss defined as blinded 
study drug and/or NSAI. 
The specific NSAI (anastrozole or letrozole) administered to patients is determined by the 
investigator.  Patients should remain on the same NSAI throughout the study.  In exceptional 
cases, in the absence of evidence of PD, the investigator may discuss a change in NSAI with the 
Lilly CRP.  NSAI is a co-administered standard-of-care treatment.  The investigator should refer 
to the NSAI label (that is, Patient Information Leaflet, Package Insert, or Summary of Product 
Characteristics).  Table JPBM.9.1 shows the treatment regimens. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 34 
LY2835219 
 
 
y 12 hours on Days 1 
PO every 24 hours on 
or 
2.5 mg PO 
 
Table JPBM.9.1. 
Treatment Regimens/Dosing Schedule 
Regimen 
Period/Cycle 
Dose Day 
Experimental Arm A 
LY2835219 
Treatment/28-day cycle 
150 mg PO every 12 hours on Days 1-28a 
 
 
Anastrozole 
or      
Letrozole 
Control (Placebo) Arm B 
 
Treatment /28-day cycle 
1 mg PO every 24 hours on Days 1-28b 
or 
2.5 mg PO every 24 hours on Days 1-28b 
 
 
Abbreviations:  ECG = electrocardiogram; PK = pharmacokinetic; NSAI = nonsteroidal aromatase inhibitor; PO 
= orally. 
a On Cycle 1 Day 1 only, patients should take one single dose of blinded study drug and initiate chronic every- 
12-hours dosing on Cycle 1, Day 2. 
b For PK and ECG purposes, NSAI should be administered at the ssame time (or up to 20 minutes after) the 
morning dose of blinded study drug through Cycle 4, Day 1.  Subsequently, the interval between administration 
of blinded study drug and NSAI may be adjusted based on the judgment of the investigator. 
The investigator or his/her designee is responsib e for the following: 
 explaining the correct use of the drugs and planned duration of each individual's 
treatment to the patient/site personnel/legal representative, 
 verifying that instructions are followed properly, 
 maintaining accurate records of study drug dispensing and collection (including the co- 
administered NSAI doses taken by the patient), 


Note: 
and returning all unused medication supplied by Lilly to Lilly or its designee at the end of 
the study. 
In some cases, sites may destroy the material if, during the investigator site selection, the 
evaluator has verified and documented that the site has appropriate facilities and written 
procedures to dispose of clinical trial materials. 
Patients will be instructed to contact the investigator as soon as possible if they have a complaint 
or problem with the study drug so that the situation can be assessed. 
 
9.2. Materials and Supplies 
LY2835219 or placebo (blinded study drug) will be supplied as capsules for oral administration. 
Blinded study drug capsules should be stored according to the product label, and not opened, 
Placebo 
Treatment/28-day cycle 
Anastrozole 
or 
Letrozole 
PO every   2 hours 
Days 1-28a 
1 mg PO every 24 hours 
Days 1-28b 
Treatment /28-day cycle 
2.5 mg PO every 24 hours on Days 1-28b 

13Y-MC-JPBM(a) Clinical Protocol 
Page 35 
LY2835219 
 
 
 
crushed, or dissolved. Blinded study drug will be labeled according to the country's regulatory 
requirements. 
Where required, letrozole and anastrazole will be supplied by Lilly and labeled according to 
country regulatory requirements.  Letrozole and anastrazole should be stored according to the 
product label and will be provided as anastrazole 1-mg or letrozole 2.5-mg tablets. 
Investigators should instruct patients to store the blinded study drug and NSAI in the original 
package provided and in a location inaccessible to children. 
9.3. Method of Assignment to Treatment 
Upon obtaining informed consent, site personnel should access the interactive web response 
system (IWRS) which will assign a patient number.  Patients who meet all criteria for enrollment 
will be randomly assigned to receive either LY2835219 or placebo.  Assignment to treatment 
groups will be determined by a computer-generated random sequence using the IWRS.  Sites 
will be prompted to enter the specific NSAI at time of randomization. 
Randomization will be stratified by the following:  nature of disease (visceral metastases versus 
bone-only metastases versus other), and prior (neo)adjuvant endocrine therapy (aromatase 
inhibitor therapy versus other versus no prior endocrine therapy). 
The IWRS will be used to assign LY2835219 or placebo and distribute NSAI supplied by Lilly. 
Site personnel will confirm that they have located the correct sstudy medication packages by 
entering a confirmation number found on the packages into the IWRS. 
The period between randomization to blinded study drug and the first dose (Cycle 1, Day 1) 
should not exceed 7 days. 
 
9.4. Selection and Timing of Doses 
Blinded study drug will be taken orally every 12 (±2) hours on Days 1 through 28 of a 28-day 
cycle, for a total of 56 doses per cycle. During all cycles, blinded study drug should be taken at 
approximately the same times each day. If a patient misses or vomits a blinded study drug dose, 
that dose should be omitted. 
Anastrozole or letrozole will be administered orally every 24 hours (±2) on Days 1 through 28 of 
a 28-day cycle for a total of 28 doses per cycle.  For PK and electrocardiogram (ECG) purposes, 
anastrozole or letrozole should be administered at the same time as (or up to 20 minutes after) 
the morning dose of blinded study drug through Cycle 4, Day 1. Subsequently, the interval 
between admin stration of blinded study drug and anastrozole or letrozole may be adjusted based 
on the judgment of the investigator.  If a patient misses or vomits an anastrozole or letrozole 
dose, tha  dose should be omitted. 
A cycle is defined as an interval of 28 days plus any subsequent delay prior to start of the next 
c  cle.  A delay in the start of a cycle due to holidays, weekends, bad weather, or other 
unforeseen circumstances will be permitted up to 7 days and not counted as a protocol 
deviation). For each 28-day cycle, a total of 56 doses of blinded study drug will be dispensed. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 36 
LY2835219 
 
 
 
In exceptional cases, for planned delays (including but not limited to vacation or holidays), 
additional study treatment may be dispensed. 
A patient may continue to receive study treatment until she meets 1 or more of the specified 
reasons for discontinuation (as described in Section 7.3.1). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 37 
LY2835219 
 
 
 
9.4.1. Special Treatment Considerations 
9.4.1.1. Dose Adjustments and Delays 
 
Table JPBM.9.2. 
Toxicity Dose Adjustments and Delays of Blinded Study Drug for 
Study JPBM 
 
Toxicity Type 
Toxicity Profile and Severity 
Dose Suspension 
Dose Reduction 
Hematologic Toxicity 
Section 9.4.1.1.3 
Grade 3 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2. 
Dose MAY be reduced 
by 1 dose level - 
investigator's discretion. 
Hematologic Toxicity 
Section 9.4.1.1.3 
Recurrent Grade 3 
Dose MUST be suspended 
until toxicity resolvess to at 
least Grade 2. 
Dose MUST be reduced 
by 1 dose level. 
Hematologic Toxicity 
Section 9.4.1.1.3 
Grade 4 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2. 
Dose MUST be 
reduced by 1 dose level. 
Hematologic toxicity: Patient 
Regardless of severity 
Dose MUST be suspended 
Dose MUST be reduced 
requires administration of 
blood cell growth factors 
Sections 9.4.1.1.3 and 9.6.4 
(Growth factors use according to 
ASCO Guidelines) 
for at least 48 hours after 
the last dose of blood cell 
growth factors was 
by 1 dose level unless 
already performed for 
incidence of toxicity that 
administered and until 
lead to the use of growth 
toxicity resolves to at least 
factor. 
Grade 2 
Nonhematologic Toxicity 
(except diarrhea) 
Section 9.4.1.1.4 
Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 7 days 
to baseline or Grade 1 
Dose MAY be suspended 
until toxicity resolves to 
either baseline or Grade 1. 
Dose MAY be reduced 
by 1 dose level - 
investigator's discretion. 
Nonhematologic Toxicity 
Section 9.4.1.1.4 
Grade 3 or 4 
Dose MUST be suspended 
until toxicity resolves to 
either baseline or Grade 1. 
Dose MUST be reduced 
by 1 dose level. 
Diarrhea 
Section 9.4.1.1.4.1 
Requires hospitalization or Grade 3 
or 4 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 1. 
Dose MUST be reduced 
by 1 dose level. 
Diarrhea 
Section 9.4.1.1.4.1 
Persistent or recurrent Grade 2 that 
does not resolve with maximal 
supportive measures within 
24 hours to at least Grade 1 
Dose SHOULD be 
suspended until toxicity 
resolves to at least Grade 1. 
Dose MAY be reduced 
by 1 dose level - 
investigator's discretion. 
Diarrhea 
Section 9.4.1.1.4.1 
Diarrhea recurs despite maximal 
supportive measures after resuming 
same dose level after initial 
Grade 2 diarrhea 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 1. 
Dose MUST be reduced 
by 1 dose level. 
Abbreviation:  ASCO = American Society of Clinical Oncology. 
Note: MAY = per the investigator's clinical judgment; SHOULD = not mandatory but highly recommended; 
MUST = mandatory. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 38 
LY2835219 
 
 
 
9.4.1.1.1. Dose Adjustments 
 
9.4.1.1.1.1. 
Blinded Study Drug 
Blinded study drug dose adjustments as outlined in Table JPBM.9.3 are allowed both within a 
cycle and between cycles.  Blinded study drug must be reduced sequentially by one dose level. 
For patients requiring dose reduction(s), any re-escalation to a prior dose level is permitted only 
after consultation with the Lilly CRP. 
Table JPBM.9.3. 
Dose Adjustments for Blinded Study Drug 
 
Dose Adjustment Level 
Oral Dose 
Frequency 
0 
150 mg 
Every 12 hours 
1 
100 mg 
Every 12 hours 
2 
50 mg 
Every 12 hours 
 
 
Blinded study drug must be discontinued if further dose reduction is required b  yond 50 mg 
every 12 hours.  In the event that blinded study drug must be discontinued, a patient may 
continue to receive anastrozole or letrozole. 
 
9.4.1.1.1.2. 
Anastrozole or Letrozole 
Per NSAI labels, dose adjustment for anastrozole or letrozole is not applicable, as only a single- 
dose strength is approved for each medication.  In exceptional cases in the absence of evidence 
of PD, the investigator may discuss a change in the specific NSAI administration (for example, 
switching from anastrozole to letrozole) with the Lilly CRP.  In the event that anastrozole or 
letrozole must be discontinued,, a patient may continue to receive blinded study drug per the 
investigator's clinical judgment. 
9.4.1.1.2. 
Dose Suspension (within a Cycle) and Cycle Delay 
Both dose suspension (within a cycle) and cycle delay are permitted.  When a dose suspension or 
cycle delay occurs related to toxicity (defined as an AE possibly related to study treatment per 
investigator judgment), the blinded study drug and/or NSAI may be suspended or delayed as 
determined by the investigator's judgment. 
Study treatment may be h  ld up to 14 days within a cycle or at start of next cycle to permit 
sufficient time for recovery from the toxicity.  If a dose suspension occurs within a cycle, the 
investigator may resume blinded study drug dosing at the same dose level for the remainder of 
the cycle or at reduced dose (assuming resolution to at least Grade 1 for non-hematological and 
at least Grade 2 for hematological toxicity). If the patient experiences the same toxicity with the 
same or greater severity (CTCAE grade) requiring a dose suspension within a cycle or at start of 
the next cycle, the patient must be dose reduced and not re-challenged a second time at the prior 
dos  level. 
Patients not recovering from toxicity within 14 days should be considered for discontinuation of 
the blinded study drug and/or co-administered NSAI. In exceptional circumstances, a delay >14 

13Y-MC-JPBM(a) Clinical Protocol 
Page 39 
LY2835219 
 
 
 
days is permitted upon agreement between the investigator and the Lilly CRP and blinded study 
drug dose adjustment is to be considered. 
In the event of a cycle delay due to logistical reasons (for example, due to patient availability), 
the patient should continue on study treatment if the patient has adequate drug supply. If a 
patient's treatment is interrupted as a result of not having sufficient drug supply, the cycle may 
be delayed up to 7 days (and not be considered a protocol violation). In exceptional 
circumstances, a delay >7 days is permitted upon agreement between the investigator and the 
Lilly CRP. 
The start of a cycle may be delayed, or a current cycle interrupted, to allow a patient with a 
locoregionally recurrent breast cancer rendered operable by study treatment to receive surgery  
radiotherapy.  For additional information, refer to Section 9.6.1. 
9.4.1.1.3. 
Hematologic Toxicity 
If a patient experiences Grade 4 hematologic toxicity, then dosing must be suspended (until the 
toxicity resolves to at least Grade 2) and the dose of blinded study drug must be reduced by one 
dose level as outlined in Table JPBM.9.3. 
If a patient experiences Grade 3 hematologic toxicity, then dosing must be suspended (until the 
toxicity resolves to at least Grade 2) and the dose of blinded study d ug may be reduced by one 
dose level as outlined in Table JPBM.9.3 at the discretion of the investigator. If the patient 
experiences a recurrent episode of Grade 3 hematologic toxicity, then dosing must be suspended 
(until the toxicity resolves to at least Grade 2) and the dose of blinded study must be reduced by 
1 dose level. 
If a patient requires administration of blood cell growth factors, the dose of study drug must be 
suspended for at least 48 hours after the last dose of blood cell growth factors was administered 
and until toxicity resolves to at least Grade 2 then reduced by 1 dose level, if a dose reduction for 
the specific event necessitating the use of the growth factors has not already occurred. 
Before the start of each cycle, hematologic toxicity must resolve to at least Grade 2. 
 
9.4.1.1.4. 
Nonhematological Toxicity 
If a patient experiences 2'Grade 3 nonhematologic toxicity, then blinded study drug and/or NSAI 
dosing must be suspended (until the toxicity resolves to either baseline or at least Grade 1) and 
the dose of blinded study drug must be reduced by one dose level as outlined in Table JPBM.9.3. 
If a patient experiences persistent or recurrent Grade 2 nonhematologic toxicity (except diarrhea; 
refer to Section 9.4.1.1.4.1) that does not resolve with maximal supportive measures within 
7 days to e ther baseline or at least Grade 1, then blinded study drug and/or NSAI dosing may be 
suspend  d (until the toxicity resolves to either baseline or at least Grade 1) and the dose of 
blinded study drug may be reduced by one dose level as outlined in Table JPBM.9.3 at the 
discretion of the investigator. 
Before the start of each cycle, nonhematologic toxicity (except alopecia and fatigue) must 
resolve to either baseline or at least Grade 1. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 40 
LY2835219 
 
 
 
 
9.4.1.1.4.1. 
Diarrhea 
A patient experiencing diarrhea requiring hospitalization (irrespective of grade, that is, requiring 
intravenous [IV] rehydration) or severe diarrhea (Grade 3 or 4; see Attachment 9) must have 
study treatment suspended (until the toxicity resolves to at least Grade 1) and must have the 
blinded study drug dose reduced by one dose level as outlined in Table JPBM.9.3. 
If a patient experiences persistent or recurrent Grade 2 diarrhea that does not resolve with 
maximal supportive measures (refer to Section 9.6.5) within 24 hours to at least Grade 1, then 
study treatment should be suspended (until the toxicity resolves to at least Grade 1) and the dose 
of blinded study drug may be reduced by one dose level as outlined in Table JPBM.9.3 at the 
discretion of the investigator. If the same dose level was resumed and diarrhea recurs despite 
maximal supportive measures, the dose of blinded study drug must be reduced by one dose level 
as outlined in Table JPBM.9.3 
 
9.5. Blinding 
This is a double-blind study. 
To preserve the blinding of the study, a minimum number of Lilly personnel will see the 
randomization table and treatment assignments before the study is complete.  Access to 
unblinded data/documents will be controlled by restricting access to the data/documents in 
Lilly's data and statistical warehouse.  Any changes to this unblinding plan may be described in 
a protocol amendment, the SAP, and/or a separate unblinding plan document. 
Efficacy information will not be shared between sites until the study is completed.  Upon overall 
study completion (see Section 8.1.1), investigators may unblind patients to study treatment 
assignment. 
9.5.1. Unblinding at lnterim Analyses 
Interim analyses for safety and efficacy will be conducted, using unblinded data, under the 
guidance of an independent Data Monitoring Committee (DMC).  The DMC will consist of at 
least 3 members, including at least 1 clinician and 1 statistician.  The DMC will communicate 
any recommendations based on interim analysis to the Lilly Senior Management Designee 
(SMD).  If necessary, the SMD may form an Internal Review Committee (IRC) to review and act 
upon the recommendations of the DMC. See Section 12.2.14 for details on the conduct of 
interim analyses. 
 
9.5.2. Emergency Unblinding 
In case of an emergency, the investigator has the sole responsibility for determining if unblinding 
of a patient's treatment assignment is warranted.  Patient safety must always be the first 
consideration in making such a determination.  If the investigator decides that unblinding is 
war anted, the investigator should make every effort to contact the Lilly CRP prior to unblinding 
a patient's treatment assignment unless this could delay emergency treatment of the patient. If a 
patient's treatment assignment is unblinded, Lilly must be notified immediately. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 41 
LY2835219 
 
 
 
Emergency unblinding for AEs must be performed through the IWRS. This option may be used 
ONLY if the patient's acute well-being requires knowledge of the patient's treatment assignment 
or if a patient discontinues treatment due to disease progression based upon RECIST 1.1 (see 
Attachment 5) and knowledge of the patient's treatment assignment is deemed essential to the 
selection of the patient's next treatment regimen. In the case of disease progression, the 
investigator must consult with the Lilly CRP prior to unblinding. 
All calls resulting in an unblinding event are recorded and reported by the IWRS. Iff the 
investigator or patient becomes unblinded, that patient will be discontinued from study treatment 
and will undergo postdiscontinuation follow-up (Attachment 1).  Long-term follow up 
procedures will be followed until death or study completion. 
 
9.5.3. lnadvertent Unblinding 
Every effort will be made to blind both the patient and the investigator to the identity of the 
treatment, but the inadvertent unblinding of a patient may occur.  A double-blind study design is 
known to be imperfect in the oncolytic setting because the potential for individual unblinding 
exists due to treatment-related signs and symptoms.  If an investigator, site personnel performing 
assessments, or patient is unblinded, the unblinding will not be sufficient cause (in and of itself) 
for that patient to be discontinued from study therapy or excluded from any safety or efficacy 
analyses. 
Additionally, there may be ethical reasonss to have the patient remain on the study treatment. For 
patients to continue on study treatment in the event of unblinding, the investigator must obtain 
specific approval from a Lilly CRP for the patient to continue in the study. 
 
9.6. Concomitant Therapy 
Appropriate documentation of all forms of premedications, supportive care, and concomitant 
medications must be captured at each visit in the eCRF.  Concomitant medications and 
supportive care therapies must also be documented at the time of discontinuation and at the 30- 
day short-term follow-up visit. 
With the exceptions listed in the sections below, therapies for cancer (including hormonal 
anticancer therapies, chemotherapy, and immunotherapy) will not be permitted while patients are 
on study treatment.  Use of megestrol acetate as an appetite stimulant is not permitted. 
The results from an in vitro human recombinant cytochrome P450 (CYP) phenotyping study 
indicate that oxidative metabolism of LY2835219 is primarily catalyzed by CYP3A. 
Radiolabeled human disposition study indicates that LY2835219 is mostly cleared by oxidative 
metabolism and therefore inhibitors and or inducers of CYP3A may alter the metabolism of 
LY2835219.  Based on these findings, grapefruit juice as well as inducers (for example, 
phenytoin or carbamazepine) and strong inhibitors of CYP3A should be substituted or avoided if 
possible (Attachment 8).  All patients may receive supportive therapy with dexamethasone, 
preferably :S7 days, if clinically indicated. Patients requiring more than 7 days of dexamethasone 
therapy will not incur a protocol deviation. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 42 
LY2835219 
 
 
 
In addition, in vitro studies in cultured human hepatocytes indicate that abemaciclib and its 
major metabolites LSN2839567 and LSN3106726 down regulate mRNA of 1 or more CYPs, 
including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2D6, and CYP3A, at clinically relevant 
concentrations. The mechanism of down regulation and its clinical relevance are presently not 
understood.  Therefore, care should be taken when coadministering substrate drugs of the above 
CYPs with narrow therapeutic margin (Attachment 8). 
9.6.1. Surgery and/or Radiotherapy for Locoregionally Recurrent 
Breast Cancer 
A patient with locoregionally recurrent breast cancer may receive surgery  radiotherapy if study 
treatment renders the tumor operable. However, such a patient should not receive study 
treatment for the period beginning at least 7 days prior to surgery and continuing until at least 
14 days after completion of surgery  radiotherapy to allow for tissue healing and recovery. 
There is no restriction on the duration of this period without study treatment and, after this period 
ends, study treatment may resume. Importantly, a patient who receives surgery  radiotherapy 
for locoregionally recurrent breast cancer is not considered noncompliant and does not incur a 
protocol deviation. 
 
9.6.2. Radiotherapy 
Except as described in Section 9.6.1, radiotherapy is not permitted without permanent 
discontinuation from study treatment.  Except for a patient w th locoregionally recurrent breast 
cancer rendered operable by study treatment who subsequ  ntly undergoes surgery + 
radiotherapy, all other patients requiring radiotherapy should discontinue permanently from 
study treatment and have a tumor assessment of the lesion(s) before receiving radiotherapy. 
9.6.3. Supportive Care 
Patients should receive full supportive car   to maximize quality of life.  Patients will receive 
supportive care as judged by their treating physician.  If it is unclear whether a therapy should be 
regarded as supportive care, the investigator should consult the Lilly CRP.  Use of any 
supportive care therapy should be reported on the eCRFs. 
 
9.6.4. Growth Factors 
Growth factors should not be administered to enable a patient to satisfy study inclusion criteria. 
Growth factors may be administered in accordance with ASCO guidelines (Smith et al. 2015). 
Dosing of blinded study drug must be suspended if the administration of growth factors is 
required and must not be recommenced within 48 hours of the last dose of growth factors having 
been administered.  Following the administration of growth factors, the dose of blinded study 
drug must be reduced by 1 dose level, if a dose reduction for the specific event necessitating the 
use of the growth factors has not already occurred. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 43 
LY2835219 
 
 
 
9.6.5. Supportive Management for Diarrhea 
At randomization, patients should receive instructions on the management of diarrhea. In the 
event of diarrhea, supportive measures should be initiated as early as possible. These include the 
following: 
 At the first sign of loose stools, the patient should initiate anti-diarrheal therapy (e.g., 
loperamide) and notify the investigator for further instructions and appropriate follow-up. 
 Patients should also be encouraged to drink fluids (e.g., 8 to 10 glasses of clear liquids 
per day). 
 Site personnel should assess response within 24 hours. 
 If diarrhea does not resolve with anti-diarrheal therapy within 24 hours to at least 
Grade 1, blinded study drug should be suspended until diarrhea is resolved to at least 
Grade 1. 
 When blinded study drug recommences, dosing should be adjusted as outlined in 
Section 9.4.1.1.4.1 and Table JPBM.9.3. 
In severe cases of diarrhea, the measuring of neutrophil counts and body temperature and 
proactive management of diarrhea with antidiarrheal agents should be considered. 
If diarrhea is severe (requiring IV rehydration) and/or associated with fever or severe 
neutropenia, broad-spectrum antibiotics such as fluoroquinolones must be prescribed. 
Patients with severe diarrhea or any diarrhea associated with severe nausea or vomiting should 
be carefully monitored and given intravenous fluid (IV hydration) and electrolyte replacement. 
9.6.6. Bisphosphonates and RANK-L Targeted Agents 
Patients with bone metastases present on baseline imaging should be appropriately treated with 
bisphosphonates or RANK-L targeted agents (for example, denosumab), per respective approved 
labels.  Initiation of treatment with bone-modifying agents must begin at least 7 days prior to 
randomization.  Patients receiving bisphosphonates or RANK-L targeted agents should not 
switch treatments (for example, replace a bisphosphonate with denosumab) while on study 
treatment.  However, exceptional cases without evidence of PD may be considered in 
consultation with the Lilly CRP.  These exceptional cases will not incur a protocol deviation. 
 
9.7. Treatment Compliance 
Treatment compliance information for study treatment will be collected through patient dosing 
diaries and/or capsule/tablet counts at each visit, with the number of capsules/tablets taken 
relative to the number expected to be taken summarized for each cycle. The patient must take 
2'75% of the planned doses for study treatment in a cycle to be deemed compliant.  As outlined 
in Section 9.4.1.1.2, dose suspensions or delays may occur and will not result in a patient being 
conssidered as noncompliant. A patient may be considered noncompliant if she is judged by the 
investigator to have intentionally or repeatedly taken 2'125% of the planned doses of study 
treatment in a cycle. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 44 
LY2835219 
 
 
 
Importantly, a patient who receives surgery  radiotherapy for locoregionally recurrent breast 
cancer is not considered noncompliant and does not incur a protocol deviation. For additional 
information, refer to Section 9.6.1. 
Potential discontinuation of a patient due to study drug noncompliance will be discussed between 
the investigator and the Lilly CRP before any determination is made to discontinue the patient. 
9.7.1. Patient Diaries 
The study will include patient diaries to provide dosing instructions, help patients with treatment 
planning, and track actual doses of study treatment taken by the patient.  Information from the 
diaries may be used for documenting study treatment compliance as well as dosing time relative 
to PK blood draws and ECG collection. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 45 
LY2835219 
 
 
 
10. Efficacy, Health Outcome/Quality-of-Life Measures, 
Safety Evaluations, Sample Collection and Testing, 
and Appropriateness of Measurements 
Written informed consent must be obtained prior to any study-specific pretreatment evaluations. 
Study procedures related to efficacy, safety, health outcome/quality-of-life measures, sample 
collection and testing assessments and their timing are described in the sections below and 
shown in the Study Schedule (Attachment 1). 
10.1. Efficacy Measures 
10.1.1. Efficacy Assessments at Baseline and durring Study Treatment 
Within 28 days of randomization, baseline tumor assessments will be performed for each patient. 
The method of assessment used at baseline must be used consistently for serial tumor assessment 
throughout the study.  Bone scintigraphy will be performed for all patients at baseline (within 28 
days of randomization).  However, prior bone scintigraphy (obtained as pa t of routine clinical 
care) within 45 days before Day 1 of Cycle 1 is also acceptable. 
must be submitted for central review. 
All tumor assessment images 
For all patients, imaging studies (computed tomography [CT], including spiral CT, or magnetic 
resonance imaging [MRI] scan of the chest, abdomen, and pelvis) will be performed locally at 
baseline and repeated between Day 21 and Day 28 of eve y second cycle beginning with Cycle 2 
and continuing through Cycle 18 (inclusive), between Day 21 and 28 of every third cycle after 
Cycle 18, and within 14 days of clinical progression per the Study Schedule (Attachment 1). It is 
recommended that CT imaging of the abdomen and pelvis be performed with IV contrast, 
whenever possible. For patients with known hypersensitivity to CT contrast material, a CT scan 
of the chest without contrast and gadolinium-enhanced MRI of the abdomen and pelvis are 
encouraged. The CT portion of a positron emission tomography (PET)-CT scan may be used as a 
method of response assessment if the site can document that the CT is of identical diagnostic 
quality to a diagnostic CT (with IV and oral contrast).  A PET scan alone or as part of a PET-CT 
may be performed as part of r 
to RECIST v1.1. 
utine clinical care but cannot be used to assess response according 
For all patients, bone scintigraphy will be performed locally at baseline and repeated between 
Day 21 and Day 2  of every sixth cycle beginning with Cycle 6.  In addition, bone scans should 
be repeated even if a complete response in target disease is identified or progression in bone is 
suspected.  For patients with new lesions identified by post-baseline bone scintigraphy, targeted 
assessment by X-ray, CT scan with bone windows, or MRI will be performed to confirm 
findings. 
F  r only those patients with bone lesions identified by bone scintigraphy at baseline, directed 
imaging using one of the following methods will be performed at baseline: X-ray, CT scan with 
bone windows, or MRI. Directed imaging using the same method as at the baseline bone lesion 

13Y-MC-JPBM(a) Clinical Protocol 
Page 46 
LY2835219 
 
 
 
assessment should be repeated between Day 21 and Day 28 of every second cycle beginning 
with Cycle 2 and continuing through Cycle 18 (inclusive), between Day 21 and Day 28 of every 
third cycle after Cycle 18, and within 14 days of clinical progression. 
For patients with locoregionally recurrent breast cancer not amenable to curative treatment, MRI 
scan of the breast will be performed at baseline, if applicable. Breast MRI, if applicable, will be 
repeated between Day 21 and Day 28 of every second cycle beginning with Cycle 2 and 
continuing through Cycle 18 (inclusive), between Day 21 and Day 28 of every third cycle after 
Cycle 18, and within 14 days of clinical progression. 
For patients with visible tumor (such as skin lesions), photography will be performed at baseline 
and each photographic image of the tumor should include a ruler.  Photography should be 
repeated on Day 1 of every second cycle beginning with Cycle 3 and continuing through C cle 
19 (inclusive), on Day 1 of every third cycle after Cycle 19, and within 14 days of clini  al 
progression. Photographic images may be taken more frequently based upon the dis 
the investigator or following the identification of new skin lesions post-baseline. 
retion of 
For patients continuing treatment during the Continued Access Period (after study completion), 
efficacy assessments (frequency and type of assessments) will be at the discretion of the 
investigator. 
10.1.2. Efficacy Assessments during Postdiscontinuation Follow-Up 
Postdiscontinuation follow-up during the study period will be conducted as described in the 
Study Schedule (Attachment 1). 
For those patients who are randomized and never receive study treatment or those who 
discontinue study treatment without objectively m  asured PD, the investigative sites will 
continue to monitor patients and periodically evaluate tumor response approximately every 
8 weeks for the first 18 months following randomization and thereafter approximately every 
12 weeks by the same method used at baseline and throughout the study until the patient has 
objective disease progression, or until the final analysis of PFS.  In addition, anticancer therapies 
initiated after study treatment discontinuation will be collected during this follow-up period. 
After the patient has objective disease progression, radiologic imaging and photographic images 
are no longer required and the patient will be followed up approximately every 12 weeks until 
the patient's death or overall study completion. 
Lilly will continue to collect survival data on all patients but may reduce data collection for other 
efficacy data.  Lilly will notify investigators when this reduced data collection can begin. 
10.1.3. Primary Efficacy Measure 
The primary efficacy measure is PFS as defined by [RECIST v1.1 (Eisenhauer et al. 2009)] 
provided in Attachment 5. 
Lilly or its designee will collect and store all tumor assessment images on all enrolled patients 
throughout the study. An independent review of a randomly selected subset of patient scans will 
be performed by independent panel of radiologists (Section 12.2.8). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 47 
LY2835219 
 
 
 
The PFS time is measured from the date of randomization to the date of objective progression or 
the date of death due to any cause, whichever is earlier. 
For those patients with nonmeasurable, bone-only disease (refer to Inclusion Criterion [4]), 
objective progression will be established if at least 1 of the following criteria is met: 
 the appearance of 1 or more new lesions (in bone or outside of bone), or 
 unequivocal progression of existing bone lesions. 
According to RECIST v1.1, the finding of a new lesion should be unequivocal and not 
attributable to findings thought to represent something other than tumor (for example, some 
'new' bone lesions may be simply healing or flare of preexisting lesions).  Pathologic fracture, 
new compression fracture, or complications of bone metastases will not be considered as 
evidence of disease progression, unless at least 1 of the above criteria is met. 
For those patients with locoregionally recurrent disease for whom surgery is performed with no 
evidence of residual disease post-operatively, objective progression will be established if at least 
1 of the following criteria is met: 
 local and/or regional recurrence, or 
 new development of metastatic disease. 
For those patients with locoregionally recurrent disease for whom surgery is performed while on 
study with evidence of residual disease post-operatively, new baseline measurements should be 
taken and RECIST applied. 
If a patient is not known to have progressed or died at the time of analysis, PFS time will be 
censored at the last known progression-free assessment.  See Section 12.2.6 for detailed 
censoring rules. 
 
10.1.4. Secondary Efficacy Measures 
The following secondary efficacy measures (Table JPBM.10.1) will be collected at the times 
shown in the Study Schedule (Attachment 1). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 48 
LY2835219 
 
 
 
Table JPBM.10.1. 
Secondary Efficacy Endpoints 
 
Endpoint 
Definition 
Overall Survival (OS) 
The time from the date of study randomization to the date of death from any cause 
Objective Response Rate 
The proportion of patients with CR or PR according to RECIST v1.1 
Disease-Control Rate (DCR) 
The proportion of patients with CR, PR, or SD according to RECIST v1.1 
Clinical Benefit Rate (CBR) 
The proportion of patients with CR, PR, or SD 2'6 months according to 
RECIST v1.1 
Duration of Response (DoR) 
The time from the date of first evidence of a confirmed CR or PR to the date 
of objective progression (according to RECIST v1.1) or death from any cause, 
whichever is earlier 
Abbreviations:  CR = complete response; PR = partial response; PS = performance status; RECIST = 
Response Evaluation Criteria in Solid Tumors; SD = stable disease. 
Overall Survival (OS): OS duration is measured from the date of randomization of any study 
drug to the date of death from any cause. For each patient who is not known to have died as of 
the data-inclusion cutoff date for a particular analysiiss,, OS will be censored for that analysis at 
the last known alive date. 
Objective Response Rate (ORR): The objective response rate is the percentage of patients with 
a best response of CR or PR. 
Duration of Response (DoR): The DoR time is defined only for responders (patients with a 
confirmed CR or PR).  It is measured from the date of first evidence of CR or PR to the date of 
objective progression or the date of death due to any cause, whichever is earlier.  For clarity, the 
start date should be determined by the initial assessment of CR or PR, not the date of 
confirmation of CR or PR.  If a responder is not known to have died or have objective 
progression as of the data inclusion cutoff date scores, DoR will be censored at the last complete 
objective progression-free disease assessment date. 
Disease Control Rate (DCR): 
CR, PR, or SD. 
The DCR is the percentage of patients with a best response of 
Clinical Benefit Rate (CBR):  The CBR is the percentage of patients with a best response of CR 
or PR, or SD for at least 6 months. 
 
10.1.5. Exploratory Measures 
 
Table JPB  .10.2. 
Exploratory Measures 
 
Biomark rs 
Potential biomarkers related to the mechanism of action of LY2835219, the cell 
cycle, and/or the pathogenesis of breast cancer 
CTS (change in tumor size) 
Change in the size of target lesions 

13Y-MC-JPBM(a) Clinical Protocol 
Page 49 
LY2835219 
 
 
 
Biomarkers: Exploratory analysis using blood and tumor tissues will be done to explore 
potential biomarkers related to the mechanism of action of LY2835219, the cell cycle, and/or the 
pathogenesis of breast cancer to better understand relationships of cellular signaling defects with 
clinical outcomes. 
Change in Tumor Size: Change in tumor size will be measured using target lesion 
measurements selected for radiological evaluation. This measurement will only be available on 
patients with measureable disease. 
 
10.2. Health Outcome/Quality-of-Life Measures 
10.2.1. Patient-Reported Outcomes 
The primary health outcomes research goal is to assess if LY2835219 combination therapy is 
able to impact the quality of life, as measured by the EORTC QLQ-C30 (Aaronson et al. 1993). 
Additionally, the EORTC QLQ-BR23 (Sprangers et al. 1996) wiillll  collect disease-spe ific data, 
and the EQ-5D 5L (Janssen et al. 2008) health status assessment will allow for comparison with 
other tumor types and disease states. 
Patient-reported questionnaires should be completed by patients when a language translation is 
available in which the patient is fluent or literate. 
At each time point identified in the Study Schedule (Attachment 1), a paper copy of the EQ-5D 
5L, EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires should be administered to the 
patient prior to extensive interaction with site staff and study drug administration. 
10.2.1.1. Health-Related Quality of Life 
Broadly used in cancer trials, validated, and available in over 80 different languages, the EORTC 
QLQ-C30 (Aaronson et al. 1993) is a reliable and validated tool. The EORTC QLQ-C30 self- 
reported general cancer instrument consists of 30 items covered by 1 of 3 dimensions: 
 global health status/quality of life (2 items) 
 functional scales (15 total items addressing either physical, role, emotional, cognitive, or 
social functioning) 
 symptom scales (13 total items addressing either fatigue, nausea/vomiting, pain, dyspnea, 
insomnia, appetite loss, constipation, diarrhea, or financial impact) 
The EORTC QLQ-BR23 (Sprangers et al. 1996) consists of 23 items covered by the following 
scales: 
 functional (body image and sexuality) 
 symptom scales (arm, breast, and systemic therapy side effects) 
 
The EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires are administered per the 
Study Schedule (Attachment 1). The recall period is the past week, completion time is typically 
5 to 7 minutes, and both questionnaires will be scored as described by the EORTC scoring 
manual (Fayers et al. 2001). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 50 
LY2835219 
 
 
 
10.2.1.2. Health Status 
The EQ-5D 5L (Janssen et al. 2008) is a standardized instrument for use across diseases as a 
measure of self-reported health status. Specifically, this questionnaire is included in this trial to 
evaluate health-state utilities associated with advanced breast cancer. These utility measures are 
an important input for economic evaluations concerning the value of treatment interventions. 
The EQ-5D 5L is designed to be used in conjunction with other patient-reported measures. 
Patients will complete the 5-dimension (mobility, self-care, usual activities, pain/discomfort, and 
anxiety/depression), 5-level (no problem, slight, moderate, severe, or extreme problem) 
assessment according to the Study Schedule (Attachment 1). A visual analog scale (VAS) 
"thermometer" measures current health state.  Additionally, EQ-5D 5L responses may be 
incorporated into cost utility analyses. 
Administration is preferably scheduled after the EORTC and before extensive contact with study 
personnel or clinicians, which could result in biased patient response.  The recall period is 
"today."  The EQ-5D 5L is designed for self-completion by respondents and is cognitively 
simple, taking only a few minutes to complete. 
10.2.2. Resource Utilization 
Investigators will be asked to report the use of concomitant medications (in particular, 
analgesics, bisphosphonates, and RANK-L targeted agents), blood product transfusions, 
radiation therapy, surgery, and hospitalization days.  Data on neurosurgical blocks will be 
recorded on the Concomitant Medication and/or surgery eCRF as appropriate.  This information 
should be collected during the study and at the 30-day follow-up visit. 
 
10.3. Safety Evaluations 
Investigators are responsible for monitoring the safety of patients who have entered this study 
and for alerting Lilly orr its designee to any event that seems unusual, even if this event may be 
considered an unanticipated benefitt to the patient. 
The investigator is responsible for the appropriate medical care of patients during the study. 
The investigator remains responsible for following, through an appropriate health care option, 
AEs that are serious, considered related to the study, or that caused the patient to discontinue 
before completing the study.  The patient should be followed until the event is resolved or 
explained.  Frequency of follow-up evaluation is left to the discretion of the investigator. 
The timing of all safety evaluations is shown in the Study Schedule (Attachment 1). 
Table JPBM.10.3 presents a summary of AE and SAE reporting guidelines and also shows which 
database or system is used to store AE and SAE data. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 51 
LY2835219 
 
 
 
Table JPBM.10.3. 
Adverse Event and Serious Adverse Event Reporting Guidelines 
 
Period 
Types of AEs/SAEs to be Reported 
Collection 
Database 
Lilly Safety 
System 
Baseline (pretreatment) 
Preexisting conditions 
All AEs 
SAEs related to protocol procedures 
x 
x 
x 
x 
Study treatment period 
All AEs 
All SAEs 
x 
x 
x 
30-day short-term 
postdiscontinuation follow-up 
All AEs 
All SAEs 
x 
x 
x 
Long-term postdiscontinuation 
follow-up 
All SAEs related to protocol procedures 
or study drug 
x 
x 
Continued access period 
All AEs 
All SAEs 
x 
x 
x 
Continued access  period follow-up 
All AEs 
All SAEs 
x 
x 
x 
After the patient is no longer 
participating in the study (that is, no 
longer receiving study therapy and 
no longer in follow-up) 
All SAEs related to protocol procedures 
or study drug that the iinvestigator 
becomes aware of 
x 
Abbreviations:  AEs = adverse events; SAEs = serious adverse events. 
 
10.3.1. Adverse Events 
Lilly has standards for reporting AEs that are to be followed regardless of applicable regulatory 
requirements that may be less stringent.  A clinical study AE is any untoward medical event 
associated with the use of a drug in humans, whether or not it is considered related to that drug. 
Lack of drug effect is not an AE in clinical trials, because the purpose of the clinical trial is to 
establish drug effec . 
Any clinically significant findings from ECGs, labs, vital sign measurements, and other 
procedures that result in a diagnosis should be reported to Lilly or its designee. 
Study ssite personnel will record the occurrence and nature of each patient's preexisting 
conditions, including clinically significant signs and symptoms of the disease under treatment in 
tthe study. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 52 
LY2835219 
 
 
 
After the ICF is signed, site personnel will record the occurrence and nature of any AEs and any 
change in the preexisting condition(s). All AEs related to protocol procedures are reported to 
Lilly or its designee. 
Investigators will be instructed to report to Lilly or its designee their assessment of the potential 
relatedness of each AE to protocol procedure and study drug via eCRF. 
The investigator will decide whether he or she interprets the observed AEs as related to disease, 
to the study medication, study procedure, or other concomitant treatment or pathologies. To 
assess the relationship of the AE to the study drug or procedure, the following terminologies are 
defined: 
 Probably related:  a direct cause and effect relationship between the study treatment and 
the AE is likely 
 Possibly related:  a cause and effect relationship between the study treatment and the AE 
has not been demonstrated at this time and is not probable, but is also not impossible 
 Does not know:  the investigator cannot determine 
 Not related:  without question, the AE is definitely not associated with the study 
treatment 
The investigator should classify all "probably related," "possibly related," or "does not know" 
AEs and SAEs as related to study drug/study procedure. 
Patients will be evaluated for AEs at each visit and will be instructed to call their physician to 
report any AEs between visits. 
The National Cancer Institute (NCI)-CTCAE v 4.0 will serve as the reference document for 
choosing appropriate terminology for, and grading the severity of, all AEs and other symptoms. 
For AEs without matching terminology within the NCI-CTCAE v 4.0 criteria, the investigator 
will be responsible for selecting the appropriate system organ class and assessing severity grade 
based on the intensity of the event. 
In addition to collecting the AE verbatim and the CTCAE severity grade, AE verbatim text will 
also be mapped by Lilly or its designee to corresponding terminology within the Medical 
Dictionary for Regulatory Activities (MedDRA) dictionary. 
If a patient's dosage is reduced or treatment is discontinued as a result of an AE, study site 
personnel must clearly report to Lilly or its designee via eCRF the circumstances and data 
leading to any such dosage reduction or discontinuation of treatment. 
10.3.1.1. Serious Adverse Events 
An SAE is any AE from this study that results in one of the following outcomes: 
 death 
 a life-threatening experience (that is, immediate risk of dying) 
 persistent or significant disability/incapacity 
 initial or prolonged inpatient hospitalization 
 congenital anomaly/birth defect 

13Y-MC-JPBM(a) Clinical Protocol 
Page 53 
LY2835219 
 
 
 
 considered significant by the investigator for any other reason 
Important medical events that may not result in death, be life-threatening, or require 
hospitalization may be considered serious adverse drug events when, based upon appropriate 
medical judgment, they may jeopardize the patient and may require medical or surgical 
intervention to prevent one of the outcomes listed in this definition. 
Serious adverse event collection begins after the patient has signed informed consent and has 
received study drug.  If a patient experiences an SAE after signing informed consent, but prior to 
receiving study drug, the event will not be reported as serious unless the investigator feels the 
event may have been caused by a protocol procedure. 
Data on SAEs that occur before the end of trial will be stored in the collection database and the 
Lilly Safety System. 
Study site personnel must alert Lilly or its designee of any SAE within 24 hours of iinvestigator 
awareness of the event via a sponsor-approved method.  If alerts are issued via telephone, they 
are to be immediately followed with official notification on study-specific SAE forms. 
This 24-hour notification requirement refers to the initial SAE information and all follow-up 
SAE information. 
Planned surgeries should not be reported as SAEs unless the underlying medical condition has 
worsened during the course of the study. 
Planned hospitalizations or procedures for preexisting conditions that are already recorded in the 
patient's medical history at the time of study enrollment should not be considered SAEs. 
Hospitalization or prolongation of hospitalization without a precipitating clinical AE (for 
example, for the administration of study therapy or other protocol-required procedure) should not 
be considered SAEs. 
Serious adverse events due to disease progression, including death, should not be reported unless 
the investigator deems them to be possibly related to the study drug. 
If an investigator becomes aware of an SAE occurring after the patient's participation in the trial 
has ended, and the investigator believes that the SAE is related to a protocol procedure or study 
drug, the investigator should report the SAE to the sponsor, and the SAE will be entered in the 
Lilly Safety System. 
Information on SAEs expected in the study population independent of drug exposure and that 
will be assessed by the sponsor in aggregate periodically during the course of the trial may be 
found in the IB. 
10.3.1.2. Suspected Unexpected Serious Adverse Reactions 
Suspected unexpected serious adverse reactions (SUSARs) are serious events that are not listed 
iin the Development Core Safety Information (DCSI) in the IB and that the investigator identifies 
as related to the study drug or study procedure. United States 21 CFR 312.32 and European 
Union Clinical Trial Directive 2001/20/EC and the associated detailed guidances or national 

13Y-MC-JPBM(a) Clinical Protocol 
Page 54 
LY2835219 
 
 
 
regulatory requirements in participating countries require the reporting of SUSARs. Lilly has 
procedures that will be followed for the recording and expedited reporting of SUSARs that are 
consistent with global regulations and associated detailed guidances. 
10.3.2. Other Safety Measures 
10.3.2.1. Electrocardiograms 
For each patient, 12-lead digital ECGs will be collected according to the Study Schedule 
(Attachment 1).  Patients must be supine for approximately 5 to 10 minutes before ECG 
collection and remain supine but awake during ECG collection. Electrocardiograms may be 
obtained at additional times, if clinically indicated. 
Electrocardiograms will be interpreted by a qualified physician (the investigator or qualified 
designee) at the site as soon after the time of ECG collection as possible, and ideally while the 
patient is still present for immediate patient management, should any clinically relevant findings 
be identified. 
After enrollment, if a clinically significant increase in the QT/corrected QT (QTc) interval from 
baseline, or other clinically significant quantitative or qualitative change from baseline, is 
present, the investigator will assess the patient for symptoms (for example, palpitations, near 
syncope, syncope) and to determine if the patient can continue in the study.  The investigator or 
qualified designee is responsible for determining if any change in patient management is needed 
and must document his/her review of the ECG printed at the time of evaluation. 
 
10.3.3. Safety Monitoring 
The Lilly CRP will monitor safety data throughout the course of the study. 
Lilly will review SAEs wiitthin time frames mandated by company procedures. The Lilly CRP 
will, as is appropriate, consult with the functionally independent Global Patient Safety 
therapeutic area physician or clinical scientist, and review: 
 trends in safety data 
 laboratory analytes 
 AEs 
 if a patient experiences elevated ALT or AST >5x ULN in the absence of liver 
metastases and elevated total bilirubin >2x ULN, clinical and laboratory monitoring 
should be initiated by the investigator.  For patients entering the study with ALT or AST 
>3x ULN in the presence of liver metastases, monitoring should be triggered if ALT or 
AST is elevated to >2x baseline. 
 details for hepatic monitoring depend upon the severity and persistence of observed 
laboratory test abnormalities. To ensure patient safety and comply with regulatory 
guidance, the investigator is to consult with the Lilly CRP regarding collection of specific 
recommended clinical information and follow-up laboratory tests. See Attachment 3. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 55 
LY2835219 
 
 
 
In the event that safety monitoring uncovers an issue that needs to be addressed by unblinding at 
the group level, only members of the DMC (an advisory group for this study formed to protect 
the integrity of data; refer to Section 12.2.14) can conduct additional analyses of the safety data. 
For the purpose of this study, in which survival is a key efficacy endpoint, all deaths and SAE 
reports will be reviewed in a blinded manner by Lilly during the clinical trial. These reporrttss will 
be reviewed to assure completeness and accuracy but will not be unblinded to Lilly during the 
clinical trial.  If a death or other clinical AE is deemed serious, unexpected, and possibly related 
to study drug, only Lilly GPS representatives external to the study team will be unblinded for 
regulatory reporting and safety monitoring purposes.  These measures will preserve the integrity 
of the data collected during this trial and minimize any potential for bias while providing for 
appropriate safety monitoring. 
10.3.4. Complaint Handling 
Lilly collects product complaints on study treatment used in clinical trials in order to ensure the 
safety of study participants, monitor quality, and to facilitate process and product improvements. 
All product complaints associated with material packaged, labeled, and released by Lilly or its 
designee will be reported directly to Lilly. 
The investigator or his/her designee is responsible for handling the following aspects of the 
product complaint process in accordance with the instructions provided for this study: 
 recording a complete description of the product complaint reported and any associated 
AEs using the study-specific complaint forms provided for this purpose 
 faxing the completed product complaint form within 24 hours to Lilly or its designee 
If the investigator is asked to return the product for investigation, he/she will return a copy of 
the product complaint form with the product. 
 
10.4. Sample Collection and Testing 
Attachment 1 lissttss  the schedule for s mple collections in this study. 
Attachment 2 lists the specific tests that will be performed for this study and whether these will 
be performed at a central or local laboratory. 
Attachment 6 provides a summary of the estimated maximum number and volume of invasive 
samples, for all sampling, during the study. 
Attachment 7 lliissts  the schedule for PK sampling during the study. 
 
10.4.1. Samples for Study Qualification and Health Monitoring 
Blood samples will be collected to determine whether patients meet inclusion/exclusion criteria 
and to monitor patient health. Enrollment and treatment decisions may be based upon results of 
ttests performed locally. If local laboratory tests are used for this purpose, then a duplicate 
specimen must be submitted to the central laboratory. Discrepancies between local and central 
laboratory that may have an impact on eligibility or treatment decisions will not be considered 

13Y-MC-JPBM(a) Clinical Protocol 
Page 56 
LY2835219 
 
 
 
protocol deviations. In addition to protocol-specified tests, investigators should consider 
monitoring of cholesterol and bone mineral density if needed, per the recommendations for 
anastrozole and letrozole in the Package Insert and Summary of Product Characteristics. 
Investigators must document their review of each laboratory safety report. 
Samples collected for specified laboratory tests will be destroyed within 60 days of receipt of 
confirmed test results. Tests are run and confirmed promptly whenever scientifically appropriate.  
When scientific circumstances warrant, however, it is acceptable to retain samples to batch the 
tests run, or to retain the samples until the end of the study to confirm that the results are valid. 
Certain samples may be retained for a longer period, if necessary,, to comply with applicable 
laws, regulations, or laboratory certification standards. 
 
10.4.2. Samples for Biomarkers 
Samples for biomarker research to be collected from all patients in this study are the following: 
 
whole blood 
 
plasma 
 
tumor tissue 
Analyses may include, but are not limited to, nucleic acid and protein profiles to better 
understand the disease process and to develop predictive biomarkers. 
These samples are described in the following sections. 
10.4.2.1. Archived Tumor Tissue 
For patients in the study, a small amount of preserved tumor tissue, previously taken to evaluate 
the patient's disease, is required to be provided by sites upon patient randomization for 
biomarker research.  However, if this sample is not available for a patient or the patient declines, 
a protocol deviation will not be incurred and the patient is eligible for the study. 
Available formalin-fixed, paraffin-embedded primary and/or metastatic tumor tissue should be in 
a whole block, partial block, or unstained slides.  Any whole block submitted will be returned to 
the site. Any partial blocks or sslides will either be returned or discarded within 15 years after last 
patient visit for the trial. 
In tumor tissue samples, the CDK4 and CDK6 pathway components (for example, Rb) and 
markers relevant to breast cancer pathogenesis may be evaluated to assess any potential 
correlation with rresponse to LY2835219. Tumor samples may be analyzed to explore potential 
tumor gene signature(s) associated with response or resistance to LY2835219 therapy. These 
studies may be analyzed at a laboratory designated by the sponsor and may include IHC of 
proteins, FISH for copy number amplifications, RNA gene-expression profiling, and/or genetic 
analyses of the tumor specimen DNA.  Such analyses may employ targeted or high-throughput 
sequencing approaches.  For this purpose, the results of this analysis will be correlated with 
clinical efficacy data. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 57 
LY2835219 
 
 
 
10.4.2.2. Blood Samples for Pharmacogenetic Evaluations 
There is growing evidence that genetic variation may impact a patient's response to therapy. 
Variable response to therapy may be due to genetic determinants that impact drug absorption, 
distribution, metabolism, and excretion, the mechanism of action of the drug, the disease 
etiology and/or the molecular subtype of the disease being treated. Therefore, where local 
regulations and ethical review boards (ERBs) allow, a blood sample will be collected forr 
pharmacogenetic analysis. 
Samples may be genotyped and analysis may be performed to evaluate a genetic association with 
response to LY2835219.  These investigations may be limited to a focused candidate gene study 
or, if appropriate, genome-wide analysis may be performed to identify regiions of the genome 
associated with the variability observed in drug response.  The pharmacogenetic biomarker 
samples will only be used for investigations related to disease and drug or class of drugs under 
study in the context of this clinical program.  They will not be used for broad exploratory 
unspecified disease or population genetic analysis. 
The samples will be coded with the patient number and stored for up to a maximum 15 years 
after the last patient visit for the study at a facility selected by the sponsor.  The samples and any 
data generated from them can only be linked back to the patient by investigator site personnel. 
The duration allows the sponsor to respond to regulatory requests related to the study drug. 
Samples will be destroyed according to a prrocess consistent wiitth  local regulation. 
10.4.2.3. Plasma Samples for Exploratory Biomarker Evaluations 
EDTA-anticoagulated plasma samples will be collected and analysis may be performed on 
biomarkers that may play a role in the LY2835219 mechanism of action (refer to Attachment 1). 
The evaluation of these samples may involve analysis of DNA, RNA, and proteins (including 
any of these components derived from exosomes) to investigate their association with observed 
clinical outcomes to study drug.  The samples will be coded with the patient number and stored 
for up to a maximum 15 years. Details ffor collecting, processing, and storing the samples are 
similar those provided in Section 10.4.2.2. 
10.4.3. Samples for Drug Concentration Measurements 
Pharmacokinetics 
At the visits and times specified in the Pharmacokinetic Sampling Schedule (Attachment 7), 
venous blood samples will be collected from at least 150 of the patients randomized in the study. 
These samples will be used to determine the plasma concentrations of LY2835219 and possibly 
LY2835219 m  tabolites, as well as plasma concentrations of anastrozole or letrozole. 
Instructions for the collection and handling of blood samples will be provided by the sponsor.  It 
is preferred that the blood samples be obtained from a peripheral location.  Blood samples will 
be allowed from central access devices, but a sample drawn from a central catheter of any type 
for PK must take precautions to prevent obtaining a dilute sample. If multiple samples are 
obtained centrally, the PK sample should be the last specimen drawn to reduce the potential for a 
diluted or improperly drawn sample.  The actual date and time (24-hour clock time) of each 

13Y-MC-JPBM(a) Clinical Protocol 
Page 58 
LY2835219 
 
 
 
sampling will be recorded. A maximum of 5 samples may be drawn at additional time points 
during the study if warranted and agreed upon between both the investigator and Lilly. 
These samples will be analyzed at a laboratory designated by the sponsor. Plasma concentrations 
of LY2835219 plus its metabolites LSN2839567, LSN3106726, and LSN3106729 will be 
assayed using a validated liquid chromatography/tandem mass spectrometry (LC/MS/MS) 
method.  Plasma concentrations of anastrozole or letrozole will also be analyzed using a 
validated LC/MS/MS method. Bioanalytical samples collected to measure study drug 
concentration and metabolism and/or protein binding, will be retained for a maximum of 1 year 
following last patient visit for the study.  The PK samples will be stored at a facility designated 
by the sponsor. 
Drug concentration information that may unblind the study will not be reported to investigative 
sites or blinded personnel until the study has been unblinded. 
 
10.5. Appropriateness of Measurements 
Efficacy measurements by radiographic imaging are standard, widely used, and generally 
recognized as reliable, accurate, and able to discriminate between effective and ineffective 
agents. 
Safety measurements by laboratory monitoring are standard, widely used, and generally 
recognized as reliable, accurate, and able to discriminate between agents with acceptable and 
unacceptable safety profiles. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 59 
LY2835219 
 
 
 
11. Data Quality Assurance 
To ensure accurate, complete, and reliable data, Lilly or its representatives will do the following: 
 provide instructional material to the study sites, as appropriate 
 sponsor start-up training to instruct the investigators and study coordinators. This session 
will give instruction on the protocol, the completion of the eCRFs, and study procedures. 
 make periodic visits to the study site 
 be available for consultation and stay in contact with the study site personnel by mail, 
telephone, and/or fax 
 review and evaluate eCRF data and use standard computer edits to detect errors in data 
collection 
 conduct a quality review of the database 
In addition, Lilly or its representatives will periodically check a sample of the patient data 
recorded against source documents at the study site.  The study may be audited by Lilly or its 
representatives, and/or regulatory agencies at any time.  Investigators will be given notice 
before an audit occurs. 
To ensure the safety of participants in the study, and to ensure accurate, complete, and reliable 
data, the investigator will keep records of laboratory tests, clinical notes, and patient medical 
records in the patient files as original source documents for the study.  If requested, the 
investigator will provide Lilly, applicable regulatory agencies, and applicable ERBs with direct 
access to original source documents. 
11.1. Data Capture System 
An electronic data capture system will be used in this trial.  The site maintains a separate source 
for the data entered by the site into the spons  r-provided electronic data capture system. 
Case report form data will be encoded and stored in a clinical trial database. 
Any data for which the paper documentation provided by the patient will serve as the source 
document wiillll  be identified and documented by each site in that site's study file. 
Bioanalytical data will be stored electronically in the bioanalytical laboratory's database.  Data 
will subsequently be transferred from the bioanalytical laboratory to Lilly. 
Data from complaint forms submitted to Lilly will be encoded and stored in the global product 
complaint management system. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 60 
LY2835219 
 
 
 
12. Sample Size and Statistical Methods 
12.1. Determination of Sample Size 
The primary objective of this study is to compare LY2835219 plus NSAI versus placebo plus 
NSAI in terms of PFS in postmenopausal women with HR+, HER2- locoregionally recurrent or 
metastatic breast cancer who have not received prior endocrine therapy in this disease setting. 
The study will enroll approximately 450 patients in 2:1 randomization (300 patienttss in 
LY2835219 plus NSAI and 150 patients in placebo plus NSAI). Patients will be randomized 
using the following stratification factors:  nature of disease (visceral metastases versus bone-only 
metastases versus other) and prior (neo)adjuvant endocrine therapy (aromatase inhibitor thera y 
versus other versus no prior endocrine therapy). 
A 3-look group-sequential design of the primary endpoint will be used to accommodate an 
event-driven plan for the interim and final PFS analyses (see Section 12.2.6 for details).  The 
final PFS analysis will be performed after approximately 270 PFS events have occurred (that is, 
a 40% censoring rate).  Assuming a hazard ratio of 0.67, this sample size yields more than 80% 
statistical power to detect superiority of the LY2835219 plus NSAI arm over the placebo plus 
NSAI arm with the use of a 1-sided log-rank test and a cumulative type I error of 0.025.  If the 
true median PFS for the placebo plus NSAI arm is 10 months, then the hazard ratio of 0.67 
amounts to an approximately 5-month (50%) improvement in median PFS for the LY2835219 
plus NSAI arm under an additional assumption of exponential survival distribution. 
12.2. Statistical and Analytical Plans 
12.2.1. General Considerations 
Statistical analysis of thiss study will be the responsibility of Lilly. 
 
Efficacy analyses will be based on the i tention-to-treat (ITT) analysis set. This population  is 
defined as all patients randomized to study treatment.  Patients will be grouped according to 
randomized treatment. 
 
Safety analyses will be based on the randomized and treated population (RT), defined as all 
randomized patients receiving at least 1 dose of blinded study drug or NSAI.  Patients will be 
grouped according to treatment received in Cycle 1. 
 
Pharmacodynamic and/or biomarker analyses will be based on the subset of patients from the 
above populations from whom a valid assay result (according to laboratory guideline) has been 
obtained. 
 
All tests of treatment effects will be conducted at a 2-sided alpha level of 0.05, unless otherwise 
stated. All confidence intervals (CIs) will be given at a 2-sided 95% level, unless otherwise 
stated. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 61 
LY2835219 
 
 
 
Any change to the data analysis methods described in the protocol will require an amendment 
ONLY if it changes a principal feature of the protocol. 
 
Before sponsor unblinding of the aggregate database, minor modifications or clarifications to the 
data analysis methods may be described and justified in the statistical analysis plan. 
 
Any other change to the data analysis methods described in the protocol, and the justification for 
making the change, will be described in the clinical study report. 
 
The assumptions for each statistical method may be evaluated.  If there is violation of 
assumptions, alternative statistical methods may be used. 
 
Additional exploratory analyses of the data will be conducted as deemed appropriate. 
 
12.2.2. Patient Disposition 
A detailed description of patient disposition will be provided. It will include a summary of the 
number and percentage of patients entered into the study, enrolled in the study, and treated, as 
well as number and percentage of patients completing the study or discontinuing (overall and by 
reason for discontinuation). 
 
A summary of all important protocol deviations will be provided. 
 
12.2.3. Patient Characteristics 
Patient characteristics will include a summary by treatment arm of the following: 
 patient demographics 
 baseline disease characteristics 
 preexisting conditions 
 historical illnesses 
 prior (neo)adjuvant endocrine therapy 
 prior (neo)adjuvant chemotherapy (including both cytotoxic and targeted agents) 
Other patient characteristics will be summarized as deemed appropriate. 
12.2.4. Concomitant Therapy 
Concomitant medications will be summarized by treatment arm. 
12.2.4.1. Postdiscontinuation Therapy 
The numbers and percentages of patients reporting postdiscontinuation therapies will be 
provided overall, by type of therapy (surgery, radiotherapy, or systemic therapy), and by drug 
name. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 62 
LY2835219 
 
 
 
12.2.5. Treatment Compliance 
The number of dose omissions, reductions, delays, the number of cycles received, and dose 
intensity will be summarized for all treated patients per treatment arm. 
 
Compliance information for blinded study drug will be collected through capsule counts at each 
cycle/visit. The estimate of percent compliance will be given by: 
Actual cumulative dose taken 
Percent Compliance = Expected cumulative dose to be taken  x 100 
 
The actual cumulative dose taken will be determined based on counting the number of capsules 
returned at each visit and subtracting that number from the number of capsules dispensed. The 
expected cumulative dose to be taken will be determined based on the assigned dose and taking 
into account any dose reductions or suspensions. 
 
Compliance information for anastrozole or letrozole will be collected at each cycle/visit.  This 
may be collected by tablet counts and/or review of the completed patient diary. For NSAI that 
has been centrally supplied by Lilly, tablet counts are required. The estimate of percent 
compliance will be done using the same formula/calculation for blinded study drug percent 
compliance. 
12.2.6. Primary Outcome and Methodology 
The primary endpoint of this study is PFS. PFS time is measured from randomization until the 
date of investigator-determined objective progression as defined by RECIST v1.1, or death from 
any cause.  Patients who have neither progressed nor died will be censored at the day of their last 
radiographic tumor assessment, if available, or date of randomization if no post-initiation (that is, 
post-baseline) radiographic assessment is available.  The detailed censoring rules are described  
in Table JPBM.12.1. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 63 
LY2835219 
 
 
 
Table JPBM.12.1. 
Rules for Determining Date of Progression or Censor for 
Progression-Free Survival 
Rule 
Situation 
Date of Progression or Censor 
Outcome 
 
1 
No baseline tumor assessments 
Date of Randomization 
Censored 
 
 
2 
No post-baseline assessments and no 
death 
Date of Randomization 
Censored 
3 
No documented progression and no 
death (with a post-baseline tumor 
assessment) 
Date of last adequate tumor assessment 
Censored 
 
 
4 
Patient lost to follow-up (or withdrew 
consent from study participation) 
before documented progression or 
death 
Date of last adequate tumor assessment 
Censored 
5 
Documented progression 
Date of documented progression. 
If a tumor assessment was done on 
multiple days, use the earliest date for 
that visit. 
Progressed 
6 
Death without documented 
progression 
7 
Documented progression or death 
after missing 2'2 consecutive post- 
baseline tumor assessments 
Date of death 
 
 
Date of last adequate tumor 
assessment before missed assessments 
or date of randomization, whichever is 
later 
Progressed 
 
 
Censored 
 
 
Note:  Progression-free survival and associated outcome is determined by the earliest of the dates above, if more 
than 1 situation applies. 
 
The PFS analysiss to test the superiority of LY2835219 to placebo in improving PFS time will use 
the log-rank test stratified by nature of disease (visceral metastases versus bone-only metastases 
versus otherr) and prior (neo)ad uvant endocrine therapy (aromatase inhibitor therapy versus other 
versus no prior endocrine therapy).  The Kaplan-Meier method (Kaplan and Meier 1958) will be 
used to estimate tthe PFS curves as well as PFS rates at every 3 months for each treatment group.  
These rates will be compared based on a normal approximation for the difference  between the 
rates. 
 
The 3-look group-sequential design of the primary endpoint will be used to accommodate an 
event-driven plan for the interim and final analyses.  There are 2 planned interim analyses and  
1 final analysis for PFS in this study. The interim analyses are planned to take place after 
approximately 189 (approximately 70% of the planned) investigator-assessed PFS events have 
occurred and approximately 230 (approximately 85% of the planned) investigator-assessed PFS 
events have occurred. The cumulative 1-sided type I error rate of .025 will be maintained using 
the following method. At the first and second interim analysis, the nominal alpha levels will be 

13Y-MC-JPBM(a) Clinical Protocol 
Page 64 
LY2835219 
 
 
 
0.0001 and 0.00015, respectively. The remaining alpha will be spent at the final analysis. The 
resulting boundary p-value for the final analysis is dependent on the exact number of events 
observed at each analysis and can be calculated using the method of Slud and Wei (1982). If the 
3 analyses are performed at exactly 189, 230, and 270 events, then the boundary p-value at the 
final analysis will be 0.0249994.  The actual boundary for the final analysis will be calculated 
based on the actual number of events observed at the time of each analysis using software that 
implements the alpha-spending scheme noted above (for example, ADDPLAN 6.0, SAS 9.2, or 
similar software). 
 
If statistical significance is not declared at the first interim PFS analysis, the second interim PFS 
analysis will be performed after 230 PFS events have been observed.  Note that the second 
interim analysis of PFS will only be performed if statistical significance is not declared at the 
first interim PFS analysis.  If statistical significance is not observed at either interim analysis, the 
final PFS analysis will be performed after approximately 270 PFS events have been observed 
based on investigator assessment. 
 
Once statistical significance is declared at either interim analysis or the final analysis, the study 
will be positive based on the primary endpoint of PFS, and testing of secondary endpoints will 
proceed as described in the SAP. 
 
The interim PFS analyses will be performed by DMC.  The requirements for unblinding the 
sponsor at the interim analyses are found in Section 12.2.14. 
 
The primary test of PFS will compare the 2 treatment groups using a log-rank test stratified by 
the randomization factors. 
 
The Cox proportional hazard model (Cox 1972) with treatment as a factor will be used to 
estimate the hazard ratio and corresponding 95% CI with Wald's test p-value after stratifying for 
the same randomization variables specified for the primary analysis. 
 
12.2.7. Secondary Outcomes and Methodology 
The secondary objectives of the study are listed in Section 6.2. 
12.2.7.1. Overall Survival 
Overall survival is an important secondary endpoint for this study. To maintain the study-wise 
type I error rate, OS will be hierarchically tested; that is, OS will only be tested inferentially for 
significance only if the test of PFS is significant.  Further details will be in the study SAP. 
12.2.7.2. Objective Response Rate, Disease Control Rate, and Clinical Benefit 
Rate 
The ORR, DCR, and CBR of each treatment arm will be calculated as defined by RECIST v1.1. 
All rates will be compared between treatment arms based on a normal approximation for the 
difference between the rates. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 65 
LY2835219 
 
 
 
12.2.8. Sensitivity Analysis 
Sensitivity analyses will be undertaken for calculation of the primary endpoint in order to 
evaluate the robustness of the analysis. The following sensitivity analyses will be performed for 
PFS: 
 
Progression-Free Survival Sensitivity Analysis 1 (censoring for receiving subsequent systemic 
anticancer therapy): if a patient is initiated on another anticancer therapy prior to objective 
progression, including any postdiscontinuation treatment systemic therapy, radiotherapy, or 
surgical intervention, PFS will be censored at the date of the last complete objective progression- 
free disease assessment before initiation of the new therapy, regardless of whether or not this 
patient subsequently had objective progression or died. 
 
Progression-Free Survival Sensitivity Analysis 2 (nonobjective progression as a PFS event): if 
a patient is discontinued from study treatment due to investigator determined non-objective 
progression (for example, symptomatic deterioration), then the patient's PFS time will be 
calculated using the date of non-objective progression as the progression date. 
 
Progression-Free Survival Sensitivity Analysis 3 (forward-dating progressions at unscheduled 
assessments):  if a patient has objective progression at an unscheduled disease assessment, then 
the PFS time for that patient will be forward-dated to the next scheduled disease assessment. 
 
Progression-Free Survival Sensitivity Analysis 4.  PFS will also be analyzed after adjusting for 
selected prognostic factors. Potentiall prognostic factors iincluded the stratification factors and 
other factors as outlined in the SAP.  The hazard ratio for treatment effect will be estimated using 
a multivariate Cox proportional hazard model constructed by selecting variables among all the 
potential variables listed in the SAP, using stepwise selection method with entry p-value 0.05  
and exit p-value 0.01.  The treatment factor will be kept out of the model throughout the 
covariate selection process and only added into the final model. 
 
Although this study is double-blinded, a blinded independent central review (BICR) of scans will 
be conducted on a randomly selected subset of patients to evaluate the potential for investigator 
bias in evaluation of time to progression, and hence the reliability of the treatment effect based  
on investigator assessment.  Details concerning the size of the subset of patients, the analysis of 
this BICR data, and decision rules for conducting a central review of all patients will be described 
in a separate SAP. 
 
An additional OS analysis will also be conducted based on the following definition using similar 
methods as stated in Section 12.2.7: time is defined as the time from the date of study 
enrollment to the date of death due to disease.  Survival time will be censored on the date the 
patient was last known to be alive for patients who have no reported event.  For patients that 
have died due to reasons not disease related, survival time will be censored at the date of death. 
Cause of death as reported by the investigator will be used in this analysis. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 66 
LY2835219 
 
 
 
12.2.9. Pharmacokinetic and Pharmacodynamic Analyses 
Pharmacokinetics analyses will be conducted on all patients who have received at least 1 dose of 
study treatment and have had samples collected (see PK sampling schedule in Attachment 7). 
Mean population PK parameters for LY2835219 in plasma (clearance, exposure, volume of 
distribution, and half-lives) and inter-individual PK variability will be computed using nonlinear 
mixed-effect modeling implemented in NONMEM.  Covariate effects (such as age, weight, sex, 
creatinine clearance, and plasma protein levels) on the PK parameters of LY2835219 in plasma 
will also be investigated. 
 
Likewise, and if warranted by the data, mean population PK parameters for anastrozole or 
letrozole in plasma and inter-individual variability estimates will also be computed using 
nonlinear mixed-effect modeling implemented in NONMEM. 
 
Finally, pharmacodynamic data (such as neutrophil, lymphocytes, or platelet counts in blood) 
collected in this study may be analyzed by means of NONMEM and connected to the population 
PK model for LY2835219 and/or NSAI in a PK/pharmacodynamic model. 
 
12.2.10. 
Biomarker Analyses 
The distributions of biomarkers with continuous measures, such a   gene or protein expression, 
will be described.  Summary statistics will include means, medians, corresponding standard 
errors, quartiles, and ranges.  Biomarkers with discrete measures, such as genotype locus, will be 
summarized in frequency tables.  Correlative analyses may be performed to investigate 
associations between biomarkers and clinical endpoints as deemed appropriate. 
 
12.2.11. 
Health Outcome/Quality-of-Life Analyses 
Patient-reported outcomes are measured through paper versions of the following: 
 
• 
EORTC  QLQ-C30  (The  European  Organization  for  Research  and  Treatment  of 
Cancer Quality of Life Questionnaire Core 30) 
• 
EORTC QLQ-BR23 (The European Organization for Research and Treatment of 
Cancer Quality of Life Questionnaire Breast cancer) 
• 
EQ 5D 5L (EuroQol 5-Dimension 5 Level) 
 
For each patient with data from baseline and at least 1 post-baseline visit, the maximum change 
from baseline score will be calculated and summarized for EORTC scale scores. The reason and 
number of missing and incomplete questionnaires/assessments by visit will be summarized for 
each instrument and study arm. 
 
Further analysis details will be described in the SAP. 
 
12.2.11.1. 
Health-Related Quality of Life 
EORTC QLQ-C30 instrument data will be scored as described by Aaronson and colleagues 
(Aaronson et al. 1993).  If not already addressed in the EORTC scoring manual (Fayers et al. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 67 
LY2835219 
 
 
 
2001), descriptive statistics for each EORTC QLQ-C30 item will be calculated. Descriptive 
statistics will be calculated for each dimension and the total score for each arm. 
 
EORTC QLQ-BR23 data will be scored as described by the EORTC scoring manual (Fayers et 
al. 2001). 
12.2.11.2. 
Resource Utilization 
Utilization data will be summarized descriptively by category across arms (for example, 
analgesic use, bisphosphonate use, transfusions, radiation, surgery, and hospitalization days), 
including a frequency table with tabular statistics.  Tests for differences in proportions between 
treatment groups and between response groups will be performed. 
12.2.11.3. 
Health State Utility 
The EQ-5D 5L data will be scored as described in an article by van Hout and colleagues 
(van Hout et al. 2012). The index score is calculated from a sett of item weights to derive a score 
of 0 to 1, with 1 representing the best health status.  Geographic-specific weights will be used as 
appropriate and when available.  The VAS is scored from 0 (worst imaginable health state) 
through 100 (best imaginable health state) to represent the patient's self-report for each day. 
EQ-5D 5L responses for each item will be summarized by frequency and corresponding 
percentages.  Descriptive statistics for the index and VAS will be calculated.  Psychometric 
analyses, including calculation of reliability coefficients (Cronbach's alpha), will also be 
performed.  The index scores and VAS will be analyzed using a repeated-measures model. 
 
12.2.12. 
Safety Analyses 
All safety summaries and analyses will be based upon the Safety Population as defined in 
Section 12.2.1. 
 
Overall exposure to study drug, the numbers of patients completing each cycle, and the dose 
intensity will be summarized using descriptive statistics.  The number of patients with any dose 
adjustment will be presented for entire treatment period as well as for each cycle.  The number of 
patients with dose reductions, dose delays, or dose omissions will also be summarized, as will  
the reasons for dose adjustments. 
 
AEs will be reported using the MedDRA dictionary.  Investigators will report a verbatim AE 
term and a CTCAE v4.0 term and severity for all AEs.  For analysis purposes, the following 
process will be used: 
 
 The CTCAE v4 term reported by the investigator will be mapped to the MedDRA 
Preferred Term (PT) and System Organ Class (SOC) using the corresponding MedDRA 
Lower Level Term (LLT), unless the reported CTCAE term is 'Other -  specify.' 
 If the reported CTCAE term is 'Other - specify,' the MedDRA LLT, PT, and SOC 
centrally mapped from the verbatim AE term will be used. 
 All listings and summaries will use the PT resulting from this process. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 68 
LY2835219 
 
 
 
Preexisting conditions are defined as AEs that begin prior to the first dose of study drug. 
 
A treatment-emergent adverse event (TEAE) is defined as an event that first occurred or 
worsened in severity after baseline. Comparisons of preexisting conditions to on-treatment 
events at the LLT level will be used in the treatment-emergent computation. 
 
The following summaries will be produced by PT within SOC: preexisting conditions,, SAEs, 
TEAEs, drug-related TEAEs, and procedure-related TEAEs. 
 
The following summaries will be produced by PT within SOC and maximum CTCAE grade: 
laboratory-based TEAEs, nonlaboratory-based TEAEs, drug-related laboratory-based TEAEs, 
and drug-related nonlaboratory-based TEAEs. 
 
Reasons for death will be summarized separately for on-therapy and within 30 days of treatment 
discontinuation. 
 
Hospitalizations and transfusions during the study treatment period or during the 30-day 
short-term follow-up period will be summarized by treatment group. 
 
12.2.13. 
Subgroup Analyses 
Subgroup analyses of PFS and OS will be performed for potential prognostic subgroup variables, 
including: 
 All baseline stratification factors 
 NSAI received while on study (letrozole versus anastrozole) 
 Disease setting (de novo metastatic versus recurrent metastatic versus locoregionally 
recurrent) 
 Measurable disease at baseline (yes versus no) 
 Number of organs involved (1 versus 2 versus 3+) 
 Age (<65 years versus 2'65 years) 
 Region (North America, Europe, Asia, and Other) 
 Race (Caucasian, Asian, and Other) 
 PgR status (positive versus negative) 
 Baseline ECOG PS (0 versus 1) 
 
If a level of a factor consists of fewer than 5% of randomized patients, analysis within that level 
may be omitted.  The final list of subgroup analyses will be provided in the SAP. 
 
Analyses will be done within subgroup and, separately, across subgroups with a test of 
interactions of subgroups with treatment performed. 
 
Other subgroup analyses may be performed as deemed appropriate. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 69 
LY2835219 
 
 
 
12.2.14. 
lnterim Analyses 
12.2.14.1. 
Safety 1nterim Analyses 
The DMC is responsible for providing external oversight of patient safety in Study JPBM 
independently of the Lilly study team and Lilly GPS. 
 
During the study, safety interim analyses will be performed approximately every 3 months. The 
first safety interim analysis will be triggered by randomization of the 90th patient, with the data 
cutoff for this analysis occurring approximately 1 month after the trigger. The safety interim 
analyses will be conducted to evaluate the overall safety profile of LY2835219 when given in 
combination with NSAI. At the recommendation of the DMC, the frequency of safetty interim 
analyses may be modified. 
 
At each interim analysis, the DMC may recommend the trial continue without modifications, 
continue with specific modifications, or be stopped for safety concerns.  There will be no 
prespecified rules for stopping the trial due to safety concerns.  The DMC me   bers will review 
unblinded safety data at each interim analysis.  If a significant safety signal is identified, the 
DMC may recommend a protocol amendment, termination of enrollmen , and/or termination of 
study treatment.  The recommendations of the DMC will be communicated to the Lilly SMD 
and, if necessary, an IRC. 
 
In the event that safety monitoring uncovers an issue that n  eds to be addressed by unblinding at 
the treatment group level, members of the DMC can conduct additional analyses of the safety 
data. Additionally, unblinding of a limited number of Lilly representatives external to the study 
team may be required for evaluation of selected SAEs for determination of regulatory reporting. 
 
12.2.14.2. 
Efficacy 1nterim Analyses 
Two efficacy interim analyses of PFS are planned, as described in Section 12.2.6. Four interim 
analyses of OS are planned (at the time of each of the 2 interim PFS analyses, at the time of the 
final PFS analysis, and at the time when approximately 75% of the OS events have been 
observed; subsequently, a final OS analysis is planned). 
 
The interim PFS analyses will be conducted to provide early efficacy information and could 
potentially result in early communication with regulatory agencies.  This analysis will be 
performed by an independent Statistical Analysis Group and provided to the DMC.  The DMC 
should recommend unblinding the sponsor if the following are observed: 
 
 The analysis of investigator-assessed PFS is significant at the alpha level specified in 
Section 12.2.6 with the observed stratified hazard ratio for investigator-assessed PFS less 
than 0.56 at the first interim analysis, or is less than 0.6 at the second interim analysis, 
and 
 Results of the analysis of the centrally reviewed PFS support the results of the 
investigator-assessed PFS analysis. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 70 
LY2835219 
 
 
 
If the analysis of PFS is positive based on these requirements, the DMC will be instructed to 
recommend to the SMD that the sponsor be unblinded. The SMD may convene an IRC to 
review the DMC's recommendation prior to sponsor unblinding. 
Overall survival will be analyzed as described in Section 12.2.7. Results of OS analyses will not 
be communicated until a significant result is observed or the final PFS analysis is performed 
The sponsor has no intent to stop the study based on interim analysis of efficacy, and all patients 
will continue follow-up for PFS until the primary PFS analysis and for OS until study close. 
Patients randomized to the control group will not be permitted to cross over to the experimental 
group, as this will confound the assessment of OS. In addition, patients willl remain blinded for 
the duration of the study unless the criteria in Section 9.5 are met. If the DMC makes a 
recommendation counter to this, for example, the DMC recommends crossing all patients over to 
the experimental treatment, FDA will be consulted before any action is taken as well as other 
regulatory agencies if deemed appropriate. 
The unblinded review of the analyses, including review of the efficacy along with the safety 
data, will be conducted by DMC. Study sites will receive information about interim results 
ONLY if they need to know for the safety of their patients. 
 
Unblinding details are specified in the unblinding plan section of the SAP. 
 
12.2.14.3. 
Pharmacokinetic/Pharmacodynamic 1nterim Analyses 
A limited number of preidentified individuals independent of the study team may receive access 
to unblinded data, as specified in the unblinding plan, prior to the interim or final database lock, 
in order to initiate the final population PK/pharmacodynamic model development processes for 
interim or final analyses.  Information that may unblind the study during the analyses will not be 
reported to study sites or blinded study team until the study has been unblinded. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 71 
LY2835219 
 
 
 
13. 1nformed Consent, Ethical Review, and Regulatory 
Considerations 
 
13.1. 1nformed Consent 
The investigator is responsible for ensuring that the patient understands the potential riskss and 
benefits of participating in the study, including answering any questions the patient may have 
throughout the study and sharing in a timely manner any new information that may be relevant to 
the patient's willingness to continue his or her participation in the trial. 
The ICF will be used to explain the potential risks and benefits of study parttiicipation to the 
patient in simple terms before the patient is entered into the study, and to document that the 
patient is satisfied with his or her understanding of the risks and beneffiittss of participating iin the 
study and desires to participate in the study. 
The investigator is responsible for ensuring that informed consent is given by each patient.  This 
includes obtaining the appropriate signatures and dates on the ICF prior to the performance of 
any protocol procedures and prior to the administration of study drug. 
As used in this protocol, the term "informed consent" includes all consent given by patients. 
 
13.2. Ethical Review 
Lilly or its representatives must approve all ICFs before they are used at the investigative site[s]. 
All ICFs must be compliant with the International Conference on Harmonisation (ICH) guideline 
on GCP. 
Documentation of ERB approval of the protocol and the ICF must be provided to Lilly before the 
study may begin at the investigative site[s]. 
The study site's ERB[ss]]  should be provided with the following: 
 the current IB or package labeling and updates during the course of the study 
 ICF 
 relevant curricula vitae 
 
13.3. Regulatory Considerations 
This study will be conducted in accordance with: 
 consensus ethics principles derived from international ethics guidelines, including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines 
 the ICH GCP Guideline (E6) 
 applicable laws and regulations. 
The investigator or designee will promptly submit the protocol to applicable ERB(s). 
Some of the obligations of Lilly will be assigned to a third-party organization. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 72 
LY2835219 
 
 
 
An identification code assigned by the investigator to each patient will be used in lieu of the 
patient's name to protect the patient's identity when reporting AEs and/or other trial-related data. 
13.3.1. lnvestigator lnformation 
Site-specific contact information may be provided in a separate document. 
Physicians with a specialty in oncology will participate as investigators in this clinical trial. 
 
13.3.2. Protocol Signatures 
The sponsor's responsible medical officer will approve the protocol, confirming that, to the best 
of his or her knowledge, the protocol accurately describes the planned design and conduct of the 
study. 
After reading the protocol, each principal investigator will sign the protocol signature page and 
send a copy of the signed page to a Lilly representative. 
13.3.3. Final Report Signature 
The clinical study report (CSR) coordinating investigator will sign the final CSR for this study, 
indicating agreement that, to the best of his or her knowledge, the rreport accurately describes the 
conduct and results of the study. 
Lilly will select an investigator to serve as the CSR coordinating investigator. 
The Lilly responsible medical officer and statistician will ssign/approve the final clinical study 
report for this study, confirming that, to the best of his or her knowledge, the report accurately 
describes the conduct and results of the study. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 73 
LY2835219 
 
 
 
14. References 
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, 
Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of 
Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in 
oncology. J Nat/ Cancer Inst. 1993;85(5):365-376. 
Amit O, Mannino F, Stone AM, Bushnell W, Denne J, Helterbrand J, Burger HU. Blinded 
independent central review of progression in cancer clinical trials: results from a meta- 
analysis. Eur J Cancer. 2011;47(12):1772-1778. 
Bray F, Ren JS, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the 
adult population in 2008. Int J Cancer. 2013;132(5):1133-1145. 
Cardoso F, Costa A, Norton L, Cameron D, Cufer T, Fallowfield L, Francis P, Gligorov J, 
Kyriakides S, Lin N, Pagani O, Senkus E, Thomssen C, Aapro M, Bergh J, Di Leo A, El 
Saghir N, Ganz PA, Gelmon K, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, 
Leadbeater M, Mayer M, Rodger A, Rugo H, Sacchini V, Sledge G, van't Veer L, Viale G, 
Krop I, Winer E. 1st International consensus guidelines for advanced breast cancer (ABC 1). 
Breast. 2012;21(3):242-252. 
Casimiro MC, Velasco-Vela'zquez M, Aguirre-Alvarado C, Pestell RG. Overview of cyclins D1 
function in cancer and the CDK inhibitor landscape:  past and present.  Expert Opin Investig 
Drugs. 2014; 23(3):295-304. 
Coleman RE, Bolten WW, Lansdown M, Dale S, Jackisch C, Merkel D, Maass N, Hadji P. 
Aromatase inhibitor-induced arthralgia:  clinical experience and treatment recommendations. 
Cancer Treat Rev. 2008;34(3):275-282. 
Cox DR. Regression models and life-tables. J Roya/ Stat Soc Ser B. 1972;74(2):187-220. 
Dworkin RH, Turk DC, Wyrwich KW, Beaton D, Cleeland CS, Farrar JT, Haythornthwaite JA, 
Jensen MP, Kerns RD, Ader DN, Brandenburg N, Burke LB, Cella D, Chandler J, Cowan P, 
Dimitrova R, Dionne R, Hertz S, Jadad AR, Katz NP, Kehlet H, Kramer LD, Manning DC, 
McCormick C, McDermott MP, McQuay HJ, Patel S, Porter L, Quessy S, Rappaport BA, 
Rauschkolb C, Revicki DA, Rothman M, Schmader KE, Stacey BR, Stauffer JW, von Stein T, 
White RE, Witter J, Zavisic S. Interpreting the clinical importance of treatment outcomes in 
chronic pain clinical trials:  IMMPACT recommendations. J Pain. 2008;9(2), 105-121. 
Eisenhauer EA, Therasse P, Bogaert J, Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, 
Gwyther S, Mooney M, Rubinstein L, Shankar L, Dodd L, Kaplan R, Lacombe D, Verweij J. 
New response evaluation criteria in solid tumours:  revised RECIST guideline (version 1.1). 
Eur J Cancer. 2009;45(2) 228-247. 
Fayers PM, Aaronson NK, Bjordal K, Groenvold M, Curran D, Bottomley A, on behalf of the 
EORTC Quality of Life Group. The EORTC QLQ-C30 Scoring Manual. 3rd edition. Brussels: 
European Organisation for Research and Treatment of Cancer, Brussels; 2001. 
Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, 
Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: 
IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on 
Cancer. Available from http://globocan.iarc.fr. 2013. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 74 
LY2835219 
 
 
 
Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, 
Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, 
Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, 
Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff 
JL, Wolff AC. American Society of Clinical Oncology/College of American Pathologists 
guideline recommendations for immunohistochemical testing of estrogen and progesterone 
receptors in breast cancer. J C/in Onco/. 2010;28(16):2784-2795. 
Janssen MF, Birnie E, Haagsma JA, Bonsel GJ. Comparing the standard EQ-5D three-level 
system with a five-level version. Va/ue Hea/th. 2008;11(2):274-284. 
Kaplan EL, Meier P. Nonparametric estimation of incomplete observations. J Amer Stat Assoc. 
1958;53:457-481. 
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, Carbone PP. Toxicity 
and response criteria of the eastern cooperative oncology group. Am J C/in Onco/. 1 
655. 
82;5:649- 
Ortega S, Malumbres M, Barbacid M. Cyclin-D dependent kinases INK4 inhibitors and Cancer. 
Biochim Biophys Acta. 2002;1602:73-87. 
Osborne CK, Pippen J, Jones SE, Parker LM, Ellis M, Come S, Gertler SZ, May JT, Burton G, 
Dimery I, Webster A, Morris C, Elledge R, Buzdar A. Double-blind, randomized trial 
comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal 
women with advanced breast cancer progressing on prior endocrine therapy: results of a North 
American trial. J C/in Onco/. 2002;20(16):3386-3395. 
Patnaik A, Rosen LS, Tolaney SM, Tolcher AW, Goldman JW, Gandhi L, Papadopoulos KP, 
Beeram M, Rasco DW, Myrand SP, Kulanthaivel P, Andrews JM, Frenzel M, Cronier D, Chan 
EM, Flaherty K, Wen PY, Shapiro G. LY2835219, a novel cell cycle inhibitor selective for 
CDK4/6, in combination with fulvestrant for patients with hormone receptor positive (HR+) 
metastatic breast cancer [abstract]. ASCO 50th Annual Meeting; 30 May-03 June 2014; 
Chicago. Abstract 534. J C/in Onco/. 2014;32:5s(suppl; abstr 534). 
Reed E, Simmonds P, Haviland J, Corner J. Quality of life and experience of care in women with 
metastatic breast cancer: a cross-sectional survey. J Pain Symptom Manage. 
2012;43(4):747-758. 
Sherr CJ. Cancer Cell Cycle. Science. 1996;274:1672-1677. 
Slud E, Wei LJ. Theory and Method:  Two-Sample Repeated Significance Tests Based on the 
Modified Wilcoxon Statistic. J Amer Stat Assoc. 1982;77(380):862-868. 
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. 
Recommendations for the Use of White Blood Cell Growth Factors: American Society of 
Clinical Oncology Clinical Practice Guideline Update. J C/in Onc 2015, 
http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.62.3488.full. Accessed 01 October 
2015. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 75 
LY2835219 
 
 
 
Sprangers MA, Groenvold M, Arraras JI, Franklin J, te Velde A, Muller M, Franzini L, 
Williams A, de Haes HC, Hopwood P, Cull A, Aaronson NK. The European Organization for 
Research and Treatment of Cancer breast cancer-specific quality-of-life questionnaire module: 
first results from a three-country field study. J C/in Onco/. 1996;14(10):2756-2768. 
van den Beuken-van Everdingen MH1, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, 
Patijn J. High prevalence of pain in patients with cancer in a large population-based study in 
The Netherlands. Pain. 2007;132(3):312-320. 
van Hout B, Janssen MF, Feng YS, Kohlmann T, Busschbach J, Golicki D, Lloyd A, Scalone L, 
Kind P, Pickard AS. Interim scoring for the EQ-5D-5L: mapping the EQ-5D--5L to EQ-5D-3L 
value sets. Va/ue Hea/th. 2012;15(5):708-715. 
Velasco-Velazquez, MA, Li Z, Casimiro M, Loro E, Homsi N, Pestell RG. Examining the role of 
cyclin D1 in breast cancer. Future Onco/. 2011;7:753-765. 
Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM,, Allison KH, Allred DC, 
Bartlett JM, Bilous M, Fitzgibbons P, Hanna W, Jenkins RB, Mangu PB, Paik S, Perez EA, 
Press MF, Spears PA, Vance GH, Viale G, Hayes DF. Recommendations for human epidermal 
growth factor receptor 2 testing in breast cancer: American Society of Clinical 
Oncology/College of American Pathologists clinical practice guideline update. J C/in Onco/. 
2013;31(31):3997-4013. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 76 
LY2835219 
 
 
 
 
 
Attachment 1. Protocol JPBM Study Schedule 
 
 
 
Protocol I3Y-MC-JPBM 
 
Baseline Schedule 
Study Period 
Baseline (BL) 
Visit 
0 
Approximate 
Visit Duration 
(days) 
Up to 28 
Relative day to 
C1D1 
28 
14 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Study Entry 
/Enrollment 
Informed Consent Form 
signed 
Section 13.1 
X 
Prior to conducting any protocol-specific tests / 
procedures 
Inclusion/Exclusion 
evaluation 
Section 7 
X 
Medical 
History 
Initial medical 
history/preexisting conditions 
X 
Historical illnesses 
X 
Include habits assessment of alcohol and tobacco 
use 
Physical 
Examination 
Physical examination 
X 
Include but not limited to height and weight 
Vital Signs 
X 
Include blood pressure, pulse, respiratory rate, 
and temperature 
ECOG performance status 
Attachment 4 
X 
Tumor 
Assessment 
Tumor measurement 
(palpable or visible) 
Section 10.1.1 
X 
Photography of skin lesions with ruler required, if 
applicable 
Radiologic imaging according 
to RECIST 1..1 
Section 10.1.1 
Attachment 5 
X 
Performed locally. For patients with 
locoregionally recurrent breast cancer, MRI scan 
of the breast; additionally, for all patients, CT or 
MRI scan of the chest, abdomen, and pelvis. CT 
scan is the best currently available and 
reproducible method to measure lesions selected 
for response assessment; it is recommended that 
CT imaging of the abdomen and pelvis be 
performed with IV contrast whenever possible. 
MRI may be used instead of CT in selected 
instances. Gadolinium-enhanced MRI is 
preferred if hypersensitivity to contrast. 
Bone Scintigraphy 
Section 10.1.1 
Attachment 5 
X 
Performed locally. Bone scintigraphy performed 
as part of routine clinical care within 45 days 
before Cycle 1 Day 1 is also acceptable. 
X-ray, or CT scan with bone 
windows, or MRI 
Section 10.1.1 
Attachment 5 
X 
Performed locally. For on/y those patients with 
bone /esions identified by bone scintigraphy at 
base/ine, all bone lesions will be evaluated at 
baseline by focused studies to enable serial 
assessment. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 77 
LY2835219 
 
 
X 
 
 
Protocol I3Y-MC-JPBM 
 
Baseline Schedule 
Study Period 
Baseline (BL) 
Visit 
0 
Approximate 
Visit Duration 
(days) 
Up to 28 
Relative day to 
C1D1 
28 
14 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Adverse Event Collection/CTCAE Grading 
Section 10.3 
X 
CTCAE = Common Terminology Criteria for 
Adverse Events 
Concomitant Medication Notation 
Section 9.6 
X 
Note:  RANK-L or bisphosphonate agents should 
be initiated 2'7 days prior to randomization, if 
applicable. 
Lab/ 
Diagnostic 
Tests 
Central hematology 
Attachment 2 
X 
Enrollment and treatment decisions may be based 
upon results of tests performed locally. If local 
laboratory tests a e used for this purpose, then a 
duplicate specimen must be submitted to the 
central laboratory. Discrepancies between local 
and central laboratory that may have an impact 
on eligibility or treatment decisions will not be 
con idered protocol deviations 
Central chemistry 
Attachment 2 
X 
Enrollment and treatment decisions may be based 
upon results of tests performed locally. If local 
laboratory tests are used for this purpose, then a 
duplicate specimen must be submitted to the 
central laboratory. Discrepancies between local 
and central laboratory that may have an impact 
on eligibility or treatment decisions will not be 
considered protocol deviations. 
Local FSH and estradiol level 
Attachment 2 
X 
Required only for women < 60 years with 
amenorrhea for at least 12 months to confirm 
post-menopausal status 
Local ECG 
Section 10.3.2.1 
X 
Patients must be supine for approximately 5 to 10 
minutes before ECG collection and remain supine 
but awake during ECG collection. 
Abbreviations:  CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; ECOG = 
Eastern Cooperative Oncology Group; FSH = follicle stimulating hormone; IV = intravenous; MRI = magnetic resonance imaging; RANK-L = 
RANK ligand; RECIST = Response Evaluation Criteria in Solid Tumors. 

LY2835219 
 
X
X
X
X
X
X
X 
X 
X 
X 
X 
X 
 
 
Protocol 13Y-MC-JPBM 
During Treatment Study 
Schedule 
Study Treatment Period 
Cycle / Visit 
1 
2 
3 
4-X 
Approximate 
Visit Duration 
(days) 
28 
28 
28 
28 
Relative day 
within a cycle 
1 
1 
21-28 
1 
1 
21-28 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Physical 
Examination 
Physical Exam 
X 
X 
X 
X 
lnclude but not limited to weight 
Vital Signs 
X 
X 
X 
X 
lnclude blood pressure, pulse, respiratory rate, and temperature. 
ECOG performance 
status 
Attachment 4 
X 
X 
X 
X 
Archived Tumor Tissue 
Section 
10.4.2.1 
X 
Whole or partial block or 15 - 20 slides should be provided upon 
patient randomization. 
Adverse Event Collection/CTCAE 
Grading 
Section 10.3 
X 
X 
X 
X 
Concomitant Medication Notation 
Section 9.6 
X 
X 
X 
X 
Lab/ 
Diagnostic 
Tests 
Central hematology 
Attachment 2 
X 
X 
X 
X 
Central hematology labs may be drawn up to 3 days prior to Day 
1 of each cycle. Additional local hematology labs may be drawn 
for treatment adjustment and patient management purposes. 
Central chemistry 
Attachment 2 
X 
X 
X 
X 
Central chemistry labs may be drawn up to 3 days prior to Day 1 
of each cycle. Additional local chemistry labs may be drawn for 
treatment adjustment and patient management purposes. 
Pharmacokinetic (PK) 
sampling 
Attachment 7 
X 
X 
X 
See Attachment 7 for specific timing. 
Pharmacogenetic blood 
sample 
Section 
10.4.2.2 
X 
Draw sample before patient is dosed on C1D1. 
Biomarker plasma 
sample 
Section 10.4.2 
X 
X 
Draw sample before patient is dosed on C1D1 and upon arrival 
at site on C2D1. 
Local ECG 
Section 
10.3.2.1 
X 
X 
X 
2 to 4 hours after the LY dose on Cycle 1 Day 1, upon arrival at 
site on Cycle 2 Day 1, 2 to 4 hours after the LY dose on Cycle 4 
Day 1. Following C4D1, no additional ECGs are required while 
the patient is on treatment (only subsequently for short-term 
follow-up). Patients must be supine for approximately 5 to 10 
minutes before ECG collection and remain supine but awake 
during ECG collection. 
 
 
13Y-MC-JPBM(a) Clinical Protocol 
Page 78 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 79 
 
 
X 
mages 
X 
 
 
 
 
Protocol I3Y-MC-JPBM 
During Treatment Study Schedule 
Study Treatment Period 
Cycle / Visit 
1 
2 
3 
4-X 
Approximate 
Visit Duration 
(days) 
28 
28 
28 
28 
Relative day 
within a cycle 
1 
1 
21-28 
1 
1 
21-28 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Tumor 
Assessment 
Tumor measurement 
(palpable or visible) 
Section 10.1.1 
X 
X 
Skin lesions identified at baseline require repeat photographic 
images on Day 1of every second cycle beginning with Cycle 3 and 
continuing through Cycle 19 (inclusive), on Day 1of every third 
cycle after Cycle 19, and within 14 days of clinical progression. 
Photographic images may be taken more frequently based upon 
the discretion of the investigator or following the identification of 
new skin lesions post-baseline. 
Radiological imaging 
according to RECIST (CT 
scan/MRI) 
Section 10.1.1 
Attachment 5 
X 
X 
Performed locally. For patients with locoregionally recurrent 
breast cancer not amenable to curative treatment, MRI scan of the 
breast is performed, if applicable, in addition to other scans. 
Imaging studies (Breast MRI and CT scan or MRI of the chest, 
abdomen, and pelvis) will be repeated on Day 21 to Day 28 of 
every second cycle beginning with Cycle 2 and continuing 
through Cycle 18 (inclusive), on Day 21 to Day 28 of every third 
cycle after Cycle 18, and within 14 days of clinical progression. 
The same method of imaging used at baseline should be used for 
each subsequent assessment. 
Bone Scintigraphy 
Section 10.1.1 
Attachment 5 
X 
Performed locally. Repeat for all patients on Day 21 to Day 28 of 
every sixth cycle beginning with Cycle 6. In addition, bone scans 
should be repeated even if a complete response is identified in 
target disease or progression in bone is suspected. Importantly, 
RECIST v1.1 emphasizes that bone scintigraphy is not adequate to 
measure bone lesions; however, bone scintigraphy can be used to 
confirm the presence or disappearance of bone lesions. 
X-ray, CT scan with bone 
windows, or MRI 
Section 10.1.1 
Attachment 5 
X 
X 
Performed locally for patients with bone lesions identified by bone 
scintigraphy at baseline. Repeat on Day 21 to Day 28 of every 
second cycle beginning with Cycle 2 and continuing through 
Cycle 18 (inclusive), on Day 21 to Day 28 of every third cycle 
after Cycle 18, and within 14 days of clinical progression. For 
patients with new lesions identified by post-baseline bone 
scintigraphy, targeted assessment by X-ray, CT scan with bone 
windows, or MRI will be performed to confirm findings. 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 80 
 
 
Cycle 
orally every 12 
of every cycle with the
Take 2.5mg tablet orally 
through 28 
 
 
Protocol I3Y-MC-JPBM 
During Treatment Study 
Schedule 
Study Treatment Period 
Cycle / Visit 
1 
2 
3 
4-X 
Approximate 
Visit Duration 
(days) 
28 
28 
28 
28 
Relative day 
within a 
cycle 
1 
1 
21-28 
1 
1 
21-28 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Health 
Outcomes 
EORTC QLQ-C30, 
EORTC QLQ-BR23, 
EQ-5D 5L 
Section 10.2 
X 
X 
X 
Patients complete prior to extensive interaction with site staff. 
On Cycle 1 Day 1, questionnaires must be administered prior to the first 
dose of study tre tment. Questionnaires should be administered on 
Cycle1 Day 1, and then Day 1 of every second cycle beginning with 
Cycle 3 through Cycle 19, and on Day 1of every third cycle after 
Cycle 19. 
Study Drug 
LY2835219 or Placebo 
(blinded randomization) 
Section 9.1 
Take 150 mg or prescribed dose orally every 12 
hours on Days 1 through 28 of every cycle, with the 
exception that the second dose on C1D1 should be 
omitted to allow for adequate study drug for at home 
dosing on C2D1. 
On Cycle 1 Day 1 only, patients should take one single dose of blinded 
study drug and initiate chronic every 12 hour dosing on Cycle 1 Day 2. 
On Cycle 2 Day 1, patients will take medication at home at least 4 hours 
prior to arrival at the clinic. On Cycle 4 Day 1, patients will take 
morning dose of blinded study drug in the clinic. 
Co- 
Administered 
Drug 
(per 
investigator 
selection) 
anastrozole 
Section 9.1 
Take 1mg tablet orally every 24 hours on Days 1 
through 28 
For PK and ECG purposes, should be taken at the same time as, or up to 
20 minutes after the morning dose of blinded study drug. Adjustment to 
timing of dose administration may be made at the discretion of the 
investigator after Cycle 4 Day 1. 
letrozole 
Section 9.1 
Take 2.5mg tablet orally every 24 hours on Days 1 
through 28 
For PK and ECG purposes, should be taken at the same time as, or up to 
20 minutes after the morning dose of blinded study drug. Adjustment to 
timing of dose administration may be made at the discretion of the 
investigator after Cycle 4 Day 1. 
Abbreviations:  C4D1 = Cycle 4 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; EORTC QLQ-BR23 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast cancer; EORTC QLQ-C30 = European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Core 30; EQ-5D 5L = EuroQol 5-Dimension 5 Level; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors. 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 81 
 
 
Includes 
X
X
 
 
Protocol I3Y-MC-JPBM 
Post Treatment Discontinuation 
Study Schedule 
Study Period 
Post-Discontinuation 
Short Term Follow-Up 
Postdiscontinuation 
Long Term Follow-Up 
Visit 
801 
802-X 
Approximate 
Visit Duration 
(days) 
30±5 
Variable 
Relative day 
30 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Physical 
Examination 
Physical Exam 
X 
Includes but not limited to weight 
Vitals 
X 
Includes blood pressure, pulse, respiratory rate, and temperature. 
ECOG Performance 
Status 
Attachment 4 
X 
Tumor 
Assessment 
Tumor measurement 
(palpable or visible) 
Section 10.1.1 
X 
X 
ONLY For patients who discontinue study treatment without objectively 
measured progressive disease (PD), continue to conduct tumor assessments 
approximately every 8 weeks for the first 18 months following randomization 
and thereafter approximately every 12 weeks until the patient has objective 
disease progression or until study completion. After the patient has objective 
disease progression, photographic images are no longer required and the 
patient will continue with post-discontinuation follow-up approximately 
every 12 weeks until the patient's death or overall study completion. 
Bone Scintigraphy 
Section 10.1.1 
Attachment 5 
X 
X 
ONLY For patients who discontinue study treatment without objectively 
measured progressive disease (PD), continue to evaluate repeat bone scans 
approximately every 6 months until objective disease progression or study 
completion. 
Radiologic imaging 
according to RECIST 
Section 10.1.1 
Attachment 5 
X 
X 
The same method of imaging used at baseline should be used for each 
subsequent assessment. ONLY For patients who discontinue study 
treatment without objectively measured progressive disease (PD), 
continue to conduct tumor assessment approximately every 8 weeks for the 
first 18 months following randomization and thereafter approximately every 
12 weeks by the same method used at baseline and throughout the study until 
the patient has objective disease progression or until study completion. After 
the patient has objective disease progression, radiologic tests are no longer 
required and the patient will continue with post-discontinuation follow-up 
approximately every 12 weeks until the patient's death or overall study 
completion 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 82 
 
 
stu 
X
X
X
 
 
Protocol I3Y-MC-JPBM 
Post Treatment Discontinuation 
Study Schedule 
Study Period 
Post-Discontinuation 
Short Term Follow-Up 
Postdiscontinuation 
Long Term Follow-Up 
Visit 
801 
802-X 
Approximate 
Visit Duration 
(days) 
30±5 
Variable 
Relative day 
30 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Tumor 
Assessment 
continued 
X-ray, CT scan with 
bone windows, or 
MRI 
Section 10.1.1 
Attachment 5 
X 
X 
ONLY For patients who discontinue study treatment without objectively 
measured progressive disease (PD), focused studies are performed for 
patients with bone lesions previously identified by bone scintigraphy. During 
long term follow up period, repeat scans should performed approximately 
every 8 weeks for the first 18 months following randomization, and 
subsequently approximately every 12 weeks until disease progression or 
tudy completion. 
Survival Information 
Section 10.1.4 
X 
X 
Although preferable to collect during a clinic visit, survival information may 
be collected by contacting the patient or family directly (for example, via 
telephone) if no procedures required. This should be collected at minimum 
every 90 days if no other procedures are performed. Additional long-term 
follow-up data collection will include post-discontinuation anticancer 
therapies. 
Adverse Events Collection/CTCAE 
Grading 
Section 10.3 
X 
X 
After Visit 801, only study protocol or drug-related events are reported. If a 
patient has ongoing AE or SAE possibly related to study drug (not co- 
administered drug) (for instance, abnormal electrolytes), the patient should be 
followed until the event is resolved, the event is no longer considered to be 
drug-related, the event becomes stable or returns to baseline, a new treatment 
is initiated for the patient, or the patient dies or is lost to follow-up. Any 
subsequent follow-up(s) for AEs will be no more than 30 days ± 5 days in 
duration. 
Concomitant Medications Notation 
Section 9.6 
X 
Lab/ Diagnostic 
Tests 
Central hematology 
Attachment 2 
X 
Central chemistry 
Attachment 2 
X 
Biomarker plasma 
sample 
Section 10.4.2 
X 
Draw sample only for patients discontinuing due to PD. 
ECG 
Section 
10.3.2.1 
X 
Patients must be supine for approximately 5 to 10 minutes before ECG 
collection and remain supine but awake during ECG collection. 
Health 
Outcomes 
EORTC QLQ-C30, 
EORTC QLQ-BR23, 
EQ-5D 5L 
Section 10.2 
X 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 83 
 
 
 
Protocol I3Y-MC-JPBM 
Post Treatment Discontinuation Study Schedule 
 
Abbreviations:  AE = adverse event; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; EORTC QLQ-BR23 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast cancer; EORTC QLQ-C30 = European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Core 30; EQ-5D 5L = EuroQol 5-Dimension 5 Level; MRI = magnetic resonance imaging; PK = pharmacokinetics; RECIST = Response Evaluation 
Criteria in Solid Tumors; SAEs = serious adverse events. 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 84 
 
 
X 
X 
X 
 
 
Protocol I3Y-MC-JPBM 
Study Schedule for the 
Continued Access Period only 
Study Period 
Patients on Study Treatment 
Continued Access Period 
Follow-Up 
Cycle 
X 
Follow-Upa 
Visit 
501-5XX 
901 
Approximate 
Visit Duration 
(days) 
28±3 
30±5 
Relative day 
within a cycle 
1 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Adverse Events Collection/CTCAE Grading 
Section 10.3 
X 
X 
Data on SAEs that occur before the end of trial will be 
stored in the collection database and the Lilly safety 
system 
Study Drug 
LY2835219 
Section 9.1 
X 
Only patients assigned to LY2835219 at randomization 
and receiving clinical benefit will continue to receive 
LY2835219 during the continued access period. 
LY2835219 is to be administered orally every 12 hours 
on Days 1 through 28 of each cycle. Patients who were 
assigned to placebo, will no longer receive placebo 
during the continued access period and cannot crossover 
to LY2835219. 
Co- 
Administered 
Drugs 
Anastrozole 
Section 9.1 
X 
Patients receiving clinical benefit will continue to 
receive anastrozole or letrozole during the continued 
access period. Anastrozole or letrozole is to be 
administered orally every 24 hours on Days 1 through 
28 of each cycle 
Letrozole 
Section 9.1 
X 
Abbreviations:  CTCAE = Common Terminology Criteria for Adverse Events; OS = overall survival; SAEs = serious adverse events. 
a  The continued access period begins after study completion (that is, after final OS analysis) and ends at the end of trial (that is, the last patient visit). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 85 
LY2835219 
 
 
 
 
 
Attachment 2. Protocol JPBM Clinical Laboratory Tests 
 
 
 
Clinical Laboratory Tests 
 
Hematologya: 
Clinical Chemistrya,d: 
Hemoglobin 
Serum Concentrations of: 
Hematocrit 
Sodium 
Erythrocyte count (RBC) 
Potassium 
Mean cell volume (MCV) 
Total Protein 
Mean cell hemoglobin concentration (MCHC) 
Total bilirubin 
Leukocytes (WBC) 
Direct bilirubin 
Neutrophils, (segmented and bands) 
Alkaline phosphatase 
Lymphocytes 
Alanine aminotransferase (ALT) 
Monocytes 
Eosinophils 
Basophils 
Platelets 
Aspartate aminotransferase (AST) 
Blood urea nitrogen (BUN) 
Creatinine 
Calcium 
Albumin 
 
Follicle Stimulating Hormone (FSH) levelb,c 
Estradiol levelb,c 
 
Abbreviations:  RBC = red blood cells; WBC = white blood cells. 
a   Assayed by Lilly-designated (central) laboratory. 
b Local or investigator-designated laboratory. 
c To be performed at baseline in order to establish eligibility only for women <60 years and ammenorrheic for at 
least 12 months. 
d Per the lletrozole and anastrozole labels, investigators should consider monitoring cholesterol. The decision to 
monitor and frequency of monitoring are at the discretion of the investigator. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 86 
LY2835219 
 
 
 
 
 
Attachment 3. Protocol JPBM Hepatic Monitoring Tests for 
Treatment-Emergent Abnormality 
 
 
Selected tests may be obtained in the event of a treatment-emergent hepatic abnormality and may 
be required in follow up with patients in consultation with the Lilly clinical research physician. 
Hepatic Monitoring Tests 
 
Hepatic Hematologya 
Haptoglobina 
Hemoglobin 
Hematocrit 
Hepatic Coagulationa 
RBC 
Prothrombin Time 
WBC 
Prothrombin Time, INR 
Neutrophils, segmented and bands 
Lymphocytes 
Hepatic Serologiesa,b 
Monocytes 
Eosinophils 
Basophils 
Platelets 
Hepatitis A antibody, total 
Hepatitis A antibody, IgM 
Hepatitis B surface antigen 
Hepatitis B surface antibody 
Hepatitis B Core antibody 
Hepatic Chemistrya 
Hepatitis C antibody 
Total bilirubin 
Hepatitis E antibody, IgG 
Direct bilirubin 
Hepatitis E antibody, IgM 
Alkaline phosphatase 
ALT 
Anti-nuclear antibodya 
AST 
GGT 
CPK 
Anti-smooth muscle antibodya 
 
Abbreviations: ALT = alanine aminotransferase; AST = aspartate aminotransferase; CPK = creatine phosphokinase; 
GGT = gamma glutamyl transferase; Ig = immunoglobulin; INR = international normalized ratio; RBC = red 
blood cells; WBC = white blood cells. 
a Assayed by Lilly-designated laboratory. 
b Reflex/confirmation dependent on regulatory requirements and/or testing availability. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 87 
LY2835219 
 
 
 
 
 
Attachment 4. Protocol JPBM ECOG Performance Status 
 
 
 
ECOG Performance Status 
 
Activity Status 
Description 
 
0 
Fully active, able to carry on all pre-disease performance 
without restriction 
 
 
1 
Restricted in physically strenuous activity but 
ambulatory and able to carry out work off a light or 
sedentary nature, e.g., light house work, office work 
 
 
2 
Ambulatory and capable of allll  selfcare but unable to 
carry out any work activities. 
50% of waking hours 
Up and about more than 
 
 
3 
Capable of only limited selfcare, confined to bed or chair 
more than 50% of waking hours 
 
 
4 
Completely disabled.  Cannot carry on any selfcare. 
Totally confined to bed or chair 
 
 
5 
Dead. 
 
 
Abbreviation:  ECOG = Eastern Cooperative Oncology 
Group. Source:  Oken et al. 1982. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 88 
LY2835219 
 
 
 
 
 
Attachment 5. Protocol JPBM REC1ST Criteria 1.1 
 
 
Response and progression will be evaluated in this study using the international criteria proposed 
by the New Response Evaluation Criteria in Solid Tumors (RECIST): Revised RECIST 
Guideline (version 1.1; Eisenhauer et al. 2009). 
Measurability of Tumor at Baseline 
Tumor lesions/lymph nodes will be categorized at baseline as measurable orr nonmeasurable. 
Measurable disease is defined by the presence of at least 1 measurable lesion. 
Measurable 
Tumor lesions:  Measured in at least 1 dimension (longest diameter in the plane of measurement 
is to be recorded) with a minimum size of: 
 10 mm by computed tomography (CT) or magnetic resonance imaging (MRI) 
scan (slice thickness 5 mm) 
 10 mm caliper measurement by clinical exam (non-measurable lesions if cannot 
be accurately measured with calipers) 
 20 mm by chest x-ray. 
Malignant lymph nodes:  To be considered pathologically enlarged and measurable, a lymph 
node must be 15 mm in short axis when assessed by CT scan (CT scan thickness recommended 
to be 5 mm). 
Nonmeasurable 
All other lesions, including small lesions (longest diameter <10 mm or pathological lymph nodes 
with 10 to <15 mm short axis) as well as truly nonmeasurable lesions.  Lesions considered truly 
non-measurable include:  leptomeningeal disease, ascites, pleural/pericardial effusions, 
lymphangitis cutis/pulmonis, inflammatory breast disease, lymphangitis involvement of skin or 
lung, abdominal masses/abdominal organomegaly identified by physical exam that is not 
measureable by reproducible imaging techniques. 
Special Considerations for Lesion Measurability 
Bone lesions: 
 Bone scan, PET scan or plain films are not considered adequate imaging 
techniques to measure bone lesions. 
 Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue 
components, that can be evaluated by cross sectional imaging techniques such as 
CT or MRI, can be considered measurable lesions if the soft tissue component 
meets the definition of measurability. 
 Blastic bone lesions are non-measurable. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 89 
LY2835219 
 
 
 
Cystic lesions: 
 Simple cysts should not be considered as malignant lesions (neither 
measurable nor nonmeasurable) 
 Cystic lesions thought to represent cystic metastases can be considered as 
measurable lesions, if they meet the definition of measurability. If noncystic 
lesions are presented in the same patients, these are preferred for selection as 
target lesions. 
Lesions with Prior Local Treatment: 
 Tumor lesions situated at a previously irradiated area, or in an area subjected to other 
loco-regional therapy, are non-measurable unless there has been demonstrated 
progression in the lesion. 
Baseline Documentation of Target and Non-Target Lesion 
Target Lesions 
When more than 1 measurable lesion is present at baseline, all lesions up to a maximum of 5 
lesions total (and a maximum of 2 lesions per organ) representative of all involved organs should 
be identified as target lesions and will be recorded and measured at baseline.  Non-nodal Target 
lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, and can be reproduced in repeated measurements.. 
Measurable lymph nodes are target lesions if they meet the c iteria of a short axis of 15 mm by 
CT scan. All measurements are to be recorded in the case record form (CRF) in millimeters (or 
decimal fractions of centimeters [cm]). 
Nontarget Lesions 
All other lesions (or sites of disease) are identiified as nontarget lesions (chosen based on their 
representativeness of involved organs and the ability to be reproduced in repeated measurements) 
and should be recorded at baseline.  Measurement of these lesions are not required but should be 
followed as 'present,' 'absent,' or in rare cases 'unequivocal progression.'  In addition, it is 
possible to record multiple nontarget lesions involving the same organ as a single item on the 
CRF (for example, multiple liver metastases recorded as 1 liver lesion). 
Lymph nodes with short axis 10 mm but <15 mm should be considered nontarget lesions. 
Nodes that have a short axis <10 mm are considered nonpathological and are not recorded or 
followed. 
 
Specifications by Methods of Measurement 
All measurements should be recorded in metric notation, using a ruler or calipers if clinically 
assesse . All baseline evaluations should be performed as closely as possible to the beginning  of 
treat   ent and never more than 4 weeks before the beginning of the treatment. 
The same method of assessment and the same technique should be used to characterize each 
identified and reported lesion at baseline and during follow-up.  Imaging-based evaluation is 

13Y-MC-JPBM(a) Clinical Protocol 
Page 90 
LY2835219 
 
 
 
should always be done rather than clinical examination unless the lesion(s) being followed 
cannot be imaged but are assessed by clinical exam. 
An adequate volume of a suitable contrast agent should be given so that the metastases are 
demonstrated to best effect and a consistent method is used on subsequent examinations for any 
given patient. If prior to enrollment it is known a patient is not able to undergo CT scans with IV 
contrast due to allergy or renal insufficiency, the decision as to whether a non-contrast CT or 
MRI (with or without IV contrast) should be used to evaluate the patient at baseline and follow- 
up should be guided by the tumor type under investigation and the anatomic location of the 
disease. 
C/inica/ Lesions:  Clinical lesions will only be considered measurable when they are superficial 
and 10 mm diameter as assessed using calipers (for example, skin nodules).  For the case of 
skin lesions, documentation by color photography, including a rulerr to estimate the size of the 
lesion is recommended.  When lesions can be evaluated by both clinical exam and imaging, 
imaging evaluation should be undertaken since it is more objective and may be reviewed at the 
end of the study. 
Chest X-Ray: Chest CT is preferred over chest x-ray when progression is an important endpoint. 
Lesions on chest x-ray may be considered measurable if they are clearly defined and surrounded 
by aerated lung. 
CT and MRI:  CT scan is the best currently available and reproducible method to measure lesions 
selected for response assessment.  Measurability of lesions on CT scan is based on the 
assumption that CT slice thickness iss 5 mm. When CT scan have slice thickness >5 mm, the 
minimum size for a measurable lesion should be twice the slice thickness.  MRI is also 
acceptable in certain situations (for example, for body scans).  If there is concern about radiation 
exposure at CT, MRI may be used instead of CT in selected instances. 
U/trasound:  Ultrasound should not be used to measure lesion size.  Ultrasound examinations 
cannot be reproduced in their entirety for independent review at a later date and, because they are 
operator dependent, it cannot be guaranteed that the same technique and measurements will be 
taken from one assessment to the next. If new lesions are identified by ultrasound in the course 
of the study, confirmation by CT or MRI is advised. 
Endoscopy, Laparoscopy:  The utilization of these techniques for objective tumor evaluation is 
not advised.  However, such techniques can be useful to confirm complete pathological response 
when biopsies are obtained or to determine relapse in trials where recurrence following complete 
response or surgical resection is an endpoint. 
Tumor Markers:  Tumor markers alone cannot be used to assess tumor response.  If markers are 
initially above the upper normal limit, they must normalize for a patient to be considered in 
complete response (CR). Specific guidelines for both prostate-specific antigen (PSA) response 
((in recurrent prostate cancer) and CA-125 response (in recurrent ovarian cancer) have been 
published. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 91 
LY2835219 
 
 
 
Cyto/ogy, Histo/ogy:  These techniques can be used to differentiate between partial responses 
(PR) and complete response (CR) in rare cases if required by protocol (for example, residual 
lesions in tumor types such as germ cell tumors, where known residual benign tumors can 
remain). When effusions are known to be a potential adverse effect of treatment (for example, 
with certain taxane compounds or angiogenesis inhibitors), the cytological confirmation of the 
neoplastic origin of any effusion that appears or worsens during treatment can be considered if 
the measurable tumor has met criteria for response or stable disease (SD) in order to differentiate 
between response (or SD) and progressive disease (PD). 
Pet Scan (FDG-PET, PET CT):  PET is not recommended for lesion assessment.  If a new lesion 
is found by PET, another assessment must be done by CT, unless the PET CT is of diagnostic 
quality.  If CT is done to confirm the results of the earlier PET scan, the date of progression must 
be reported as the earlier date of the PET scan. 
Bone Scan:  If lesions measured by bone scan are reported at baseline, it is necessary to repeat 
the bone scan when trying to identify a complete response (CR) or partial response (PR) in target 
disease or when progression in bone is suspected. 
 
Response Criteria 
Evaluation of Target Lesions 
Comp/ete Response (CR): Disappearance of all target lesions. 
 
 
Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to <10 mm.  Tumor marker 
results must have normalized. 
Partia/ Response (PR): At least a 30% decrease in the sum of diameter of target lesions, taking 
as reference the baseline sum diameters. 
Progressive Disease (PD):  At least a 20% increase in the sum of the diameters of target lesions, 
taking as reference the smallest sum on study (including the baseline sum if that is the smallest). 
In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase 
of at least 5 mm.  The appearance of 1 or more new lesions is also considered progression. 
For equivocal findings of progression (for example, very small and uncertain new lesions; cystic 
changes or necrosis in existing lesions), treatment may continue until the next scheduled 
assessment.  If at the next scheduled assessment, progression is confirmed, the date of 
progression should be the earlier date when progression was suspected. 
Stab/e Disease (SD): Neither sufficient shrinkage to qualify for PR nor sufficient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study. 
Not Eva/uab/e: When an incomplete radiologic assessment of target lesions is performed or 
there is a change in the method of measurement from baseline that impacts the ability to make a 
reliable evaluation of response. 
Evaluation of Nontarget Lesions 
Comp/ete Response: Disappearance of all nontarget lesions and normalization of tumor marker 
level.  All lymph nodes must be non-pathological or normal in size (<10mm short axis). 

13Y-MC-JPBM(a) Clinical Protocol 
Page 92 
LY2835219 
 
 
 
Non-CR/ non-PD: Persistence of 1 or more nontarget lesions and/or maintenance of tumor 
marker level above the normal limits. 
 
Progressive Disease: Unequivocal progression of existing nontarget lesions. The appearance of 
1 or more new lesions is also considered progression. 
Not Eva/uab/e:  When a change in method of measurement from baseline occurs and impacts the 
ability to make a reliable evaluation of response. 
Evaluation of Best Overall Response 
The best overall response is the best response recorded from the start of the study treatment until 
the earliest of objective progression or start of new anticancer therapy, taking into account any 
requirement for confirmation.  The patient's best overall response assignment will depend on the 
findings of both target and nontarget disease and will also take into consideration the appearance 
of new lesions.  The Best Overall Response will be calculated via an algorithm using the 
assessment responses provided by the investigator over the course of the trial. 
Time Point Response 
It is assumed that at each protocol-specified time point, a response assessment occurs. (When no 
imaging/measurement is done at all at a particular time point, the patient is not evaluable (NE) at 
that time point.)  Table 1 provides a summary of the overall response status calculation at each 
time point for patients who have measurab/e disease at baseline. 
Table 1. Time Point Response: Patients with Target ( Nontarget) Disease 
 
Target Lesions 
Non-Target Lesions 
New Lesions 
Overall Response 
CR 
CR 
No 
CR 
CR 
Non-CR/non-PD 
No 
PR 
CR 
Not evaluated 
No 
PR 
PR 
Non-PD or not all evaluated 
No 
PR 
SD 
Non-PD or not all evaluated 
No 
SD 
Not allll evaluated 
Non-PD 
No 
NE 
PD 
Any 
Yes or No 
PD 
Any 
PD 
Yes or No 
PD 
Any 
Any 
Yes 
PD 
Abbreviations: CR = complete response; PR = partial response; SD = stable disease.; PD = progressive disease; 
NE = inevaluable. 
 
 
Table 2 is to be used when patients have nonmeasurab/e disease only. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 93 
LY2835219 
 
 
 
 
Table 2. Time Point Response: Patients with Nontarget Disease Only 
 
Nontarget Lesions 
New Lesions 
Overall Response 
CR 
No 
CR 
Non-CR/non-PD 
No 
Non-CR/non-PDa 
Not all evaluated 
No 
NE 
Unequivocal PD 
Yes or No 
PD 
Any 
Yes 
PD 
Abbreviations:  CR = complete response; PD = progressive disease ; NE = inevaluable. 
a    non-CR/non-PD is preferred over SD for nontarget disease. 
 
 
 
Frequency of Tumor Re-Evaluation 
A baseline tumor evaluation must be performed within 4 weeks before patie 
 
 
t begins study 
treatment.  Frequency of tumor re-evaluation while on and adapted to tre tment should be 
protocol-specific and adapted to the type and schedule of treatment.  I   the context of Phase 2 
studies where the beneficial effect therapy is not known, follow-up every 6-8 weeks is 
reasonable.  Normally, all target and non-target sites are evaluated at each assessment using the 
same method.  However, bone scans may need to be repeated only when CR is identified in 
target disease or when progression in bone is suspected. 
 
Confirmatory Measurement/Duration of Response 
Confirmation: 
The main goal of confirmation of objective response in clinical trials is to avoid overestimating 
the response rate observed.  The confirmation of response is particularly important in 
nonrandomized tria/s where response (CR/PR) is the primary end point.  In this setting, to be 
assigned a status of PR/CR, changes in tumor measurements must be confirmed by repeat 
assessmentss that should be performed no less than 4 weeks after the criteria for response are first 
met.  To confirm a response of CR, a full assessment of all target and nontarget lesions that were 
present at baseline must occur, including those measured by bone scan.  To confirm a PR or SD, 
a full assessment of target lesions that were present at baseline must occur;  assessment of 
nontargets is not required. 
However, in randomized tria/ (Phase 2 or 3) or studies where SD or progression is the primary 
endpoints, confirmation of response is not required.  But, elimination of the requirement may 
increase the importance of central review to protect against bias, in particular of studies which 
are not blinded. 
IIn the case of SD, follow-up measurements must have met the SD criteria at least once after start 
of treatment at a minimum interval not less than 6 weeks measured from randomization. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 94 
LY2835219 
 
 
 
Duration of Overa// Response 
The duration of overall response is measured from the time measurement criteria are first met for 
CR or PR (whichever is first recorded) until the first date that disease is recurrent or objective 
progression is observed (taking as reference for PD the smallest measurements recorded on 
study). 
The duration of overall CR is measured from the time measurement criteria are first met for CR 
until the first date that recurrent disease is objectively documented. 
Duration of Stab/e Disease 
Stable disease is measured from the start of the treatment (in randomized trials, from date of 
randomization) until the criteria for objective progression are met, taking as reference the 
smallest sum on study (if the baseline sum is the smallest, that is the reference for calculation of 
PD). 
1ndependent Review of Response and Progression 
When objective response (CR + PR) is the primary end point, and when key drug development 
decisions are based on the observation of a minimum number of responders, it is recommended 
that all claimed responses be reviewed by an experrtt((ss)) independent of the study. If the study is a 
randomized trial, ideally reviewers should be blinded to treatment assignment. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 95 
LY2835219 
 
 
Samples
7 mL 
4  mL 
Blood 
Blood 
 
 
 
Attachment 6. Protocol JPBM Sampling Summary 
 
 
This table summarizes the purpose for sampling, sample types, maximum volume per sample, 
maximum number of samples, and maximum total volume during the study.  The summary 
below provides estimates. More samples could be required in the case of retests, additional 
health monitoring (if needed), or for patients continuing treatment beyond the protocol-specified 
number of cycles in the study.  Fewer samples may actually be taken (for example, patients who 
discontinue from the study). 
Protocol I3Y-MC-JPBM Sampling Summarya 
 
Purpose 
Sample 
Type 
Maximum 
Amount per 
Sample 
Maximum 
Number 
Samples 
Maximum Total 
A   ount 
Screening/Study qualification 
(Hematology and Clinical Chemistry) 
Blood 
7 mL 
1 
7 mL 
Safety/Health monitoring 
(Hematology and Clinical Chemistry) 
Blood 
7 mL 
17 
119 mL 
Pharmacokinetic sample 
Blood 
4  mL 
5 
20 mL 
Pharmacogenetic blood sample 
10 mL 
1 
10 mL 
Blood 
Biomarker plasma sample 
Blood 
6 mL 
3 
18 mL 
Total blood volume 
Blo d 
174 mL 
Hepatic monitoringb 
Blood 
3 - 30 mL 
- 
- 
a Covers Cycles 1 through 16 and one post-discontinuation follow up visit. 
b Based on laboratory safety values, unscheduled hepatic monitoring testing may be performed as part of patient 
follow-up, in consultation with the designated medical monitor. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 96 
LY2835219 
 
 
Day of visit 
 
 
 
Attachment 7. Protocol JPBM Electrocardiogram and 
Pharmacokinetic Sampling Schedule 
 
 
The schedule for PK sampling is summarized in the table below.  The date and exact time of 
collection for each venous blood sample should be documented on the laboratory requisition. 
Pharmacokinetic Sampling Schedule 
 
Cycle(C) and 
Day(D) 
ECG 
PK 
Sample 
Number 
Study Drug 
Dose 
Dosing of 
anastrozole / 
letrozole 
Sampling Time for ECG and 
PK from Blooda 
Baseline  
(Day -14 to Day -1) 
X 
Day of visit 
C1D1 
X 
1 
Xb 
Xb 
2-4hrs after NSAI and blinded 
study drug dosed in clinic 
C2D1 
X 
2 
Xc 
Xc 
Upon arrival at site (that is, at 
least 4 hrs after taking NSAI 
and blinded study drug doses 
at home) 
C2D1 
3 
3±0.5 hrs after arrival at site 
(that is, at least 7±0.5 hrs after 
taking NSAI and blinded 
study drug doses at home. 
C3D1 
4 
Xb 
Xb 
Prior to NSAI and blinded 
study drug doses. Patient is 
dosed in clinic after sample 
collection. 
C3D1 
5 
3±0.5hrs after NSAI and 
blinded study drug dosing in 
clinic 
C4D1 
X 
Xb 
Xb 
2-4hrs after NSAI and blinded 
study drug dosing in clinic. 
30 Day Follow-Up 
X 
Day of visit 
Abbreviation:  hrs = hours; NSAI = nonsteroidal aromatase inhibitor; PK = pharmacokinetic. 
a Samples of approximately 4 mL of whole blood will be drawn from at least 150 patients randomized in the study 
for measurement of study treatment and LY2835219 metabolites concentrations. 
b Patient is administered NSAI and study drug doses in clinic. On Cycle 1 Day 1 only, patients should take one 
single dose of blinded study drug and initiate chronic every 12 hours dosing on Cycle 1 Day 2 
c Patient should take NSAI and study drug doses at home at least 4 hours before arrival at site. The time of NSAI 
and study drug dose intake must be recorded that day.. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 97 
LY2835219 
 
 
 
 
 
Attachment 8. Protocol JPBM 1nducers, Strong 1nhibitors of 
CYP3A, or Substrates of CYPs with Narrow Therapeutic 
Range 
The  information  in  this  attachment  is  provided  for  guidance  to  investigators  and  does  not 
preclude the use of these medications if clinically indicated. 
Inducers of CYP3A 
Carbamazepine 
Dexamethasonea 
Phenobarbital/phenobarbitone 
Phenytoin 
Rifapentine 
Rifampin 
Rifabutin 
St. John's wort 
 
a   Important note:  All patients may receive supportive therapy with dexamethasone, prefera  ly 
7 days, if clinically indicated. 
Strong inhibitors of CYP3A 
All HIV protease inhibitors 
Clarithromycin 
Itraconazole 
Ketoconazole 
  Nefazodone 
 
 
Cytochrome P450 Substrates with Narrow Therapeutic R nge 
Cytochrome P450 
Substrate 
CYP1A2 
Theophylline 
Tizanidine 
CYP2C8 
Paclitaxel 
CYP2C9 
Warfarin 
Phenytoin 
CYP2D6 
Thioridazine 
Pimozide 
CYP3A 
Alfentanil 
Astemizole 
Cisapride 
Cyclosporine 
Dihydroergotamine 
Ergotamine 
Fentanyl 
Pimozide 
Quinidine 
Sirolimus 
Tacrolimus 
Terfenidine 

 
 
 
 
LY2835219 
 
 
Attachment 9. Protocol JPBM CTCAE 4.03 Diarrhea Definition 
 
 
 
 
Diarrhea will be evaluated in this study using the criteria proposed by Common Terminology Criteria for Adverse Events (CTCAE) 
v4.0 revised:  CTCAE 4.03-June 14, 2010:  Gastrointestinal disorders. 
 
Gastrointestinal Disorders 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Increase > 7 stools per day 
Diarrhea 
Increase of <4 stools 
per day over baseline; 
mild increase in 
ostomy output 
compared to baseline. 
Increase of 4-6 stools 
per day over baseline; 
moderate increase in 
ostomy output 
compared to baseline 
over baseline; 
incontinence; 
hospitalization indicated; 
severe increase in ostomy 
output compared to 
baseline; limiting self-care 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
ADL 
Definition:  a disorder characterized by frequent and watery bowel movements 
Abbreviation:  ADL = Activities of Daily Living. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13Y-MC-JPBM(a) Clinical Protocol 
Page 98 

13Y-MC-JPBM(a) Clinical Protocol 
Page 99 
LY2835219 
 
 
 
 
 
Attachment 10.      Protocol JPBM Amendment (a) Summary 
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 
Study of Nonsteroidal Aromatase 1nhibitors (Anastrozole 
or Letrozole) plus LY2835219, a CDK4/6 1nhibitor, or 
Placebo in Postmenopausal Women with Hormone 
Receptor-Positive, HER2-Negative Locoregionally 
Recurrent or Metastatic Breast Cancer with No Prior 
Systemic Therapy in this Disease Setting 
 
 
Study I3Y-MC-JPBM A Randomized, Double-Blind, Placebo-Controlled, Phase 3 St dy of 
Nonsteroidal Aromatase Inhibitors (Anastrozole or Letrozole)) plus LY2835219, a CDK4/6 
Inhibitor, or Placebo in Postmenopausal Women with Hormone Receptor-Posittive, HER2- 
Negative Locoregionally Recurrent or Metastatic Breast Cancer with No Prior Systemic Therapy 
in this Disease Setting has been amended. The new protocol is indicated by amendment (a) and 
will be used to conduct the study in place of any preceding version. 
The overall changes made to this protocol are as follows: 
 Updated CDK4/6 to CDK4 and CDK6 throughout the document 
 Updated the statistical analyses and statistical methods in Synopsis, Sections 8.1 Summary of 
Study Design, 12.1 Determinattion of Sample Size, 12.2.6 Primary Outcome and 
Methodology, 12.2.7.1 Overall Survival, and 12.2.14.2 Efficacy Interim Analyses 
 Incorporated rationale for amendment Section 5.1 Rationale for Amendment (a) 
 Incorporated Table JPBM 9.2 Toxicity D 
for Study JPBM for clarification 
se Adjustments and Delays of Blinded Study Drug 
 Clarified dose suspension and dose reduction for Grade 3 hematologic toxicity and growth 
factor administration Section 9.  .1.1.3 Hematologic Toxicity 
 Clarified supportive management of diarrhea Sections 9.4.1.1.4.1  Diarrhea and 9.6.5 
Supportive Management for Diarrhea 
 Clarified emergency unblinding if patient discontinues treatment Section 9.5.2 Emergency 
Unblinding 
 Incorporated information on substrate drugs of CYPs with narrow therapeutic margin in 
Section 9.6 Concomitant Therapy and Attachment 8 Protocol JPBL Inducers and Strong 
Inhibitors of CYP3A4 or Substrates of CYPs with Narrow Therapeutic Range 
 Clarified growth factor administration Section 9.6.4 Growth Factors 
 Clarified local ECG follow-up after C4D1 Attachment 1 Study Schedule 
Minor typographical and formatting edits were made throughout the document for clarity and 
consistency. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 100 
LY2835219 
 
 
 
Revised Protocol Sections 
 
 
2. Synopsis 
 
Study Rationale 
LY2835219 is an oral, selective, and potent small molecule cyclin-dependent kinase (CDK) 4 
and 6 (CDK4/6 and CDK6) dual inhibitor with antitumor activity within multiple preclinical 
pharmacology models and an acceptable toxicity profile in nonclinical species.  LY2835219 
mesylate has been shown to significantly inhibit tumor growth in multiple murine xenograft 
models for human cancer.  Studies with LY2835219 across breast cancer cell lines indic  te 
differential sensitivity to CDK4/6 and CDK6 inhibition based on histological and genetic 
characteristics.  Growth inhibition in vitro across a diverse panel of 46 breast cancer cell lines, 
representing the known molecular subgroups of breast cancer, indicates that sensitivity to 
CDK4/6 and CDK6 inhibition is greater in estrogen receptor-positive (ER+) breast cancers with 
luminal histology. 
Note: 
Deletions have been identified by strikethroughs. 
Additions have been identified by the use of underscore. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 101 
LY2835219 
 
 
 
Length of Study:  approximately 91 months 
Planned interim analysis: 218analyses: 189 (approximately 70% of the planned) progression-free survival (PFS) 
events and 230 (approximately 85% of the planned) PFS events 
Diagnosis and Main Criteria for Inclusion and Exclusions: 
Patients will be excluded from the study if they meet any of the following criteria: 12) have visceral crisis,, 
lymphangitic spread, or leptomeningeal carcinomatosis; 13) have inflammatory breast cancer; 14)  have clinical 
evidence or a history of central nervous system (CNS) metastasis; 15) are currently receiving or have previously 
received endocrine therapy for locoregionally recurrent or metastatic breast cancer; 16) have received prior 
(neo)adjuvant endocrine therapy with a disease-free interval :S12 months from completion of treatment; 17) are 
currently receiving or have previously received chemotherapy for locoregionally recurrent or metastatic breast 
cancer; 18) have received prior treatment with everolimus; 19) have received prior treatment with any CDK4/6 and 
CDK6 inhibitor (or participated in any CDK4/6 and CDK6 inhibitor clinical trial for which treatment assignment is 
still blinded); 20) have initiated bisphosphonates or approved RANK ligand (RANK-L) targeted agents <7 days  prior 
to randomization; 21) are currently receiving an investigational drug in a clinical trial or participating in any other 
type of medical research judged not to be scientifically or medically compatible with this study; 22) have received 
treatment with a drug that has not received regulatory approval for any indication within 14 or 21 days of 
randomization for a nonmyelosuppressive or myelosuppressive agent, respectively; 23) have had major surgery 
within 14 days prior to randomization; 24) have received recent (within 28 days prior to rrandomization) yellow fever 
vaccination; 25) have serious preexisting medical conditions that, in the judgment of tthe investigator, would preclude 
participation in this study; 26) have a personal history of any of the following conditions:  syncope of cardiovascular 
etiology, ventricular tachycardia, ventricular fibrillation, or sudden cardiac arrest; 27) have a history of any other 
cancer (except non-melanoma skin cancer or carcinoma in-situ of the cervix), unless in complete remission with no 
therapy for a minimum of 3 years; 28) have received an autologous or allogeneic stem-cell transplant; 29) have 
active bacterial or fungal infection or detectable viral infection. 
Statistical Methods: 
Statistical: 
A 3-look group sequential design on the primary endpoint of PFS will be utilized, with 2 interim and primary PFS 
analyses and 1 final PFS analysis occurring at approximately 218 PFS events189, 230, and 312270 investigator- 
assessed PFS events, respectively.  The Lan-DeMets method, utilizing a powerA fixed alpha-spending function with 
a power parameter of 14,method will be used to maintain the cumulative 1-sided type I error rate of .025. Assuming 
a hazard ratio of 0.71467, this design yields at leastmore than 80% statistical power to detect superiority of the 
LY2835219 plus NSAI arm over placebo plus NSAI arm with the use of a 1-sided log-rank test and a cumulative 
type I error rate of 0.025. 
OS is an important secondary endpoint for this study.  OS will be tested only if the test of PFS is significant.  The 
final OS analysis will be testedoccur after approximately 315 OS events have been observed, with a cumulative 1- 
sided type I error rate of .025.  The test of OS will be a pooled analysis including a subset of patients from Study 
I3Y-MC-JPBL. 
 
5. 1ntroduction 
Breast can er is one of the most common cancers in women.  In 2012, there were approximately 
1.7 million new cases of breast cancer worldwide; since 2008, the worldwide incidence of breast 
cancer has increased by more than 20% and mortality has increased by 14% (Bray et al. 2013; 
Ferlay et al. 2013). While early stage disease is treatable, patients with metastatic breast cancer 
(mBC) have a median overall survival (OS) of only 2 to 3 years (Cardoso et al. 2012). The 
treatment for women diagnosed with hormone receptor positive (HR++) mBC includes 

13Y-MC-JPBM(a) Clinical Protocol 
Page 102 
LY2835219 
 
 
 
endocrine therapy. In postmenopausal women, aromatase inhibitors (including anastrozole and 
letrozole) are recommended for the initial treatment of mBC, if not used in the adjuvant setting 
or if discontinued for at least 12 months (Cardoso et al. 2012). However, de novo or acquired 
resistance to adjuvant endocrine therapy and metastatic breast cancer remains an important 
clinical challenge. 
Cyclin D1 interacts with cyclin-dependent kinases 4 and 6 (hereafter CDK4/6 and CDK6) in an 
active protein complex that promotes cell proliferation (Velasco-Velazquez et al. 2011).  Many 
HR+ breast cancers demonstrate an intact retinoblastoma tumor suppressive function, however, 
overexpression of cyclin D1 protein by oncogenic signaling occurs in approximately 30% to  
50% of cancers.  Cyclin D1 is regarded as the most frequently overexpressed gene in primary 
breast cancer, with amplification of the encoding gene, CCND1, occurring in approximately 15% 
of breast cancers (Casimiro et al. 2014).  Therefore, CDK4/6 and CDK6 represents a potential 
therapeutic target for HR+ breast cancer.  Consequently, further evaluation of CDK4/6 and 
CDK6 inhibitors to improve clinical outcomes for women with HR+ breast cancer is warranted. 
During the cell cycle, the G1 restriction point controls entry into S phase and is essential for 
proper regulation of cell proliferation (Sherr 1996; Ortega et al. 2002).  CDK4/6 and CDK6 
participates in a complex with the D-type cyclins to initiate progression through the 
G1 restriction point. The CDK4/6 and CDK6 - cyclin D1 complex regulates the G1 restriction 
point through phosphorylation and inactivation of the retinoblastoma (Rb) tumor suppressor 
protein, thereby promoting S phase entry.  Alterations in this pathway occur frequently in human 
cancers and involve: 1) loss of functional CDK inhibitors through deletion or epigenetic 
silencing; 2) activating mutations and/or overexpression of CDK4/6 and CDK6 or the D-type 
cyclins; and 3) loss of functional Rb through mutation or deletion. Except for tumors with 
functional loss of Rb, which functions downstream of the CDK4/6 and CDK6 - cyclin D1 
complex, most cancers are potentially sensitive to pharmacologic inhibition of CDK4/6 and 
CDK6.  From a therapeutic standpoint, the goal of inhibiting CDK4/6 and CDK6 with a small 
molecule is to prevent cell cycle progression through the G1 restriction point, thus arresting 
tumor growth. 
LY2835219 represents a selective and potent small molecule inhibitor of CDK4/6 and CDK6 
with acceptable physical characteristics, pharmacokinetic (PK) properties, and safety profile in 
nonclinical species.  There may be important opportunities to tailor therapy with LY2835219 for 
pattiients with breast cancer.  Specifically, studies with LY2835219 indicate differential 
sensitivity to CDK4/6 and CDK6 inhibition based on histological and genetic 
characteristics. Growth inhibition in vitro across a diverse panel of 46 breast cancer cell lines, 
representing tthe known molecular subgroups of breast cancer, indicates that sensitivity to 
CDK4/6 a d CDK6 inhibition is greater in ER+ breast cancers with luminal histology. In 
accordance with the known biology of CDK4/6 and CDK6, the results also indicate that many of 
these sensitive cell lines are also characterized as having amplification of CCND1, which is the 
gene that encodes cyclin D1. These results are consistent with previous studies which 
demonstrate that effective induction of G1 cell cycle arrest by LY2835219 is dependent upon the 
presence of Rb. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 103 
LY2835219 
 
 
 
5.1. Rationale for Amendment (a) 
Study JPBM protocol was amended to update the dosing guidance for cases of hematologic 
toxicity and diarrhea and guidance on the use of blood cell growth factors. Lilly conducted a 
review across several clinical trials of abemaciclib in breast cancer and concluded that there were 
some inconsistencies.  This amendment will harmonize the dosing guidance and clarify that 
blood cell growth factors are only to be used in a manner consistent with American Society of 
Clinical Oncology (ASCO) guidelines. 
Further modifications were performed for clarity with supportive management for diarrhea and 
coadministration with substrate drugs of CYPs with narrow therapeutic margin. 
Furthermore, the statistical analysis plan (SAP) was updated.  The number of events required to 
perform the final PFS analysis was decreased from 312 events to 270 events based on the 
following rationale.  The results of PALOMA-1 (palbociclib + letrozole vs letrozole) and 
PALOMA-3 (palbociclib + fulvestrant vs fulvestrant) indicate the effect of CDK 4 and 6 
inhibitors in combination with endocrine therapy may have a larger effect than w s originally 
assumed during the development of this protocol.  As a result, the assumed hazard ratio has been 
changed from 0.714 (corresponding to an increase in median PFS from 10 months to 14 months) 
to 0.67 (increase in median PFS from 10 months to 15 months).  In addition, the interim analysis 
boundaries, timing of interim analyses, and OS analysis plan were modified. 
Minor typographical and formatting edits were made throughou the document for clarity and 
consistency. 
 
7.2.  Exclusion Criteria 
Patients will be excluded from the study if they meet any of the following criteria: 
  
[19]  have received prior treatment with any CDK4/6 and CDK6 inhibitor 
(or participated in any CDK4/6 and CDK6 inhibitor clinical trial for 
which treatment assignment is still blinded) 
 
8.1.  Summary of Study Design 
Database lock for the inter m analysisanalyses for efficacy will occur when approximately 
218189 and 230 investigator-assessed PFS events have been observed.  Database lock for the 
primaryfinal analysi  of the PFS endpoint will occur when approximately 312270 investigator- 
assessed PFS eve  ts have been observed.  The final analysis of OS will occur when 
approximately 315 OS events have been observed. All patients will be followed for survival 
information until death or study completion, whichever comes first. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 104 
LY2835219 
 
 
 
9.4.1.1.  Dose Adjustments and Delays 
 
Table JPBM.9.2. 
Toxicity Dose Adjustments and Delays of Blinded Study Drug for 
Study JPBM 
 
Toxicity Type 
Toxicity Profile and Severity 
Dose Suspension 
Dose Reduction 
Hematologic Toxicity 
Section 9.4.1.1.3 
Grade 3 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2. 
Dose MAY be reduced 
by 1 dose level - 
investigator's 
discretion
Hematologic Toxicity 
Section 9.4.1.1.3 
Recurrent Grade 3 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2. 
Dose MUST be 
reduced by 1 dose level 
Hematologic Toxicity 
Section 9.4.1.1.3 
Grade 4 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 2. 
Dose MUST be reduced 
by 1 dose lev l. 
Hematologic toxicity: Patient 
Regardless of severity 
Dose MUST be suspended 
Dos   MUST be reduced 
requires administration of 
blood cell growth factors 
Sections 9.4.1.1.3 and 9.6.4 
(Growth factors use according to 
ASCO Guidelines) 
for at least 48 hours after 
the last dose of blood 
cell growth factors was 
by 1 dose level unless 
already performed for 
incidence of toxicity that 
administered and until 
lead to the use of growth 
toxicity resolves to at least 
factor. 
Grade 2 
Nonhematologic Toxicity 
Persistent or recurrentt Grade 2 that 
Dose MAY be suspended 
Dose MAY be reduced 
(except diarrhea) 
does not resolve with maximal 
until t  xicity resolves to 
by 1 dose level - 
Section 9.4.1.1.4 
supportive measures within 7 days 
either baseline or Grade 1. 
investigator's discretion. 
to baseline or Grade 1 
Nonhematologic Toxicity 
Section 9.4.1.1.4 
Grade 3 or 4 
Dose MUST be suspended 
until toxicity resolves to 
either baseline or Grade 1. 
Dose MUST be reduced 
by 1 dose level. 
Diarrhea 
Section 9.4.1.1.4.1 
Requires hospitaliza ion or Grade 3 
or 4 
Dose MUST be suspended 
until toxicity resolves to at 
least Grade 1. 
Dose MUST be reduced 
by 1 dose level. 
Diarrhea 
Persistent or recurrent Grade 2 that 
Dose SHOULD be 
Dose MAY be reduced 
Section 9.4.1.1.4.1 
does not resolve with maximal 
suspended until toxicity 
by 1 dose level - 
s  pportive measures within 
resolves to at least Grade 1. 
investigator's discretion. 
24 hours to at least Grade 1 
Diarrhea 
Diarrhea recurs despite maximal 
Dose MUST be suspended 
Dose MUST be reduced 
Section 9.4.1.1.4.1 
supportive measures after resuming 
until toxicity resolves to at 
by 1 dose level. 
same dose level after initial 
least Grade 1. 
Grade 2 diarrhea 
Abbreviation:  ASCO = American Society of Clinical Oncology. 
Note: MAY = per the investigator's clinical judgment; SHOULD = not mandatory but highly recommended; 
MUST = mandatory. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 105 
LY2835219 
 
 
 
Table JPBM.9.2.3. 
Dose Adjustments for Blinded Study Drug 
 
9.4.1.1.3.  Hematologic Toxicity 
If a patient experiences Grade 4 hematologic toxicity, then dosing must be suspended (until the 
toxicity resolves to either baseline or at least Grade 2) and the dose of blinded study drug must 
be reduced by one dose level as outlined in Table JPBM.9.2. Table JPBM.9.3. 
If a patient experiences Grade 3 hematologic toxicity, then dosing must be suspended (until the 
toxicity resolves to either baseline or at least Grade 2) and the dose of blinded study drug may be 
reduced by one dose level as outlined in Table JPBM.9.2 Table JPBM.9.3 at the discretion of the 
investigator.  If the patient experiences a recurrent episode of Grade 3 hematologic toxicity, the 
dosing must be suspended (until the toxicity resolves to at least Grade 2) and the dose of blinded 
study must be reduced by 1 dose level. 
If a patient requires administration of blood cell growth factors, the dose of study drug must be 
suspended for at least 48 hours after the last dose of blood cell growth factors was administered 
and until toxicity resolves to at least Grade 2 then reduced by 1 dose level, if a dose reduction 
for the specific event necessitating the use of the growth factors has not already occurred. 
Before the start of each cycle, hematologic toxicity must resolve to either baseline or at least 
Grade 2. 
9.4.1.1.4.1. Diarrhea 
A patient experiencing diarrhea requiiring hospitalization (irrespective of grade, that is, requiring 
intravenous [IV] rehydration) or severe diarrhea (Grade 3 or 4; see Attachment 9) must have 
study treatment suspended (until the toxicity resolves to either baseline or at least Grade 1) and 
must have the blinded study drug dose reduced by one dose level as outlined in Table JPBM.9.2 
Table JPBM.9.3. 
If a patient experiences persistent or recurrent Grade 2 diarrhea that does not resolve with 
maximal supportive measures (refer to Section 9.6.5) within 3 days to either baseline or24 hours 
to at least Grade 1, then study trea ment should be suspended (until the toxicity resolves to either 
baseline or at least Grade 1) and the dose of blinded study drug may be reduced by one dose 
level as outlined in Table JPBM.9.2Table JPBM.9.3 at the discretion of the investigator. If the 
same dose level was resumed and diarrhea recurs despite maximal supportive measures, the dose 
off blinded study drug must be reduced by one dose level as outlined in 
Table JPBM.9.2 Table JPBM.9.3 
 
9.5.2.  Emergency Unblinding 
Emergency unblinding for AEs must be performed through the IWRS. This option may be used 
ONLY if the patient's acute well-being requires knowledge of the patient's treatment 
ass gnment. or if a patient discontinues treatment due to disease progression based upon 
RECIST 1.1 (see Attachment 5) and knowledge of the patient's treatment assignment is deemed 
essential to the selection of the patient's next treatment regimen. In the case of disease 
progression, the investigator must consult with the Lilly CRP prior to unblinding. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 106 
LY2835219 
 
 
 
9.6. Concomitant Therapy 
Radiolabeled human disposition study indicates that LY2835219 is mostly cleared by oxidative 
metabolism and therefore inhibitors and or inducers of CYP3A may alter the metabolism of 
LY2835219. Based on these findings, grapefruit juice as well as inducers (for example, 
phenytoin or carbamazepine) and strong inhibitors of CYP3A4CYP3A should be substituted or 
avoided if possible (Attachment 8). All patients may receive supportive therapy with 
dexamethasone, preferably :S7 days, if clinically indicated. Patients requiring more than 7 days 
of dexamethasone therapy will not incur a protocol deviation. 
In addition, in vitro studies in primary cultures of cultured human hepatocytes indicate that 
LY2835219 might inhibit the metabolism of abemaciclib and its major metabolites LSN28395 7 
and LSN3106726 down regulate mRNA of 1 or more CYPs, including CYP1A2, CYP2B6, 
CYP2C8, CYP2C9, CYP2D6, and CYP3A, at clinically relevant concentrations.  The 
mechanism of down regulation and its clinical relevance are presently not understood. 
Therefore, care should be taken when coadministering substrate drugs in vivo in humans.  Based 
on this finding, bupropion and efavirenz, which are sensitive CYP2B6 substra es, should be 
substituted or avoided if possible.of the above CYPs with narrow therapeut c margin 
(Attachment 8). 
 
9.6.4. Growth FactorFactors 
Growth factors should not be administered to enable a patient to satisfy study inclusion criteria. 
Growth factors may be administered in accordance with A  CO guidelines (Smith et al. 2006; 
Rizzo et al. 2008).2015). Dosing of blinded study drug must be suspended if the administration 
of growth factors is required and must not be recom   enced within 48 hours of the last dose of 
growth factors having been administered. Following the administration of growth factors, the 
dose of blinded study drug must be reduced by 1 dose level, if a dose reduction for the specific 
event necessitating the use of the growth factors has not already occurred. 
 
9.6.5. Supportive Management for Diarrhea 
At randomization, patients should receive instructions on the management of diarrhea.  In the 
event of diarrhea, supportive measures should be initiated as early as possible. These include the 
following: 
 At the first sign of loose stools, the patient should initiate anti-diarrheal therapy (e.g. 
loperamide) and notify the investigator for further instructions and appropriate follow-up. 
 Site personnel should assess response within 1 to 3 days. 
 If diarrhea does not resolve with anti-diarrheal therapy within 3 days to either baseline or 
Grade 1, then dosing should be adjusted as outlined in Section 9.4.1.1.1.1 and 
Table JPBM.9.2. 
 Patients should also be encouraged to drink fluids (e.g., 8 to 10 glasses of clear liquids 
per day). 
 Site personnel should assess response within 24 hours. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 107 
LY2835219 
 
 
 
 If diarrhea does not resolve with anti-diarrheal therapy within 24 hours to at least 
Grade 1, blinded study drug should be suspended until diarrhea is resolved to at least 
Grade 1. 
 When blinded study drug recommences, dosing should be adjusted as outlined in 
Section 9.4.1.1.4.1 and Table JPBM.9.3 
In potentially severe cases of diarrhea, the measuring of neutrophil counts and body temperature 
and proactive management of diarrhea with antidiarrheal agents should be considered. 
If diarrhea is severe (requiring IV rehydration) and/or associated with fever or severe (Grade 3 or 
4) neutropenia, broad-spectrum antibiotics such as fluoroquinolones must be prescribed. 
Patients with severe diarrhea or any diarrhea associated with severe nausea or vomiting sho  ld 
be carefully monitored and given intravenous fluid (IV hydration) and electrolyte replacement. 
 
10.1.2.  Efficacy Assessments during Postdiscontinuation Follow-Up 
For those patients who are randomized and never receive study treatment or tho  e who 
discontinue study treatment without objectively measured PD, the investiga ive sites will 
continue to monitor patients and periodically evaluate tumor response approximately every 
8 weeks for the first 18 months following randomization and thereafter approximately every 
12 weeks by the same method used at baseline and throughout the study until the patient has 
objective disease progression, or until the primaryfinal analysis of PFS.  In addition, anticancer 
therapies initiated after study treatment discontinuation will be collected during this follow-up 
period.  After the patient has objective disease progression, radiologic imaging and photographic 
images are no longer required and the patient will be followed up approximately every 12 weeks 
until the patient's death or overall study completion. 
10.4.2.1.  Archived Tumor Tissue 
In tumor tissue samples, the CDK4/6 and CDK6 pathway components (for example, Rb) and 
markers relevant to breast cancer pathogenesis may be evaluated to assess any potential 
correlation with response to LY283  219.  Tumor samples may be analyzed to explore potential 
tumor gene signature(s) associated with response or resistance to LY2835219 therapy. These 
studies may be analyzed at a laboratory designated by the sponsor and may include IHC of 
proteins, FISH for copy number amplifications, RNA gene-expression profiling, and/or genetic 
analyses of the tumor specimen DNA.  Such analyses may employ targeted or high-throughput 
sequencing approaches.  For this purpose, the results of this analysis will be correlated with 
clinical efficacy data. 
 
12.1.  Determination of Sample Size 
A 3-look group-sequential design of the primary endpoint will be used to accommodate an 
event-driven plan for the interim and primaryfinal PFS analyses (see Section 12.2.6 for details). 
The primaryfinal PFS analysis will be performed after approximately 312 270 PFS events have 
occurred (that is, a 30% 40% censoring rate). Assuming a hazard ratio of 0.71467, this sample 
size yields at leastmore than 80% statistical power to detect superiority of the LY2835219 plus 

13Y-MC-JPBM(a) Clinical Protocol 
Page 108 
LY2835219 
 
 
k
.
 
NSAI arm over the placebo plus NSAI arm with the use of a 1-sided log-rank test and a 
cumulative type I error of 0.025. If the true median PFS for the placebo plus NSAI arm is 10 
months, then the hazard ratio of 0.71467 amounts to an approximately 45-month (4050%) 
improvement in median PFS for the LY2835219 plus NSAI arm under an additional assumption 
of exponential survival distribution.  Assuming approximately 10% screening failure, the study 
will enter approximately 500 patients. 
 
12.2.6.  Primary Outcome and Methodology 
The 3-look group-sequential design of the primary endpoint will be used to accommodate an 
event-driven plan for the interim and primary analysis.final analyses. There is 1are 2 planned 
interim analysisanalyses and 1 primaryfinal analysis for PFS in this study.  The interim analysis 
isanalyses are planned to take place after approximately 218 189 (approximately 70% of the 
planned) investigator-assessed PFS events have occurred. and approximately 230 (appr  ximately 
85% of the planned) investigator-assessed PFS events have occurred.  The cumulative 1-sided 
type I error rate of .025 will be maintained using the Lan-DeMets method.  Specifically, a power 
a-spending function with a power parameter (rho) of 14 will be used for this interim efficacy 
following method.  At the first and second interim analysis, the nominal alpha levels will be 
0.0001 and 0.00015, respectively. The remaining alpha will be spent a the final analysis. The 
resulting boundary p-value for the final analysiss is dependent on the exact number of events 
observed at each analysis: 
*   

14 
k 
 
Here, tk is the information fraction at time k, and a is the cumulative 1-sided type 1 error rate, 
.025. 
 
Therefore, if the interim analysis is  and can be calculated using the method of Slud and Wei 
(1982). If the 3 analyses are performed afterat exactly 218 events have been observed, a nominal 
1-sided p-value of less than 0.00016   (corresponding approximately to an observed hazard 
ratio <0.6 under an exponential model) will need to be observed to declare statistical significance 
(see Table JPBM.12.2). 
 
Table JPBM.12.2.. 
Properties of Design for Progression-Free Survival 
 
Information 
Fraction 
Cumulative 
Events 
Cumulative 
Alpha Spent 
Cumulative 
Beta Spent 
Boundary Reject H0 
(one-sided p-value) 
0.7 
218 
0.000169 
0 
<0.000169 
1.0 
312 
0.025 
0.2 
<0.024997 
Abb eviation:  H0 = null hypothesis. 
189, 230, and 270 events, then the boundary p-value at the final analysis will be 0.0249994. The 
actual alpha spent boundary for the final analysis will be calculated based on the actual number 
of events observed at the time of each analysis using software that implements the alpha- 
*

13Y-MC-JPBM(a) Clinical Protocol 
Page 109 
LY2835219 
 
 
 
spending function scheme noted above (for example, ADDPLAN 6.0 or, SAS 9.2, or similar 
software). 
 
If the If statistical significance is not declared at the first interim PFS analysis, the second interim 
analysis crosses PFS analysis will be performed after 230 PFS events have been observed. Note 
that the boundary second interim analysis of PFS will only be performed if statistical 
significance is not declared at the pre-specified level, this analysis will be considered the primary 
first interim PFS analysis. If statistical significance is not declaredobserved at the either interim 
PFS analysis, the primary final PFS analysis will be performed after approximately 312 270 PFS 
events have been observed based on investigator assessment. 
 
There is no intent to stop the study if the interim analysis crosses the boundary of significa  ce at 
the pre-specified level. Treatment and follow-up of patients per the study schedule (Attachment 
1) will continue and patients will not be crossed over. The study will continue and the pre- 
specified analysis of PFS at 312 events will be performed to meet requirements of certain 
regulatory authorities.  The study will only be stopped early if both the DMC and global 
regulatory authorities agree that the scientific objectivess of the study are clearly met and 
unequivocal. 
 
Once statistical significance is declared at either interim analysis o  the final analysis, the study 
will be positive based on the primary endpoint of PFS, and testing of secondary endpoints will 
proceed as described in the SAP. 
 
The interim PFS analyses will be performed by DMC. The requirements for unblinding the 
sponsor at the interim analyses are found in Section 12.2.14. 
 
The primary test of PFS wiill compare the 2 treatment groups using a log-rank test stratified by 
the randomization factors. 
 
12.2.7.1.  Overalll Surviva 
Overall survival is an important s 
 
condary endpoint for this study.  Given that a hazard ratio for 
the effect of LY2835219 on O is anticipated to be smaller than that anticipated for PFS, to 
improve the precision of estimating the effect of LY2835219 on OS in this setting, a pooled 
analysis is planned for t  e main analysis of OS.  As noted in the Food and Drug Administration 
(FDA) Guidance for Industry on Integrated Summary of Effectiveness (2008) and in the EMA 
Guidance "Points to Consider on Application with 1.Meta-analyses; 2.One Pivotal Study 
(CPMP/EWP/2330/99, 2001)," an appropriate use of pooled analyses is during the assessment of 
drug effects on a secondary endpoint that requires more power than the individual trials can 
provide. 
 
Study I3Y-MC-JPBL (JPBL) is a study which randomizes patients with either locally advanced 
disease not amenable to curative treatment by surgery or metastatic disease to LY2835219 plus 
fulvestrant or placebo plus fulvestrant as either a first or second therapy for locally advanced or 
metastatic disease. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 110 
LY2835219 
 
 
 
Given the inclusion of patients receiving a first therapy for locally advanced or metastatic disease 
in the 2 trials (Studies JPBL and JPBM), that patients in both studies receive endocrine therapy 
in combination with LY2835219 or placebo, and the similarity of the study schedules 
(Attachment 1), it is rational and scientifically valid to conduct a pooled OS analysis using all 
patients from Study JPBM and those patients from Study JPBL who receive initial therapy for 
locally advanced or metastatic disease on study. 
 
To maintain the study-wise type I error rate, OS will be hierarchically tested.  Overall survival; 
that is, OS will only be tested inferentially for significance only if the test of PFS is significant, 
and an alpha-spending scheme will be employed to maintain a study-wise type I error rate of 
.025. The final pooled OS analysis will occur when at least 315 OS events have been obsserved 
events in Study JPBM and all events for the final analysis have been observed in Study JPBL, as 
specified in the study's protocol. Note: while the pooled analysis is considered the pri ary OS 
analysis for this study, a subgroup analysis of Study JPBM OS data alone will be performed for 
descriptive purposes. Further details of the pooled testing of OS, including interim analyses, are 
described in the Study JPBM will be in the study SAP. 
 
12.2.14.2. Efficacy 1nterim Analyses 
OneTwo efficacy interim analysisanalyses of PFS and 1 interim analysis of pooled OS data are 
planned, as described in Sections Section 12.2.6 and 12.2.7. 
 
.  Four interim analyses of OS are planned (at the time of each of the 2 interim PFS analyses, at 
the time of the final PFS analysis, and at the time when approximately 75% of the OS events 
have been observed; subsequently, a final OS analysis is planned). 
 
The interim PFS analysisanalyses will be conducted to provide early efficacy information and 
could potentially result in early communication with regulatory agencies.  This analysis will be 
performed by an independent Statistical Analysis Group and provided to the DMC.  .The DMC 
should recommend unblinding the spo  sor if the following are observed: 
 The analysis of investigator-assessed PFS is significant at the alpha level specified in 
Section 12.2.6 with the observed stratified hazard ratio for investigator-assessed PFS less 
than 0.56 at the first interim analysis, or is less than 0.6 at the second interim analysis, 
and 
 Results of the analysis of the centrally reviewed PFS support the results of the 
investigator-assessed PFS analysis. 
If the analysis of PFS is positive based on these requirements, the DMC will be instructed to 
recomme d to the SMD that the sponsor be unblinded. The SMD may convene an IRC to 
review the DMC's recommendation prior to sponsor unblinding. 
O erall survival will be analyzed as described in Section 12.2.7. Results of OS analyses will not 
be communicated until a significant result is observed or the final PFS analysis is performed. 

13Y-MC-JPBM(a) Clinical Protocol 
Page 111 
LY2835219 
 
 
 
The sponsor has no intent to stop the study based on interim analysis of efficacy, and all patients 
will continue follow-up for PFS until the primary PFS analysis and for OS until study close. 
Patients randomized to the control group will not be permitted to cross over to the experimental 
group, as this will confound the assessment of OS. In addition, patients will remain blinded forr 
the duration of the study unless the criteria in Section 9.5 are met. If the DMC makes a 
recommendation counter to this, for example, the DMC recommends crossing all patients over to 
the experimental treatment, FDA will be consulted before any action is taken as well as other 
regulatory agencies if deemed appropriate. 
 
14.  References 
Rizzo JD, Somerfield MR, Hagerty KL, Seidenfeld J, Bohlius J, Bennett CL, Cella DF, 
Djulbegovic B, Goode MJ, Jakubowski AA, Rarick MU, Regan DH, Lichtin AE; American 
Society of Clinical Oncology; American Society of Hematology. Use of epoetin and 
darbepoetin in patients with cancer: 2007 American Society of Clinical Oncolog /American 
Society of Hematology clinical practice guideline update. J C/in Onco/. 26(1): 32-149. Epub 
2007 Oct 22. Erratum in:  J C/in Onco/. 2008;26(7):1192. 
Slud E, Wei LJ. Theory and Method:  Two-Sample Repeated Significance Tests Based on the 
Modified Wilcoxon Statistic. J Amer Stat Assoc. 1982;77(380):862-868. 
Smith TJ, Khatcheressian J, Lyman GH, Ozer H, Armitage JO, Bal ucci L, Bennett CL, Cantor 
SB, Crawford J, Cross SJ, Demetri G, Desch CE, Pizzo PA, Schiffer CA, Schwartzberg L, 
Somerfield MR, Somlo G, Wade JC, Wade JL, Winn RJ, W zniak AJ, Wolff AC. Update of 
recommendations for the use of white blood cell growth factors:  an evidence-based clinical 
practice guideline. J C/in Onco/. 2006;24:3187-3205. 
Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, 
Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. 
Recommendations for the Use of White Blo  d Cell Growth Factors: American Society of 
Clinical Oncology Clinical Practice Guideline Update. J C/in Onc 2015, 
http://jco.ascopubs.org/content/early/2015/07/08/JCO.2015.62.3488.full. Accessed 01 October 
2015. 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 112 
 
 
X 
X 
X 
X 
X 
X
X 
X
 
 
Attachment 1.  Protocol JPBM Study Schedule 
 
Protocol I3Y-MC-JPBM 
During Treatment Study 
Schedule 
Study Treatment Period 
Cycle / Visit 
1 
2 
3 
4-X 
Approximate 
Visit Duration 
(days) 
28 
28 
28 
28 
Relative day 
within a cycle 
1 
1 
21-28 
1 
1 
21-28 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Physical 
Examination 
Physical Exam 
X 
X 
X 
X 
Include but not limited to weight 
Vital Signs 
X 
X 
X 
X 
Include blood pressure, pulse, respiratory rate, and temperature 
ECOG performance 
status
Attachment 4 
X 
X 
X 
X 
Archived Tumor Tissue 
Section 
10.4.2.1 
X 
 
Whole or partial block or 15 - 20 slides should be provided 
upon patient randomization. 
Adverse Event Collection/CTCAE 
Grading 
Section 10.3 
X 
X 
 
X 
X 
Concomitant Medication Notation 
Section 9.6 
X 
X 
X 
X 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 113 
 
 
X 
X 
X 
X 
X 
X
X 
 
 
Protocol I3Y-MC-JPBM 
During Treatment Study 
Schedule 
Study Treatment Period 
Cycle / Visit 
1 
2 
3 
4-X 
Approximate 
Visit Duration 
(days) 
28 
28 
28 
28 
Relative day 
within a cycle 
1 
1 
21-28 
1 
1 
21-28 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Lab/ 
Diagnostic 
Tests 
Central hematology 
Attachment 2 
X 
X 
X 
X 
Central h matology labs may be drawn up to 3 days prior to 
Day 1 of each cycle. Additional local hematology labs may be 
drawn for treatment adjustment and patient management 
purposes. 
Central chemistry 
Attachment 2 
X 
X 
X 
X 
Central chemistry labs may be drawn up to 3 days prior to 
Day 1 of each cycle. Additional local chemistry labs may be 
drawn for treatment adjustment and patient management 
purposes. 
Pharmacokinetic (PK) 
sampling 
Attachment 7 
X 
X 
 
X 
See Attachment 7 for specific timing. 
Pharmacogenetic blood 
sample 
Section 
10.4.2.2 
X 
 
Draw sample before patient is dosed on C1D1. 
Biomarker plasma 
sample 
Section 10.4.2 
X 
X 
Draw sample before patient is dosed on C1D1 and upon arrival 
at site on C2D1. 
Local ECG 
Section 
10.3.2.1 
X 
X 
X 
2 to 4 hours after the LY dose on Cycle 1 Day 1, upon arrival at 
site on Cycle 2 Day 1, 2 to 4 hours after the LY dose on Cycle 
4 Day 1. Following C4D1, no additional ECGs are required 
while the patient is on treatment (only subsequently for short- 
term follow-up). Patients must be supine for approximately 
5 to 10 minutes before ECG collection and remain supine but 
awake during ECG collection. 
Abbreviations:  C4D1 = Cycle 4 Day 1; CT = computed tomography; CTCAE = Common Terminology Criteria for Adverse Events; ECG = electrocardiogram; ECOG = Eastern Cooperative Oncology 
Group; EORTC QLQ-BR23 = European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-Breast cancer; EORTC QLQ-C30 = European Organization for Research and 
Treatment of Cancer Quality of Life Questionnaire-Core 30; EQ-5D 5L = EuroQol 5-Dimension 5 Level; MRI = magnetic resonance imaging; RECIST = Response Evaluation Criteria in Solid Tumors. 

LY2835219 
13Y-MC-JPBM(a) Clinical Protocol 
Page 114 
 
 
X 
X 
X 
 
 
Protocol I3Y-MC-JPBM 
Study Schedule for the 
Continued Access Period only 
Study Period 
Patients on Study Treatment 
Continued Access Period 
Follow-Up 
Cycle 
X 
Follow-Upa 
Visit 
501-5XX 
901 
Approximate 
Visit Duration 
(days) 
28±3 
30±5 
Relative day 
within a cycle 
1 
Procedure 
Category 
Procedure 
Protocol 
Reference 
Comments 
Adverse Events Collection/CTCAE Grading 
Section 10.3 
X 
X 
Data on SAEs that occur before the end of trial will be 
stored in the collection database and the Lilly safety 
system 
Study Drug 
LY2835219 
Section 9.1 
X 
Only patients assigned to LY2835219 at randomization 
and receiving clinical benefit will continue to receive 
LY2835219 during the continued access period. 
LY2835219 is to be administered orally every 12 hours 
on Days 1 through 28 of each cycle. Patients who were 
assigned to placebo, will no longer receive placebo 
during the continued access period and cannot crossover 
to LY2835219. 
Co- 
Administered 
Drugs 
Anastrozole 
Section 9.1 
X 
Patients receiving clinical benefit will continue to 
receive anastrozole or letrozole during the continued 
access period. Anastrozole or letrozole is to be 
administered orally every 24 hours on Days 1 through 
28 of each cycle 
Letrozole 
Section 9.1 
X 

 
13Y-MC-JPBM(a) Clinical Protocol 
Page 115 
 
 
Attachment 8. Protocol JPBM 1nducers and, Strong 1nhibitors of CYP3A4CYP3A, or 
Substrates of CYPs with Narrow Therapeutic Range 
Inducers of CYP3A4 CYP3A 
Carbamazepine 
Dexamethasonea 
Phenobarbital/phenobarbitone 
Phenytoin 
Rifapentine 
Rifampin 
Rifabutin 
St. John's wort 
 
a   Important note:  All patients may receive supportive therapy with dexamethasone, preferably 
 
7 days, if clinically indicated. 
Strong inhibitors of CYP3A4 CYP3A 
All HIV protease inhibitors 
Clarithromycin 
Itraconazole 
Ketoconazole 
Nefazodone 
 
a   Important note:  All patients may receive supportive therapy with dexamethasone, preferably :S7 days, if 
clinically indicated. Patients requiring more than 7 days of dexamethaso e therapy will not incur a protocol 
deviation. 
Cytochrome P450 Substrates with Narrow Therapeutic Range 
Cytochrome P450 
Substrate 
CYP1A2 
Theop ylline 
Tiz nidine 
CYP2C8 
Paclitaxel 
CYP2C9 
Warfarin 
Phenytoin 
CYP2D6 
Thioridazine 
Pimozide 
CYP3A 
Alfentanil 
Astemizole 
Cisapride 
Cyclosporine 
Dihydroergotamine 
Ergotamine 
Fentanyl 
Pimozide 
Quinidine 
Sirolimus 
Tacrolimus 
Terfenidine 
 
 
 
 
 
LY2835219 

 
 
 
 
LY2835219 
 
 
Attachment 9.  Protocol JPBM CTCAE 4.03 Diarrhea Definition 
Diarrhea will be evaluated in this study using the criteria proposed by Common Terminology Criteria for Adverse Events (CTCAE) 
v4.0 revised:  CTCAE 4.03-June 14, 2010:  Gastrointestinal disorders. 
 
Gastrointestinal Disorders 
Grade 
Adverse Event 
1 
2 
3 
4 
5 
Increase <= > 7 stools per 
Diarrhea 
Increase of <4 stools 
per day over baseline; 
mild increase in 
ostomy output 
compared to baseline. 
Increase of 4-6 stools 
per day over baseline; 
moderate increase in 
ostomy output 
compared to baseline 
day over baseline; 
incontinence; 
hospitalization indicated; 
severe increase in ostomy 
output compared to 
baseline; limiting self-care 
Life-threatening 
consequences; urgent 
intervention indicated 
Death 
ADL 
Definition:  a disorder characterized by frequent and watery bowel movements 
Abbreviation:  ADL = Activities of Daily Living. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
13Y-MC-JPBM(a) Clinical Protocol 
Page 116 

 
 
Leo Document ID = 68c57dda-4c1c-47e0-876c-44cba55cc733 
Approver: 
Approval Date & Time: 13-Nov-2015 14:57:19 GMT 
Signature meaning: Approved 
Approver: 
Approval Date & Time: 13-Nov-2015 18:46:17 GMT 
Signature meaning: Approved